---
document_datetime: 2023-09-21 17:50:36
document_pages: 105
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/opsumit-epar-public-assessment-report_en.pdf
document_name: opsumit-epar-public-assessment-report_en.pdf
version: success
processing_time: 121.8621083
conversion_datetime: 2025-12-20 18:29:28.567658
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

24 October 2013 EMA/457699/2013 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Opsumit

International non-proprietary name: MACITENTAN

Procedure No. EMEA/H/C/002697/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

+44 (0)20 7418 8400

<!-- image -->

+44 (0)20 7523 7455

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Product information

| Name of the medicinal product:                 | Opsumit                                                                                                                                                                                                                                                                                                                                                                                                          |
|------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                     | Actelion Registration Ltd. Chiswick Tower, 13th Floor 389 Chiswick High Road London W4 4AL United Kingdom                                                                                                                                                                                                                                                                                                        |
| Active substance:                              | MACITENTAN                                                                                                                                                                                                                                                                                                                                                                                                       |
| International Nonproprietary Name/Common Name: | MACITENTAN                                                                                                                                                                                                                                                                                                                                                                                                       |
| Pharmaco-therapeutic group (ATC Code):         | other anti-hypertensives, ATC code: C02KX04                                                                                                                                                                                                                                                                                                                                                                      |
| Therapeutic indication(s):                     | Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease (see section 5.1). |
| Pharmaceutical form(s):                        | Film-coated tablet                                                                                                                                                                                                                                                                                                                                                                                               |
| Strength(s):                                   | 10 mg                                                                                                                                                                                                                                                                                                                                                                                                            |
| Route(s) of administration:                    | Oral use                                                                                                                                                                                                                                                                                                                                                                                                         |
| Packaging:                                     | Bottle (HDPE) and blister (PVC/PE/PVdC/Alu)                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Package size(s):   | 15 tablets and 30 tablets   |
|--------------------|-----------------------------|

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 8                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................8      |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................9               |                                                                                                          |
| 2. Scientific discussion..............................................................................                     | 11                                                                                                       |
| 2.1. Introduction.......................................................................................................11 |                                                                                                          |
| 2.2. Quality aspects                                                                                                       | ..................................................................................................13     |
| 2.2.1. Introduction....................................................................................................13  |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................13     |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                          | ................................................................................16                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................19                       |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ......................19                                                                                 |
| 2.2.6. Recommendation for future quality development.................................................19                    |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                  | ............................................................................................19           |
| 2.3.1. Pharmacology                                                                                                        | .................................................................................................19      |
| 2.3.2. Pharmacokinetics.............................................................................................21     |                                                                                                          |
| 2.3.3. Toxicology                                                                                                          | ......................................................................................................23 |
| 2.3.4. Ecotoxicity/environmental risk assessment                                                                           | .........................................................27                                              |
| 2.3.5. Discussion on non-clinical aspects......................................................................28          |                                                                                                          |
| 2.3.6. Conclusion on non-clinical aspects                                                                                  | .....................................................................30                                  |
| 2.4. Clinical aspects                                                                                                      | ..................................................................................................30     |
| 2.4.1. Introduction....................................................................................................30  |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................33     |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................39        |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................42            |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................46             |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                     | ..................................................................................................46     |
| 2.5.1. Dose response studies......................................................................................47       |                                                                                                          |
| 2.5.2. Main study......................................................................................................48  |                                                                                                          |
| 2.5.3. Discussion on clinical efficacy............................................................................67       |                                                                                                          |
| 2.5.4. Conclusions on the clinical efficacy.....................................................................70         |                                                                                                          |
| 2.6. Clinical safety                                                                                                       | ....................................................................................................70   |
| 2.6.1. Discussion on clinical safety                                                                                       | ..............................................................................86                         |
| 2.6.2. Conclusions on the clinical safety.......................................................................93         |                                                                                                          |
| 2.7. Pharmacovigilance..............................................................................................93     |                                                                                                          |
| 2.8. Risk Management Plan                                                                                                  | ........................................................................................93               |
| 3. Proposal for risk minimisation measures                                                                                 | .............................................. 94                                                        |

<div style=\"page-break-after: always\"></div>

## 4. Benefit-Risk Balance ............................................................................. 96 5. Recommendations  ............................................................................... 102

<div style=\"page-break-after: always\"></div>

## List of abbreviations

6MWD

6-minute walk distance

6MWT

6-minute walk test

AE

adverse event

ALT

alanine aminotransferase

APAH

Associated PAH

AST

aspartate aminotransferase

AUC

area under the curve

BP

blood pressure

BSEP

Bile salts export pump

CEC

Clinical Event Committee

CHMP

Committee for Medicinal Products for Human Use (Europe)

CL

Confidence limit

CI

cardiac index

CI

confidence interval

Cmax

Maximum concentration

CTD

Connective Tissue Disorder

CV

coefficient of variation

DBIL

Direct bilirubin

DBP

Diastolic blood pressure

DDI

drug-drug interaction

dPAP

Diastolic pulmonary artery pressure

DRA

Drug Regulatory Affairs (department)

DSMB

Data Safety Monitoring Board

ECG

electrocardiogram

EM(E)A

European Medicines (Evaluation) Agency

EOS

End of study

EOT                  End of double-blind treatment

ERA

Endothelin Receptor Antagonist

ET

Endothelin

FC

Functional Class

FPAH

Familial Pulmonary Arterial Hypertension

GC

Gas Chromatography

GQM

Global Quality Management (department)

HIV

Human immunodeficiency virus

HPLC

High Performance Liquid Chromatography

HR

Heart rate

IC50

Concentration that causes 50% inhibition

Ki

Inhibition constant

i.v.

intravenous

ICF

Informed consent form

ICH

International Conference on Harmonisation

IPAH

Idiopathic Pulmonary Arterial Hypertension

LSM

least squares mean

MAH

Marketing Application Holder

MDR

Multidrug resistant protein

MedDRA

Medical Dictionary for Regulatory Activities

mPAP

Mean pulmonary artery pressure

mRAP

mean right atrial pressure

NIH

National Institute of Health

NNT

Number needed to treat

<div style=\"page-break-after: always\"></div>

| NT-pro-BNP   | N-terminal pro-B type natriuretic peptide     |
|--------------|-----------------------------------------------|
| NTCP         | Na + -taurocholate cotransporting polypeptide |
| NYHA         | New York Heart Association                    |
| OATP         | organic anion transporting polypeptide        |
| OD           | Once daily                                    |
| OL           | Open Label                                    |
| PAH          | Pulmonary Arterial Hypertension               |
| PBPK         | Physiologically Based Pharmacokinetic         |
| PD           | Pharmacodynamic                               |
| PDE5I        | phosphodiesterase type 5 inhibitor            |
| P-gp         | P glycoprotein                                |
| Ph. Eur.     | European Pharmacopoeia                        |
| PK           | Pharmacokinetics                              |
| PPH          | Primary Pulmonary Hypertension                |
| PRAC         | Pharmacovigilance Risk Assessment Committee   |
| PVR          | Pulmonary Vascular Resistance                 |
| QoL          | Quality of Life                               |
| QSAR         | Quantitative Structure-Activity Relationship  |
| RH           | Relative Humidity                             |
| RMP          | Risk Management Plan                          |
| SAE          | Serious Adverse Event                         |
| SAP          | Statistical Analysis Plan                     |
| SCPS         | Summary of Clinical Pharmacology Studies      |
| SCS          | Summary of Clinical Safety                    |
| SD           | standard deviation                            |
| SDAC         | Statistical Data Analysis Center              |
| SiSBP        | Sitting systolic blood pressure               |
| SmPC         | Summary of Product Characteristics            |
| SMQ          | Standardized MedDRA queries                   |
| SOC          | system organ class                            |
| SOP          | Standard operating procedure                  |
| sPAP         | Systolic pulmonary artery pressure            |
| SUSAR        | Suspected unexpected serious adverse reaction |
| SvO2         | Mixed venous oxygen saturation                |
| T1/2         | half life                                     |
| Tmax         | Time to reach Cmax                            |
| TPR          | Total Pulmonary Resistance                    |
| TTC          | Threshold of Toxicological Concern            |
| WHO          | World Health Organisation                     |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The  applicant  Actelion  Registration  Ltd.  submitted  on  25  October  2012  an  application  for Marketing  Authorisation  to  the  European  Medicines  Agency  (EMA)  for  Opsumit,  through  the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004 . The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 19 January 2012.

The medicinal product 'macitentan' was designated by the European Commission as an orphan medicinal product for the treatment of pulmonary arterial hypertension under number EU/3/11/2009 on 29 September 2011.

The applicant initially applied for the following indication:

Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients  of  WHO  Functional  Class  II  to  IV  to  reduce  morbidity  and  mortality.  Opsumit  is effective when used as monotherapy or in combination with phosphodiesterase-5 inhibitors or inhaled prostanoids.

Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with congenital heart disease (see section 5.1).

The finally approved indication is:

Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.

Efficacy  has  been  shown  in  a  PAH  population  including  idiopathic  and  heritable  PAH,  PAH associated  with  connective  tissue  disorders,  and  PAH  associated  with  corrected  simple congenital heart disease (see section 5.1).' The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application. The applicant indicated that Opsumit (macitentan) was considered to be a new active substance.

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain tests or studies.

Following the CHMP positive opinion on this marketing authorisationn, the committee for Orphan Medicinal products (COMP) reviewed the designation of of Opsumit as an Oprphan medicinal product in the approved indication. The outcome of the COMP review can be found on the Agency website: ema.europa.eu/Find medicine/Rare disease designations.

<div style=\"page-break-after: always\"></div>

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) [P/0087/2012] on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products approved for the same condition.

## Applicant's request for consideration

## New active Substance status

The applicant requested the active substance macitentan contained in the above medicinal product to be considered as a new active substance in itself, as the applicant claims that it is not a constituent of a product previously authorised within the Union.

## Protocol Assistance

The applicant did not seek Protocol Assistance at the CHMP.

## Licensing status

The product was not licensed in any country at the time of submission of the application.

## 1.2. Manufacturers

## Manufacturer responsible for batch release

Janssen-Cilag S.p.A. Via C. Janssen IT-04010 Borgo San Michele Latina Italy

## 1.3. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP:

Rapporteur: Concepcion Prieto Yerro Co-Rapporteur:  Pieter de Graeff

The application was received by the EMA on 25 October 2012.

- The procedure started on 21 November 2012.

<div style=\"page-break-after: always\"></div>

- The Rapporteur's first Assessment Report was circulated to all CHMP members on 8 February 2013. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 8 February 2013 .
- PRAC RMP Advice and assessment overview, adopted by PRAC on 7 March 2013.
- During the meeting on 21 March 2013, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 21 March 2013.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 23 May 2013.
- PRAC RMP Advice and assessment overview, adopted by PRAC on 10 July 2013.
- The summary report of the inspection carried out at the following sites of SERAPHIN study site 8401 - Mexico and site 5101- China and MAH facilities Actelion Switzerland between 19 February 2013 and 12 April 2013 was issued on 15 May 2013.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 19 July 2013.
- During the CHMP meeting on 25 July 2013, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 16 August 2013.
-    PRAC RMP Advice and assessment overview, adopted on 5 September 2013.
- During the CHMP meeting on 19 September 2013 outstanding issues were addressed by the applicant during an oral explanation before the CHMP and the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 23 September 2013.
- PRAC RMP Advice and assessment overview, adopted on 10 October 2013.
- During the meeting on 24 October 2013, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Opsumit.
- The CHMP adopted a report on similarity of macitentan with ambrisentan, bosentan, sildenafil and iloprost on 24 October 2013.

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Pulmonary  Arterial  Hypertension  (PAH)  is  a  chronic  and  progressive  disease  of  the  small pulmonary arteries that is characterised by vascular proliferation and remodelling. It results in increased  pulmonary  artery  pressure  and  pulmonary  vascular  resistance  and,  ultimately,  right ventricular  heart  failure  and  death.  Although  the  pathogenesis  of  PAH  is  not  completely understood, it likely involves an imbalance in the normal relationships between vasodilators and vasoconstrictors, growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic determinants that are probably consequences of pulmonary endothelial cell dysfunction and/or injury.

PAH  is  defined  by  right-heart  catheterization  showing  a  precapillary  pulmonary  hypertension (mean  pulmonary  artery  pressure  &gt;  25  mmHg  at  rest  or  &gt;  30  mmHg  with  exercise,  with  a pulmonary  artery  wedge  pressure  &lt;  15  mmHg).  There  is  a  female-to-male  preponderance (1.7:1), with patients most commonly presenting in the third and fourth decades, although the age range is from infancy to greater than 60 years.

The  annual  incidence  of  idiopathic  pulmonary  hypertension  has  been  estimated  within  1  or  2 cases per million individuals per year. This is well within the criteria defined for the prevalence of orphan diseases.

The median life expectancy from the time of the diagnosis in patients with idiopathic PAH (IPAH), before  the  availability  of  disease-specific  (targeted)  therapy,  was  2.8  years  through  the  mid1980. PAH is a rare, progressive, life-threatening disease with a poor prognosis.

Current clinical classification of PAH comprises apparently heterogeneous conditions, which share comparable clinical and hemodynamic pictures and virtually identical pathologic changes of the lung  microcirculation.  PAH  includes  idiopathic  (IPAH,  formerly  termed  primary  pulmonary hypertension) and familial forms (FPAH), PAH associated with various conditions (APAH), such as scleroderma and other connective tissue diseases (CTD), congenital heart defects with systemicto-pulmonary shunts, portal hypertension, human immunodeficiency virus infection, exposure to drugs  and  toxins  and  other  more  rare  settings:  thyroid  disorders,  glycogen  storage  disease, Gaucher´s  disease,  hereditary  hemorrhagic  telangiectasia,  hemoglobinopathies  (Sickle  disease especially), myelo-proliferative disorders, splenectomy, PAH associated with significant venous or capillary involvement and finally, persistent pulmonary hypertension of the newborn.

The functional classification is the measure of the limits imposed on a patient by a disease. It is a critical  element  of  the  assessment  of  patients  with  PAH.  There  are  two  classification  systems that, in practice, are used interchangeably when characterizing patients with PAH:

## A. New York Heart Association (NYHA) functional classification

- Class 1: No symptoms with ordinary physical activity.
- Class 2: Symptoms with ordinary activity. Slight limitation of activity.
- Class 3: Symptoms with less than ordinary activity. Marked limitation of activity.
- Class 4: Symptoms with any activity or even at rest.

<div style=\"page-break-after: always\"></div>

## B. World Health Organization (WHO) functional assessment classification

- Class I: Patients with PH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope.
- Class II: Patients with PH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
- Class III: Patients with PH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope.
- Class IV: Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right-heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

Variables associated with poor survival includes, among others, a NYHA/WHO Functional Class (FC) III or IV and the presence of Raynaud's phenomenon.  Patients with a NYHA/WHO Class I or II  have  a  median  survival  of  59  months  (approximately  5  years),  while  patients  with  a NYHA/WHO  Class  III  have  a  median  survival  of  32  months  (2.6 years),  and  patients  with  a NYHA/WHO Class IV have a median survival of 6 months.  For Primary Pulmonary Hypertension (PPH),  the  US  National  Institute  of  Health  (NIH)  registry  showed  survival  rates  for  untreated patients of 68%, 48%, and 34% after 1, 3, and 5 years from diagnosis, respectively. Although advances  in  therapies  and  patient  management  have  improved  these  rates,  there  is  still  no known cure for PPH or other forms of PAH.

Symptoms  of  PAH  include  dyspnoea  (most  commonly),  fatigue,  chest  pain  or  discomfort, dizziness,  syncope,  near  syncope,  edema,  leg  edema,  and  palpitations.    When  the  disease  is advanced,  the  clinical  manifestations  include  cyanosis,  dyspnoea  on  exertion,  hemoptysis, atypical chest pain or angina pectoris, syncope, heart failure, arrhythmias and cerebrovascular accidents.

General measures recommended for patients with PAH is to engage in activities appropriate to their physical capabilities in order to prevent deconditioning and worsening of overall function. At present,  conventional  treatment  for  patients  with  PAH  includes  calcium-channel  blockers, anticoagulants, diuretics and oxygen. In addition, two phosphodiesterase-5 inhibitors (sildenafil, tadalafil), two oral endothelin-receptor antagonists (ERA) (bosentan, ambrisentan), an intravenous  prostacyclin  (epoprostenol),  an  inhaled  prostacylin  (iloprost)  and  a  subcutaneous prostacyclin (treprostinil) have also been licensed for the treatment of PAH in various European countries. Of these, sildenafil (Revatio®), tadalafil (Adcirca®), bosentan (Tracleer®), ambrisentan (Volibris®) and iloprost (Ventavis®) have been authorised through the centralised procedure. Sildenafil, tadalafil and ambrisentan are indicated for patients with primary and CTDassociated  PAH,  while  bosentan  is  indicated  for  patients  with  primary  PAH,  sclerodermaassociated PAH, and PAH associated to congenital systemic-to-pulmonary shunts and Eisenmenger's physiology. Iloprost is indicated only for patients with primary PAH. Four of these medicinal products are licensed for patients with NYHA FC II and III disease severity (sildenafil, tadalafil, bosentan and ambrisentan), whereas the remaining ones are licensed for patients with

<div style=\"page-break-after: always\"></div>

NYHA class III only. An additional ERA, sitaxentan (Thelin®), was withdrawn from the market in 2010 due to concerns about liver toxicity.

Macitentan (ACT-064992)(N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4pyrimidinyl]-N'-propylsulfamide) is an orally active, dual endothelin (ET) receptor antagonist. In vitro, macitentan selectively inhibits the binding of ET-1 to ETA and ETB receptors as well as the effects mediated by these receptors in functional assays.

Macitentan belongs to the class of endothelin receptor antagonists (ERA), but has a molecular structure,  physicochemical  properties,  receptor-binding  kinetics,  and  efficacy  in  nonclinical models that differentiate it from previously authorized compounds.

The  selection  of  macitentan  for  development  as  a  dual  ERA  was  further  guided  by  the compound's pharmacokinetic characteristics which are consistent with once-daily (OD) dosing, its favourable  drug-drug  interaction  profile,  and  its  low  propensity  to  inhibit  intrahepatic  bile  salt transport, which is believed by the applicant to translate into a favourable liver safety profile.

## 2.2. Quality aspects

## 2.2.1. Introduction

Opsumit is a film-coated tablet containing an active substance not previously authorised in the EU at the time of the submission of this application.

The finished product is presented as film-coated tablets, containing 10 mg of macitentan. Other ingredients are: lactose monohydrate,  microcrystalline  cellulose, sodium  starch  glycolate, povidone,  magnesium  stearate,  polysorbate  80,  polyvinyl  alcohol,  titanium  dioxide,  talc,  soya lecithin, xanthan gum (see section 6.1 of the SmPC).

The product is available in blisters and bottles as described in section 6.5 of the SmPC.

## 2.2.2. Active Substance

The  active  substance  macitentan  appears  as  white  to  off-white  crystalline  powder  insoluble  in water and aqueous solutions in room temperature at pH 1.2, 4, 6.8, 7, 9 and is slightly soluble in methanol and ethanol.

The chemical name of macitentan is N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide, corresponding to the structural formula below:

<!-- image -->

The molecular formula is C19H20Br2N6O4S and its relative molecular mass 588.27 g/mol. Its pKa is 6.2 and the partition coefficient LogD is 2.9 (lipophilic). The molecule is achiral thus having no

<div style=\"page-break-after: always\"></div>

stereoisomers. Several polymorphic forms have been described including different solvates. All macitentan batches manufactured so far for clinical studies and commercial purposes correspond to the same stable polymorphic form which is a true polymorph with a melting point of 135°C. It is the thermodynamically most stable form at room temperature. Long-term stability studies on several clinical and registration batches showed no polymorphic change of macitentan after up to 36 months of storage at 30 °C / 65% RH. Results of the dynamic vapour sorption of macitentan show that it is not hygroscopic.

<div style=\"page-break-after: always\"></div>

## Manufacture

Macitentan  is  manufactured  in  three  chemical  steps  and  a  last  milling  step,  which  were  all described  in  sufficient  detail.  A  flow  diagram  for  the  synthesis  of  macitentan  is  provided, including starting materials, intermediates, solvents and reagents for each stage. The rationale for  the  choice  of  the  starting  materials  is  considered  acceptable.  The  manufacturing  process development includes a detailed description of the optimisation steps for the active substance. The  two  last  chemical  steps  were  optimised  thereby  limiting  the  formation  of  impurities  and increasing the yield. The applicant has applied the design of experiments approach and applied a multivariate analysis with the identified key parameters of the process step. Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products,  starting  materials  and  reagents  have  been  presented.  The  characterisation  of  the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterisation. Batch analysis data show that the active substance can be manufactured reproducibly.

## Specification

Macitentan specification includes tests and limits for appearance (visual), colour (visual), clarity and  colour  of  solution  (Ph.  Eur.),  identification  (IR,  HPLC),  sulphated  ash  (Ph.  Eur.),  heavy metals (Ph. Eur.), water content (Ph. Eur.), residual solvents (GC), related substances (HPLC), assay (HPLC), particle size distribution (laser light diffraction) and microbial purity (Ph. Eur.).

Potential  impurities  that  could  be  present  in  the  starting  material  are  either  controlled  in  the starting material itself or in the intermediate. Potential genotoxic impurities were evaluated for genotoxic concern by in silico QSAR analyses for those showing genotoxic alerts. The results of these analyses showed no concern. The potential genotoxicity of the starting material has been further investigated and was found negative in a full Ames test.  The calculated TTC is 150ppm (10mg daily dose), however the starting material was not detected in the last two campaigns. Since the starting  material  was  found  negative  in  the  Ames  test,  negative  results  from  the in silico genotoxicity  predictions  on  its  impurities  are  enough  to  consider  them  too  as  nongenotoxic. Therefore, no routine controls below the TTC value are deemed necessary for these two impurities on the starting material or on the active substance.

Overall, the discussion on the potential genotoxic impurities is considered sufficient. The limits for impurities are in line with European Guidance (NfG on impurities - ICH topic Q3A (R2).

The  analytical  methods  used  have  been  adequately  described  and  appropriately  validated  in accordance with the ICH guidelines.

Batch analysis results are provided for three registration batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability

The stability of macitentan active substance was investigated on three registration batches under accelerated (40 °C / 75% RH) and long-term (30 °C / 65% RH) storage conditions.

Stability data of another three clinical batches were produced by the same manufacturer using the same route of synthesis as the registration batches were also presented as supportive data.

<div style=\"page-break-after: always\"></div>

During stability testing the following characteristics are tested: appearance, colour, clarity and colour of a solution, water, assay, related substances, microbial quality (not routinely tested), and  particle  size  distribution  (not  routinely  tested).  All  analytical  methods  were  the  same  as those used at release; they were shown to be stability indicating.

After storage for six months at 40 °C / 75% RH and 48 months at 30 °C / 65% RH, no change in the physical and chemical characteristics was observed.

Photostability  testing  (forced  degradation  testing  according  ICH  Q1B)  was  carried  out  on  one batch  in  line  with  the  relevant  Guideline  ICH  Topic  Q1B  Photostability  Testing  of  New  Active Substances and Medicinal Products. A confirmatory photostability study was performed on one recent batch. The results were consistent with those obtained from the initial studies and show macitentan is stable to light  in  the  solid  state  but  degradation  was  observed  in  solution  in  all solvents tested. The method is considered stability indicating.

Overall, the stability data support the proposed retest period and storage conditions.

## 2.2.3. Finished Medicinal Product

## Pharmaceutical Development

Prior to the initiation of formulation development studies, an excipient compatibility study with the active substance was performed. It was concluded that all excipients investigated could be used for further development. The selected excipients are well-known for use in pharmaceutical products and are commonly used excipients in film-coated tablet formulations.

A  capsule  formulation  in  different  strengths  was  initially  developed  to  provide  dose  flexibility. This  formulation  was  used  in  early  Phase  1  studies  as  well  as  in  one  Phase  2  study.  For  the formulation and manufacturing process development the physicochemical properties of the active substance were taken into account. A tablet formulation was developed from the capsule and was  optimised  with  regard  to  the  effect  of  key  formulation  attributes  on  stability  and  tablet characteristics.    The  dissolution  profiles  of  10 mg  capsule  and  10 mg  film-coated  tablets  were compared  and  were  found  equivalent.  In  addition,  a  clinical  pharmacology  comparison  study between macitentan 10 mg capsules and macitentan 10 mg film-coated tablets was performed in healthy  subjects.  The  study  showed  that  the  PK  of  macitentan  and  its  active  metabolite  were comparable  for  the  two  formulations.  Given  that  the  intended  use  is  a  chronic,  multiple-dose regimen, the minor difference found in Cmax of macitentan between the two formulations was not considered relevant. The results adequately supported comparability of data obtained with the two formulations and that no dose adaptation was needed when switching from the capsule to the tablet formulation in the development of the product. The film-coated tablets were therefore used in clinical Phases 1, 2 and 3.

The dissolution method has been shown to be discriminatory with regard to the factors that can vary  during  manufacture  and  are  likely  to  or  have  shown  to  affect  the  performance  and  with regard to distinguishing tablets which have been exposed to accelerated or inappropriate storage conditions.

According to ICH Q6A guideline, the specification for solid oral dosage forms normally includes a test  to  measure  the  release  of  active  substance  from  the  finished  product.  According  to  the decision  tree  #7(1),  a  single-point  dissolution  acceptance  criterion  with  a  lower  limit  was included in the specifications for Opsumit.

<div style=\"page-break-after: always\"></div>

Following  the  selection  of  the  wet  granulation  method  the  process  has  been  optimised  with regard to the granulation parameters  and  the tablet characteristics.  The  manufacturing parameters  were  further  adapted  as  appropriate  for  the  equipment  intended  for  full-scale manufacture at proposed site for commercial manufacture. The process used is not associated to conditions  that  could  generate  a  conversion  of  the  desired  polymorphic  form    of  the  active substance into other polymorphs.

## Adventitious agents

The manufacturing processes of neither the active substance nor the finished product involve any materials of human or animal origin apart from lactose, which fulfils the necessary requirements. It is confirmed that the lactose is produced from milk from healthy animals in the same condition as  those  used  to  collect  milk  for  human  consumption  and  that  the  lactose  has  been  prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on  Minimising  the  Risk  of  Transmitting  Animal  Spongiform  Encephalopathy  Agents  Via  Human and veterinary medicinal products.

## Manufacture of the product

The  manufacture  of  macitentan  film-coated  tablets  involves  conventional  wet  granulation  and coating processes. No critical steps were identified. However, suitable in-process controls have been  introduced  at  each  manufacturingstep  to  ensure  reproducible  quality  for  the  finished product.  The  manufacturing  process  is  adequately  described  and  as  it  is  considered  to  be  a standard  process,  validation  data  do  not  have  to  be  incorporated  in  the  dossier  before registration. A  satisfactory process  validation  protocol  has  been  submitted.  The  process validation  at  commercial  scale  will  be  performed  by  the  proposed  manufacturer  prior  to marketing the product.

## Product specification

The finished product release specifications include appropriate tests for appearance and colour (visual), identification (HPLC and IR), water content (Ph. Eur.), tablet mass (gravimetry), assay (HPLC), content uniformity (Ph. Eur.), degradation products (HPLC), dissolution (Ph. Eur.) and microbiological quality (Ph. Eur.).

Analytical  methods  used  have  been  adequately  described  and  appropriately  validated  in accordance with the ICH guidelines.

Batch analysis results are submitted for three registration batches. The batch analysis data are within the set specification limits and show that Opsumit film-coated tablets can be manufactured reproducibly.

## Stability of the product

The stability of Opsumit 10 mg film-coated tablets was investigated in three registration batches stored  in  the  both  proposed  blister  and  bottle  packaging  intended  for  the  market  under accelerated (40°C ±2°C / 75% ±5% RH) and long term conditions (25°C ±2°C / 60% ±5% RH

<div style=\"page-break-after: always\"></div>

and 30°C ±2°C / 75% ±5%RH). All relevant characteristics such as appearance, colour, average mass  of  10  tablets,  water  content,  content,  dissolution,  degradation  products  and  microbial quality were determined. The HPLC methods used are identical to those used for the release and have been shown to be stability indicating.

Up to 18 months data were available and no significant changes of the physical, chemical and pharmaceutical characteristics were observed.  A slight increase of the level of the main degradation product is observed after three months at 40 °C/ 75% RH. However under long term conditions  no  significant  changes  of  the  physical,  chemical  and  pharmaceutical  characteristics were observed.

In addition, up to 60 months supportive stability data were presented from the clinical batches. These batches were produced by a different manufacturer but have the same composition and the same manufacturing process as the registration batches. The composition of the commercial film-coated tablets is also the same as the ones used in clinical studies. The blister of the clinical batches was different to that of the registration ones.

A comparison was performed between the stability data from the clinical and registration batches for  each  packaging  configuration  (bottle,  blister)  and  storage  condition.  The  main  quality attributes susceptible to change during stability , i.e., assay, amount of degradation product and dissolution, were evaluated. No significant change in the dissolution rate is observed for either the  clinical  or  the  registration  batches  packed  into  blisters.  Results  with  regard  to  the degradation between the clinical and the registration batches are similar.

In-use  stability  testing  has  been  conducted  on  one  Opsumit  registration  batch  in  bottles. Appearance of the tablets, assay, related substances as well as dissolution were evaluated. All methods used are the same as the analytical methods used at release. For all parameters tested, no significant difference is observed.

Photostability  has  been  investigated  on  one  registration  batch  in  accordance  with  ICH  Q1B guideline.  During  photostability  testing  the  following  characteristics  were  tested:  appearance, colour, content and degradation products. All methods were the same as the analytical methods used at release and the results were evaluated against the current specifications. No significant differences  could  be  observed  between  the  samples  exposed  to  intense  light  and  the  control samples.  No  increase  in  related  substances  was  observed  in  any  of  the  samples.  Therefore, Opsumit film-coated tablets can be considered as photostable and thus in accordance with the ICH Q1B guideline it is not necessary to store the finished product protected from light.

Overall, the stability data support the proposed shelf life and storage conditions.

<div style=\"page-break-after: always\"></div>

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information  on  development,  manufacture  and  control  of  the  active  substance  has  been presented  in  a  satisfactory  manner.  Development  of  the  finished  product  had  to  take  into account  the  particular  characteristics  of  the  active  substance.  The  choice  of  formulation,  of excipients  and  the  manufacturing  process  has  been  justified.  The  results  of  tests  carried  out indicate  consistency  and  uniformity  of  important  product  quality  characteristics,  and  these  in turn lead to the conclusion that the product should have a satisfactory and uniform performance in the clinic.

## 2.2.5. Conclusions  on  the  chemical,  pharmaceutical  and  biological aspects

The quality of this product is considered to be acceptable when used in accordance with the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendation for future quality development

Not applicable.

## 2.3. Non-clinical aspects

The nonclinical safety program for macitentan includes studies on general toxicity, carcinogenicity, reproductive toxicity, juvenile toxicity, mutagenicity, and phototoxicity, as well as safety pharmacology. The testing strategy was primarily based on the ICH M3 guideline and other applicable ICH nonclinical safety guidelines.

## 2.3.1. Pharmacology

## Primary pharmacodynamic studies

In vitro pharmacology assays show that macitentan is able to inhibit the binding of endothelin-1 (ET-1) to its receptors endothelin A (ETA) and endothelin B (ETB), to inhibit ETA or ETB receptormediated  functional  responses  as  intracellular  accumulation  of  Ca  and  IP1  and  ET-1  induced contraction  of  isolated  tissues  (rat  aorta  and  trachea).  However,  the  free  therapeutic  plasma concentrations  of  macitentan  (2.5  nM)  is  in  the  range  of  the  concentration  that  causes  50% inhibition (IC50) and Kb values for the ETA receptor (IC50=0.5 nM, Kb=0.81 nM), but it is lower than  the  values  for  the  ETB  receptor  (IC50=391  nM,  Kb=128  nM).  Since  macitentan  is  highly bound to plasma protein, the Kb and IC50 for ETB receptor were calculated based on the unbound fraction  of  macitentan  in  the  culture  medium.  The  values  (IC50=13  nM,  Kb=24  nM)  are  also higher than the free plasma concentrations of macitentan in PAH patients treated with 10 mg of macitentan. Therefore, based on in vitro studies macitentan can be regarded as an ERA that is approximately 100-fold more selective for ETA as compared to ETB.  On the other hand, plasma ET-1  concentration,  a  marker  of  ETB  blockade,  was  increased  in  animals  and  humans  after treatment with macitentan, indicating that ETB receptor is inhibited by macitentan in vivo .

<div style=\"page-break-after: always\"></div>

Macitentan has relatively slow dissociation kinetics, when compared to other products in its class (ambrisentan  and  bosentan).  This  results  in  a  prolonged  receptor  occupancy.  The  slow dissociation  of  macitentan  from  the  receptors  leads  to  an  inhibition  that  is  insurmountable  to (high  levels  of)  ET-1  when  macitentan  concentrations  are  &gt;1-10  nM,  which  is  below  clinical plasma levels. In vivo pharmacodynamics studies were conducted in rats. The pharmacodynamic effects of macitentan have been investigated in normal rats and in rat disease models in which ET-1 plays a pathological role.

Macitentan  reduced  systemic  arterial  blood  pressure  only  in  rat  models  of  hypertension associated with an increased expression of ET-1 (DOCA-salt and Dahl salt-sensitive rats) but not in  healthy  (normotensive)  rats  (with  no  activation  of  the  ET  system).  The  duration  of  this response depended on the dose. The data indicate that macitentan exhibits a sustained duration of action when compared to ambrisentan and bosentan. The slow release of macitentan from the receptor  and  the  fact  that  increases  in  ET-1  concentration  do  not  result  in  displacement  of macitentan  from  the  receptor,  as  well  as  the  formation  of  an  active  metabolite,  ACT-132577 (M6), with a relatively long half-life time might all contribute to this difference. The dose at which maximal  effect  of  macitentan  treatment  was  observed  varied  somewhat  between  studies, however at 10 mg/kg maximal or almost maximal effects were seen. At this dose Cmax and AUC in the rat are within the range of those in humans receiving 10 mg.

Two  circulating  macitentan  metabolites  have  been  identified  in  humans:  ACT-132577  (active metabolite M6) and ACT-373898 (inactive metabolite on endothelin receptors M5). ACT-132577 is approximately 8-fold less potent than macitentan on ETA and 2-fold less potent on ETB. Similar to macitentan, the free therapeutic plasma concentrations of ACT-132577 (7.4 nM) is lower than the IC50 and Kb values for the ETB (IC50 total=987 nM, Kb total=319 nM, IC50 free=94 nM, Kb free=139 nM). Based on the high exposure, and prolonged half-life this metabolite most likely contributes to the in vivo efficacy of macitentan treatment.

The dependence of a hemodynamic effect following macitentan treatment on activation of the ET-system as seen in rat models of hypertension is also seen in humans. Also in humans, the clinical efficacy of macitentan is dependent on local ET system activation as 10  mg macitentan/day  decreases  blood  pressure  in  patients  with  essential  hypertension  but  not  in healthy subjects.

In  dogs,  macitentan  treatment  did  result  in  reduction  in  systemic  blood  pressure  (see  safety pharmacology). It thus appears that dogs are more sensitive than humans, and rats may be a better predictive model for effects of macitentan on blood pressure.

Repeated oral administration of macitentan was not associated with tachyphylaxis and cessation of treatment did not result in a rebound effect. Macitentan was able to further decrease blood pressure  when  given  on  top  of  the  other  ET  receptor  antagonists  (bosentan  or  ambrisentan). Conversely, these compounds were not able to cause additional blood pressure reduction when given on top of macitentan.

In animal models of pulmonary hypertension (monocrotaline-induced and the bleomycin-induced rat models) macitentan reduced pulmonary arterial pressure, pulmonary arterial wall thickness, right ventricular hypertrophy and increased survival. The first clear effect on mean (5 minutes) pulmonary artery pressure (mPAP) was generally seen at a dose of 1 mg/kg and the (almost) maximal  effect  at  10  mg/kg,  which  is  similar  to  the  effective  doses  found  in  the  systemic

<div style=\"page-break-after: always\"></div>

hypertension rat models. A further increase in dose did not result in significant additional effect, only in the duration of the effect. In none of the in vivo studies heart rate was affected.

## Secondary pharmacodynamic studies

Only one secondary pharmacodynamics study was provided showing that macitentan did not bind to a panel of 63 receptors and enzymes. No unexpected risks have been identified in animal or clinical  studies. Therefore further non-clinical studies on additional pharmacological targets are not deemed necessary.

Safety pharmacology programme

Potential  safety  pharmacology  effects  were  evaluated  on  central  nervous  system,  respiratory function and the cardiovascular system.

The only observation was a decrease in arterial blood pressure in dogs at all tested doses. This effect was not observed in healthy rats, but more importantly also not in humans.

Combined treatment of macitentan with a PDE5 inhibitor (sildenafil or tadalafil) induced additive effects on maximal blood pressure reduction and synergistic effects on the extent and duration (ABC) of mean arterial pressure reduction in hypertensive rats.

## 2.3.2. Pharmacokinetics

The pharmacokinetic and metabolic profiles of macitentan have been characterized in rats and dogs.

The analytical method to measure the plasma concentrations of macitentan and its metabolites ACT-132577 (M6, active) and ACT-373898 (M5, inactive), independently or in combination, were validated using LC-MS/MS. Stability of macitentan and ACT-132577 in plasma was demonstrated for at least 1 year and stability of ACT-373898 was demonstrated for up to 2 years.

In  vitro  data  showed  that  macitentan  permeates  rapidly  through  membranes  and  is  not  a substrate of human P-gp. Macitentan was absorbed slowly after oral dosing in the rat, whereas peak plasma concentrations were reached 2 h post-dose in dog.

Oral bioavailability was about 80% in the dog and about 30% in the rat, which increased to 89% at higher doses. After IV administration, macitentan showed a low plasma clearance in rat and dog. The volume of distribution was 1-2 L/kg in rats and about 1 L/kg in dogs, which indicates reasonable  distribution  into  tissues.  Exposure  to  macitentan  increased  dose-proportionally following IV administration in rat and dog and after oral administration in dog.

Following oral administration in rat, exposure increased more than proportionally between 1 and 30 mg/kg. This non-proportional behaviour may be caused by saturation of metabolic clearance. Non-linearity was not observed in humans and therefore this finding seems of limited relevance.

Particle  size  had  a  significant  effect  on  macitentan  exposure  indicating  drug  dissolution  in  the gastrointestinal tract as a limiting factor for oral absorption. Macitentan has an active circulating metabolite, ACT-132577, which has comparable pharmacokinetic properties as macitentan. Only systemic plasma clearance was lower than macitentan, resulting in a longer half-life. Following

<div style=\"page-break-after: always\"></div>

repeated doses, the exposure to macitentan and the metabolite ACT-132577 increased less than dose-proportionally in mice, rats and dogs. There was no plasma accumulation of macitentan or ACT-132577 observed. In contrast, a decrease in the systemic exposure of macitentan and ACT132577  was  observed  in  rat  and  dog.  This  effect  can  be  explained  by  auto-induction  of macitentan metabolism in rat and dog, while auto-induction in mouse was not exhibited. Autoinduction is not expected in humans.

Binding to plasma proteins is high in all species examined for macitentan (&gt;99%), and for the metabolites  ACT-132577  (98.3-99.9%)  and  ACT-373898  (91.0-98.5%).  Partitioning  of  either macitentan or ACT-132577 into red blood cells was limited in any of the species investigated. Drug-related radioactivity distributed into most tissues within 2 hours after oral administration. Highest tissue concentrations were  measured  in  liver, kidney, plasma,  blood  and  lung. Macitentan-related  radioactivity  also  distributed  into  the  brain,  although  to  a  limited  extent (tissue-plasma  ratio:  0.02-0.06).  After  7  days,  drug-related  radioactivity  was  still  observed  in half  of  the  tissues  examined,  suggesting  some  accumulation  in  these  organs  when  using macitentan daily.

Extensive in  vitro metabolism  was  observed  resulting  in  one  major  metabolite  ACT-132577 retaining pharmacological activity. No human specific metabolites were observed in vitro . In both the pre-clinical species (rat and dog) and humans macitentan is extensively metabolised before excretion. The applicant investigated the biotransformation pattern in plasma, urine, and faeces of  rat,  dog  and  humans  and  in  bile  of  rat  and  dog.  Data  from  the  excreta  indicate  that  the biotransformation  pattern  could  be  different  between  the  non-clinical  species  and  humans. However, as macitentan and its two circulating metabolites ACT-132577 and ACT-373898  were present  in  rat  and  dog  in  comparable  or  higher  absolute  amounts  than  in  humans,  they  are adequately covered in the animal toxicity programme.

The predominant route of elimination of drug-related radioactivity was via feces in rats and dogs (67-81%) independent of the route of administration. The recovery of the majority of the dose in feces  suggests  biliary  elimination  as  the  major  route  of  excretion.  [ 14 C]Macitentan-derived material  was  excreted  in  milk  of  rats.  Concentrations  of  radioactivity  in  milk  were  below  the plasma concentrations until 48 hours post-dose. However, 96 hours post-dose the milk-plasma ratio was 2.0.

The interactions of macitentan and its major human metabolite ACT-132577 with a panel of drug transporters  (P-gp,  OATPB1,  OATPB3,  OCT1,  OCT2,  OAT1,  OAT3,  BSEP,  NCTP,  MATE-1  and MATE-2) have been studied in order to investigate potential drug-drug interactions. Macitentan (but  not  ACT-132577)  could  be  an  inhibitor  of  drug  transporter  BCRP  at  clinically  relevant intestinal concentrations.

Macitentan  and  its  metabolites  ACT-080803  (M3)  and  ACT-132577  (M6)  are  not  inducers  of CYP3A4 at clinically relevant concentrations.

Macitentan has four primary metabolic pathways. Oxidative depropylation of the sulfamide yields the  pharmacologically  active  metabolite  ACT-132577.  This  reaction  is  dependent  on  the cytochrome  P450  system,  mainly  CYP3A4  (approximately  99%)  with  minor  contributions  of CYP2C8, CYP2C9 and CYP2C19. Other metabolic pathways yield products without pharmacological activity.  Several  members of the CYP2C  family, namely  CYP2C8, CYP2C9 and CYP2C19, as well as CYP3A4, are involved in the formation of these metabolites .

<div style=\"page-break-after: always\"></div>

Potentially  drugs  that  are  inhibitors  of  CYP3A4  could  have  an  effect  on  the  metabolism  of macitentan  and  thus  could  lead  to  drug-drug  interactions.  Multiple  clinical  studies  were performed  regarding  potential  drug-drug  interactions  with  other  drugs  (warfarin,  sildenafil, ketoconazole, rifampicin, and cyclosporin).  (see clinical section).

No clinically relevant interactions were observed for macitentan and its active metabolite M6 with drugs that are inhibitors of CYP3A4. However, concomitant treatment with rifampicin, a potent inducer of CYP3A4, reduced the steady-state exposure to macitentan by 79% but did not affect the exposure to the active metabolite. Reduced efficacy of macitentan in the presence of a potent inducer of CYP3A4 such as rifampicin should be considered.

## 2.3.3. Toxicology

Mice  and  rats  were  used  for  the  single  dose  toxicity  studies  and  mice,  rats  and  dogs  for  the repeated-dose toxicity studies.  Rats and rabbits were used for the reproductive toxicity studies, and  rats  and  mice  for  the  carcinogenicity  studies.  In  mice,  rats  and  rabbits,  macitentan  was administered orally by gavage whereas dogs received drug-containing capsules. Impurities and metabolites  were  toxicologically  qualified  in  these  studies  and  in  the  in  vitro  and  in  vivo genotoxicity studies.

## Single dose toxicity

Single doses of up to 2000 mg/kg by oral gavage in mouse and rat indicate that macitentan has low potential for acute toxicity. Mice showed transient overt symptoms including ptosis and/or slightly  subdued  behaviour  during  the  first  hour  after  administration,  whereas  rats  showed  no remarkable findings.

## Repeat dose toxicity

Repeat-dose  toxicity  studies  with  macitentan  were  performed  by  oral  administration  for  time intervals  up  to  13  weeks  in  mice,  26  weeks  in  rats,  and  up  to  39  weeks  in  dogs.  The pharmacodynamic target and the major pathways of macitentan metabolism in humans were all represented in these species. Thus the choice of mice, rats, and dogs was appropriate for the toxicity  evaluation  of  macitentan.  In  addition,  a  two-week  study  was  performed  in  rabbits  to establish suitable dosages for the pilot embryo-fetal toxicity studies in this species.

Safety margins or exposure margins were calculated based on combined exposure to macitentan and the pharmacologically active metabolite ACT-132577 in males and females. Male rats were less exposed to the drug after treatment with the same doses than females.

Macitentan  was  well  tolerated  from  chronic  treatment  up  to  relatively  high  dose  levels.  Drugrelated mortality was observed in the 13-week toxicity study in male Wistar rats after 2 weeks of treatment at 1500 mg/kg/day. Prolonged clotting times led to excessive bleeding and mortality.

In the 4-week dog toxicity study at 500 mg/kg/day, one dog died due to drug-related anorexia. The mortality rate increased in the carcinogenicity studies at 400 mg/kg/day in female mice and at 250 mg/kg/day in female rats after approximately 1 year of treatment. A cause of death could not be established.

<div style=\"page-break-after: always\"></div>

Overt  symptoms were limited  to  the  high  doses  and  included  occasional  breathing  difficulties, piloerection, coldness, unsteady gait and subdued behaviour in mice, hunched posture, prostrate position,  laboured  respiration,  coldness  of  limbs;  haemorrhages  in  rats,  and  decreased  food consumption, reduced activity; subdued behaviour; and a rise in body temperature in dogs. In rabbits, there was a severe reduction in body weight and food consumption and a concomitant treatment-related morbidity, but the low dose of 25 mg/kg/day was well tolerated.

In  the  mouse, rat, and dog toxicity studies, the heart, liver, and testes were identified as the main organs affected by treatment with macitentan. Minor or secondary changes were observed in RBC, the haemostatic system, thyroid, kidney, uterus, ovary and nasal cavity.

Arterial intimal thickening characterized by proliferation of the intimal layer was found in dogs treated with macitentan at doses ≥30 mg/kg/day, independently of the treatment duration. The right and, less often, the left coronary arteries were the preferred target. These findings were often associated with breaks of the internal elastic lamina. After subacute (4-week) treatment with doses higher than 50 mg/kg/day, atrial fibrosis with chronic inflammation, epicarditis, and neovascularization were also observed. Thus, the cardiac NOEL was established at 5 mg/kg/day in all three studies, providing an acceptable safety margin (&gt;5.8) to maximal human exposure at 10 mg/day.

Public literature suggests that the observed coronary arteriopathy is a class effect of endothelin receptor antagonists in dogs. I n vivo studies described in the pharmacology section show that macitentan decreases arterial blood pressure in dogs in a dose-dependent manner. As result of exaggerated pharmacology on ETA receptors (inhibition of vasoconstriction), marked hypotension, sustained vasodilatation in the coronary vascular bed and reflex tachycardia may alter  flow  dynamics  and  lead  to  increased  shear  stress  and  tension  on  the  coronary  wall  with subsequent microscopic trauma. Although the effect of macitentan on the heart rate is limited in dogs, provided literature suggests that the dog is a species particularly sensitive to hemodynamic changes and related coronary vascular and myocardial effects. Coronary and myocardial lesions were not observed in rats or mice. Clinically, data regarding MACE and ECG do not raise any concerns regarding the long term cardiovascular safety of macitentan.

The effects on the liver included increased weight and centrilobular hypertrophy. These findings are considered to be an adaptation to the increased metabolic demand and enzyme induction by macitentan. The increased incidence of hepatodiaphragmatic herniation observed only after 104 weeks  of  treatment  in  rats  was  considered  to  be  related  to  the  induced  life-long  liver hypertrophy.

In  mice,  focal  hepatocellular  necrosis  and  increased  plasma  levels  of  the  liver  enzymes  (AST, ALT) were observed in dose-range finding studies of 2- and 13-weeks' duration performed for the mouse carcinogenicity study. These findings were associated with bile duct proliferation and gall bladder hyperplasia, accumulation of pigmented macrophages and granulocytic infiltration. The necrotic  foci  and  the  associated  inflammatory  reaction  in  the  liver  were  in  some  cases accompanied by increased polymorphonuclear leukocyte counts in lymph nodes and increased granulopoiesis in the bone marrow.

A  dose-range  finding  study  in  B6C3F1-mice  revealed  that  CD-1  are  more  susceptible  to hepatocellular necrosis than B6C3F1 mice.

<div style=\"page-break-after: always\"></div>

The slightly decreased concentrations of albumin, cholesterol, bilirubin and/or urea and increased concentrations of triglyceride in plasma further point to a slightly decreased liver function.

In  vitro cytotoxicity  studies  in  mouse  and  human  liver  slices  did  not  measure  mitochondrial toxicity  and  only  found  cytotoxicity  at  concentrations  far  above  the in  vivo concentration  at clinical therapeutic dose in humans. Thus, the liver toxicity found in the repeated dose studies can be explained by indirect mechanisms and therefore does not provide specific evidence for mitochondrial toxicity.

Bosentan but not ambrisentan inhibited human hepatic transporters, which have been discussed as  a  potential  mechanism  for  the  increased  hepatotoxicity  observed  for  this  agent  in  humans. However, macitentan and metabolite M6 are not expected to interfere with hepatic and bile salt transport.

Drug-related  effects  on  the  male  reproductive  system  were  identified  in  rats  and  dogs.  The alterations found included dilation of seminiferous tubules, tubular degeneration and hypospermatogenesis.  The  NOAELs  for  dilation  of  seminiferous  tubules  in  rats  were  50 mg/kg/day (8.2 fold the exposure in patients treated with 10 mg/day of macitentan) in the 13week toxicity study, 250 mg/kg/day (11.6 fold the exposure in patients treated with 10 mg/day of macitentan) in 26-week rat toxicity studies and it was not determined, but it is lower than 10 mg/kg/day (4.2 fold the exposure in patients treated with 10 mg/day of macitentan) in the 104weeks  carcinogenicity  study.  These  findings  suggest  that  the  testicular  risk  increases  after chronic treatment. In the 39-week dog toxicity study, the NOEL was established at 5 mg/kg/day (5.8 fold the exposure in patients treated with 10 mg/day of macitentan). Seminology showed an increased percentage of morphologically abnormal sperm at 50 and 250 mg/kg/day, only in the 26-week rat study (NOEL was 10 mg/kg/day, 2.3 fold the exposure in patients). It is difficult to assess the clinical relevance of hypospermatogenesis  and  tubular degeneration  because individual cases have been reported in different rats and dogs studies, including animals from control  groups.  The  chronic  treatment  also  induced  an  increase  in  the  prostate  weight  at  250 mg/kg/day (NOEL was 50 mg/kg/day, 8.2 fold the exposure in patients treated with 10 mg/day of macitentan) in rats. Adverse effects induced by macitentan in rat male reproductive organs were reversible.

Haematological alterations as decreased haematocrit, RBC count and haemoglobin and increased WBC and platelet were observed in different mice, rat and dog toxicity studies. The changes were minimal, found at doses that indicate acceptable safety margins for humans (8.2 in rats, 5.8 in male dogs and 17 in female dogs) and reversible.

A prolonged aPTT was observed in male rats treated with 250 mg/kg/day during 13 or 26 weeks. The finding is considered to have limited relevance to humans as it was observed only at high dose levels that provide safety margins higher than 7, in only one species and only in males.

The observed increased thyroid weight, possibly a reflection of follicular cell hypertrophy, seems to be a secondary effect of drug-metabolizing enzyme induction in the liver. A similar effect has also been reported with bosentan, which is also an inducer of P450 enzymes.. A benign follicular cell adenoma was recorded for the thyroid of one male rat and a cystic follicular hyperplasia for one female rat treated with high doses of macitentan. Although both these findings can be seen as  a  spontaneous  background  change,  an  association  with  the  treatment-related  follicular  cell hypertrophy  cannot  be  excluded.  A  treatment-related  altered  thyroid  function  (mild  thyroid

<div style=\"page-break-after: always\"></div>

hormone imbalance in male rats) has been reported for bosentan, but not for ambrisentan. Thus far, there is no evidence of bosentan affecting thyroid function (thyroxin, TSH) in humans.

The kidney was also affected by macitentan in Wistar rats. Treatment longer than 13 weeks at ≥50  mg/kg/day  induced  an  increase  in  male  kidney  weights  Treatment  during  26  weeks increased the incidence of hyaline/pigment droplets in males at ≥ 50 mg/kg/day and in females at  250  mg/kg/day.  The  alterations  were  reversible  and  the  NOEL  for  kidney  damage  was established  at  10  mg/kg/day  (2.3  fold  the  exposure  in  patients  treated  with  10  mg/day  of macitentan).

An  increased  incidence  of  endometrial  cysts  in  the  uterus,  associated  with  increased  uterus weights, was observed in the mouse carcinogenicity study at ≥100 mg/kg/day providing a safety margin of 46, and in the rat carcinogenicity study at all doses tested. However, uterine cysts in senescent rats are considered of limited clinical relevance because the mechanism leading to this finding may be due to specific rat hormonal changes induced by macitentan.

Additionally, angiomatous change in the rat ovaries was found at the highest dose (250/50 mg/kg/day) tested. The NOAEL for the ovary effects was established at 50/25 mg/kg/day, 13.4 fold the exposure level in humans treated with 10 mg of macitentan.

Finally,  proliferation  of  nasal  mucosa  and  increased  incidence  of  inflammatory  infiltration  were seen in nasal cavities in mouse carcinogenicity study at all dose levels. Hyaline inclusions and increased  secretion  were  found  at  doses  ≥  30  mg/kg/day.  Similar  effects  on  the  nasal  cavity have also been observed in animals treated other ERAs. However, nonclinical data macitentan do not indicate a higher risk with macitentan than with ambrisentan, bosentan or sitaxentan, based on the number of affected species, the time of onset and severity of nasal cavity findings.

## Genotoxicity

The  genotoxic  potential  of  macitentan  was  evaluated  using  a  conventional  battery  of  tests: genetic mutation in bacteria and in L5178Y mouse lymphoma cells, chromosomal aberration in human lymphocytes and rat micronucleus in vivo. All in vitro and in vivo tests were performed according to the ICH requirements (CHMP/ICH/126642/08. Guidance on Genotoxicity Testing and Data  Interpretation  for  Pharmaceuticals  intended  for  Human  use  (ICH  S  2  (R1))  and  resulted negative. Thus, it can be concluded that macitentan is not genotoxic.

The  metabolite  of  macitentan  ACT-373898  (M5)  and  the  impurity  ACT-080803  (degradation product in the active substance) are not mutagenic.

## Carcinogenicity

No oncogenic potential was evident in mice or rats after 104 weeks of treatment with macitentan at doses that provide a safety margin for carcinogenicity ≥ 20.

The combination of reproductive and developmental toxicity studies allowed evaluating all states advised in the ICH S5 guideline.

<div style=\"page-break-after: always\"></div>

## Reproduction Toxicity

The  NOEL  for  male  and  female  fertility  and  early  embryonic  development  in  rats  was  250 mg/kg/day. However, the observed effects of macitentan on testes (tubular dilatation, tubular atrophy  and  hypospermatogenesis)  during  long-term  treatment  could  affect  the  reproduction. Testes  were  also  target  organs  of  macitentan  in  the  offspring  (F1)  of  females  treated  during pregnancy and lactation and in juvenile treated animals. In both studies, the fertility was also affected. Additionally, testicular toxicity has not been adequately assessed in clinical trials. Thus, effects of macitentan on male human fertility cannot be excluded.

Macitentan showed clear dose-dependent teratogenic effects in rats and rabbits. In both species there  were  cardiovascular  and  mandibular  arch  fusion  abnormalities.  The  observed  effects  are class  effects  of  ET  receptor  antagonists.  A  NOEL  for  embryo-fetal  development  was  not established. In line with other ERAs, a pregnancy contraindication is included in the SmPC.

Pharmacokinetic  studies  in  rats  have  shown  that  macitentan  is  excreted  into  milk.  Therefore, macitentan, like other ERAs, is also contraindicated during breast-feeding.

## Other toxicity studies

The juvenile toxicity study did not show new target organ toxicity as compared to adult animals but juvenile animals are more sensitive to macitentan than adults. Effects on development and on reproductive variables were found at doses that suppose an exposure level 6.7 and 3.8 fold, respectively,  the  levels  reached  in  humans  treated  with  10  mg/day  of  macitentan.  Risk  for human development and reproduction cannot be discarded.

All  impurities  which  were  present  in  former  batches  and  the  proposed  specification  of  future batches of macitentan are regarded as appropriately qualified.

In  an  in  vitro  system  using  Balb/c  3T3  fibroblast  cell  cultures,  macitentan  exhibited  weak phototoxicity  at  high  concentrations.  An  in  vivo  study  in  hairless  rats  showed  no  phototoxic effects up to the high dose level of 60 mg/kg/day corresponding 24-fold the human exposure at 10 mg per day. It can be concluded that there is no relevant risk of phototoxicity for patients treated with macitentan at 10 mg per day.

## 2.3.4. Ecotoxicity/environmental risk assessment

The MAH submitted information related to the environmental risk assessment. After review of the data,  the  CHMP  considered  the  need  to  perform  Log  Know  determination  using  a  different method.

As a result of the above considerations, the available data do not allow to conclude definitively on the potential risk of macitentan to the environment.

In  the  context  of  the  obligation  of  the  MAH  to  take  due  account  of  technical  and  scientific progress, the CHMP recommends the following points for further investigation:

<div style=\"page-break-after: always\"></div>

The  applicant  has  agreed  with  the  recommendation  to  perform  a  log  Kow  determination  for macitentan, according to the slow stirring method (OECD 123).

## 2.3.5. Discussion on non-clinical aspects

Macitentan  has  been  developed  as  an  oral  therapy  for  the  long-term  treatment  of  pulmonary arterial hypertension (PAH). Pulmonary Arterial Hypertension (PAH) is a chronic and progressive disease  of  the  small  pulmonary  arteries  that  is  characterised  by  vascular  proliferation  and remodelling. It results in increased pulmonary artery pressure and pulmonary vascular resistance and, ultimately, right ventricular heart failure and death. Although the pathogenesis of PAH is not completely  understood,  it  likely  involves  an  imbalance  in  the  normal  relationships  between vasodilators  and  vasoconstrictors,  growth  inhibitors  and  mitogenic  factors,  and  antithrombotic and prothrombotic determinants that are probably consequences of pulmonary endothelial cell dysfunction and/or injury.

Macitentan  is  able  to  block  the  binding  of  ET-1  to  ETA  and  ETB  receptor.  Although  the pathophysiology  of  PAH  is  not  fully  understood,  ET-1  and  its  receptors  ETA  and  ETB  are  upregulated in PAH, are considered mediators of the pathological changes leading to the disease and  are  targets  for  currently  available  PAH-specific  therapies.  Therefore,  the  development  of Opsumit in the treatment of PAH is justified from a mechanistic perspective.

The pharmacological studies provided by the applicant support that macitentan is an inhibitor of ETA and ETB receptors and it inhibits the effects mediated by these receptors, as intracellular accumulation of Ca and IP1 and induced contraction of isolated tissues (rat aorta and trachea). However, the free therapeutic plasma concentrations of macitentan (2.5 nM) and ACT-132577 (M6) (7.4 nM) are lower than the IC50 and Kb values for the ETB receptor. Thus, based on in vitro data macitentan can be regarded as an ERA that is approximately 100-fold more selective for ETA  as  compared  to  ETB. On  the  other  hand,  plasma  ET-1  concentration,  a  marker  of  ETB blockade, was increased in animals and humans after treatment with macitentan, indicating that ETB receptor is inhibited by macitentan in vivo .

Efficacy of macitentan was demonstrated in animal models of systemic hypertension, pulmonary hypertension and pulmonary fibrosis. Comparative efficacy studies have shown that macitentan could  provide  a  therapeutic  advantage  over  the  currently  available  therapies  bosentan  and ambrisentan.

The metabolite ACT-132577 is also active. It is approximately 8-fold less potent than macitentan on ETA and 2-fold less potent on ETB, and it may contribute to the overall pharmacological effect of macitentan in vivo .

Safety pharmacology studies did not revealed any adverse neurobehavioral or respiratory effects.

Arterial intimal thickening characterized by proliferation of the intimal layer was found in dogs treated with macitentan at doses ≥30 mg/kg/day, independently of the treatment duration. In vitro and in  vivo studies  show  that  macitentan  decreases  arterial  blood  pressure  in  dogs  in  a dose-dependent  manner.  The  effect  of  macitentan  on  blood  pressure  is  limited  to  dogs,  and provided  literature  suggests  that  the  dog  is  a  species  particularly  sensitive  to  hemodynamic changes and related coronary vascular and myocardial effects. Coronary and myocardial lesions

<div style=\"page-break-after: always\"></div>

were not observed in rats or mice. Clinically, data regarding MACE and ECG do not raise any concerns regarding the long term cardiovascular safety of macitentan.

Combined treatment of macitentan with phosphodiesterase 5 inhibitor (sildenafil) increased the duration  of  blood  pressure-lowering  effect  induced  by  the  monotheraphy  in  hypertensive  rats. Other relevant pharmacodynamic drug interactions have been monitored in the clinical setting, and therefore additional non-clinical studies are not warranted.

The pharmacokinetic and metabolic profile of macitentan was characterized in the rat and the dog.

Macitentan metabolism in rats and dogs shows large similarities to the pattern observed in man and all human metabolites were present in animals, supporting the relevance of these species for the preclinical  safety  program of macitentan, although data from the excreta indicate that the biotransformation pattern could be different between the non-clinical species.

The primary metabolism of macitentan is catalyzed by P450 enzymes, mainly by CYP3A4 with contributions of CYP2C8, CYP2C9 and CYP2C19.

The  potential  interactions  of  macitentan  and  its  major  human  metabolite  M6  with  a  panel  of transporter (P-gp, OATPB1, OATPB3, OCT1, OCT2, OAT1, OAT3, BSEP, NCTP, MATE-1 and MATE2) have been studied in order to characterize potential drug-drug interactions. Macitentan (but not  ACT-132577)  could  be  an  inhibitor  of  BCRP  at  clinically  relevant  intestinal  concentrations. Macitentan  and  its  metabolites  ACT-080803  and  ACT-132577  are  not  inducers  of  CYP3A4  at clinically relevant concentrations.

Macitentan  passed  into  the  milk  of  lactating  rats.  Therefore,  macitentan  is  contraindicated  in lactation.

Macitentan was well tolerated from chronic treatment up to relatively high dose levels.

In  the  mouse, rat, and dog toxicity studies, the heart, liver, and testes were identified as the main organs affected by treatment with macitentan. Minor or secondary changes were observed in RBC, the hemostatic system, thyroid, uterus, kidney and nasal cavity. The clinical relevance of testicular findings (tubular dilation, tubular atrophy and hypospermatogenesis) is unknown and a potential risk for male fertility cannot be discarded based on these animal studies.

There were no evidences of genotoxic and carcinogenic potential associated with macitentan.

Macitentan showed clear dose-dependent teratogenic effects in rats and rabbits. In both species there were cardiovascular and mandibular arch fusion abnormalities. The observed effects are to be class effect of ET receptor antagonists. In line with other ERAs, a pregnancy contraindication is included in the SmPC.

The juvenile toxicity study did not show new target organ toxicity as compared to adult animals but  juvenile  animals  are  more  sensitive  to  macitentan  than  adults.  The  SmPC  in  section  5.3 provides adequate information related to the juvenile toxicity findings.

The MAH submitted information related to the environmental risk assessment. After review of the data, the CHMP considered the need to perform Log Kow determination using a different method.

<div style=\"page-break-after: always\"></div>

As a result of the above considerations, the available data do not allow to conclude definitively on the potential risk of macitentan to the environment.

In  the  context  of  the  obligation  of  the  MAH  to  take  due  account  of  technical  and  scientific progress, the CHMP recommends the following points for further investigation:

The  applicant  has  accepted  the  recommendation  to  perform  a  log  Kow  determination  for macitentan, according to the slow stirring method (OECD 123).

## 2.3.6. Conclusion on non-clinical aspects

From  a  non-clinical  point  of  view,  Opsumit  would  be  recommended  for  approval.  The  SmPC appropriately reflects the non clinical data submitted with macitentan.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

A  routine  inspection  has  been  conducted  for  the  pivotal  study  SERAPHIN,  at  two  Clinical Investigator sites in Mexico (19-22 February, 2013) and China (19-22 March 2013), and at the Sponsor site (Actelion) in Switzerland (8-12 April 2013). The final Integrated Inspection Report (IIR) ( INS/GCP/2012/027; EMEA/H/C/002697) is dated on 15 May 2013.

The inspectors' conclusion is that the study has been conducted in compliance with GCP at the sites and that the study report can be used for evaluation and assessment of the application.

- Tabular overview of clinical pharmacology studies

Table O-PK-01. Completed clinical pharmacology studies

| Study                            | Characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Single-ascending dose AC-055-101 | Objectives: Investigation of the PK, PD, safety and tolerability of macitentan in male subjects. Enrolled: 56 healthy subjects Evaluable PK: 42 macitentan-treated subjects. Evaluable PD & safety: 56 subjects (42 on macitentan, 14 on placebo). Demographics: Male; Caucasian; Age: 19-49 years; Weight: 55.4-98.0 kg; BMI: 19.4-27.8 kg/m2. Treatments: Single oral capsule dose; Macitentan (6 subjects/group): 0.2, 1, 5, 25, 100, 300, 600 mg; Placebo (2 subjects/group). Design: single-ascending dose placebo-controlled, double-blind. |

<div style=\"page-break-after: always\"></div>

| Study                                                      | Characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Multiple-ascending dose AC-055-102                         | Objectives: Investigation of the PK, PD, safety and tolerability of macitentan in male subjects. Enrolled: 32 healthy subjects; Evaluable PK: 24 macitentan-treated subjects. Evaluable PD & safety: 32 subjects (24 on macitentan, 8 on placebo). Demographics: Male; Caucasian; Age: 20-50 years; Weight: 58.2-97.4 kg; BMI: 19.6-28.0 kg/m2. Treatments: Once daily oral, capsule dose for 10 days; Macitentan (6 subjects/group): 1, 3, 10, 30 mg; Placebo (2 subjects/group). Design: Multiple-ascending dose, placebo-controlled, double-blind. |
| Tablet-capsule biocomparison study AC-055-108              | Objectives: Biocomparison of tablet and capsule formulations of macitentan in healthy male subjects. Safety and tolerability. Enrolled: 12 healthy subjects. Evaluable PK: 11 subjects. Evaluable safety: 12 subjects. Demographics: Male; Caucasian, 10 subjects; Hispanic, 1 subject; Black, 1 subject. Age: 20-44 years; Weight: 66.0- 78.0 kg; BMI: 19.5-27.0 kg/m2. Treatment A: Single oral, macitentan 10 mg, tablet. Treatment B: Single oral, macitentan 10 mg, capsule. Design: Open-label, 2-way crossover.                                |
| Absorption, distribution, metabolism, excretion AC-055-104 | and Objectives: Investigation of the mass balance, PK, metabolism and safety in healthy male subjects. Enrolled and Evaluable (PK & safety): 6 healthy subjects. Demographics: Male; Caucasian; Age: 47-62 years; Weight: 68.8-88.1 kg; BMI: 24.7-27.4 kg/m2. Treatments: Single oral, 14C-macitentan 10 mg capsule. Design: Open-label.                                                                                                                                                                                                              |
| Effect of food intake AC-055-103                           | Objectives: Investigation of the effect of food on the PK of macitentan in male subjects. Safety and tolerability. Enrolled and Evaluable (PK & safety): 10 healthy subjects. Demographics: Male; Caucasian; Age: 26-36 years; Weight: 62.1-97.4 kg; BMI: 20.5-27.3 kg/m2. Treatments: Single oral, macitentan 10 mg capsule on 2 occasions. Design: Open-label, 2-way cross-over, single dose (once in fed state and once in fasted state).                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Study                                                                              | Characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Macitentan-warfarin Drug-drug interaction AC-055-105                               | Objectives: Investigation of the effect of macitentan on the PK and PD of warfarin in healthy male subjects. Safety and tolerability. Enrolled: 14 healthy subjects. Evaluable PK & PD: 12 macitentan-treated subjects (excluded 2 macitentan-treated subjects: 1 did not receive warfarin dose in one administration during treatment A; 1 did not receive Treatment B). Evaluable safety: 14 macitentan-treated subjects (Treatment A), 13 subjects (Treatment B). Demographics: Male; Caucasian; Age: 24-45 years; Weight: 60.7-89.4 kg; BMI: 20.1-26.6 kg/m2. Treatment A: Oral macitentan, capsule. 30 mg o.d. (Day 1), 10 mg o.d. (Days 2-8). Concomitant oral warfarin 25 mg (Day 4). Treatment B: Single oral warfarin, dose 25 mg (Day 1). |
| Macitentan-sildenafil Drug-drug interaction AC-055-106                             | Design: Open-label, 2-way, crossover. Objectives: Evaluation of PK interactions between macitentan and sildenafil in healthy male subjects. Safety and tolerability. Enrolled and Evaluable (PK & safety): 12 healthy subjects. Demographics: Male; Caucasian, 10 subjects; Asian, 2 subjects; Age: 20-33 years; Weight: 70-86 kg; BMI: 20.9-28.1 kg/m2. Treatments: Treatment A: Oral macitentan capsule. 30 mg o.d. (Day 1), 10 mg (Days 2-4). Treatment B: Oral sildenafil, 20 mg t.i.d. (Days 1-3). Single 20 mg dose (Day 4). Treatment C: Oral macitentan 30 mg o.d. (Day 1), 10 mg o.d. (Days 2-4). Concomitant sildenafil 20 mg t.i.d. (Days 1- 3). Single 20 mg dose (Day 4). Design: Open-label, 3-way crossover.                         |
| Macitentan- ketoconazole Drug- drug interaction AC-055-107                         | Objectives: Investigation of the effect of ketoconazole on the PK of macitentan in healthy male subjects. Safety and tolerability. Enrolled: 12 healthy subjects. Evaluable PK: 10 macitentan-treated subjects. Evaluable safety: 10 macitentan-treated subjects (Treatment A), 11 macitentan-treated Subjects (Treatment B). Demographics: Male, Caucasian; Age range: 22-38 years; Weight: 63.0-85.5 kg; BMI: 19.0-28.4 kg/m2. Treatment A: Single oral macitentan 10 mg capsule dose. Treatment B: Ketoconazole 400 mg o.d. for 24 days. Concomitant single oral macitentan 10 mg dose (Day 5).                                                                                                                                                  |
| Macitentan- cyclosporine, macitentan- rifampicin Drug- drug interaction AC-055-111 | Design: Open-label, 2-way crossover Objectives: Investigation of the effects of cyclosporine and rifampicin on the PK of macitentan in healthy male subjects. Enrolled and Evaluable (PK & safety): Part A: 10 healthy subjects; Part B: 10 healthy subjects. Demographics: Part A: Male, Caucasian; Age range: 18-40 years; Weight range: 55.0-85.0 kg; BMI range: 18.1-26.5 kg/m2. Part B: Male, Caucasian; Age range: 20-44 years; Weight range: 61.0-83.0 kg; BMI range: 21.3-25.1 kg/m2. Treatments:                                                                                                                                                                                                                                           |
| Ethnic sensitivity study AC-055-109                                                | Design: Open-label, 2-part, 1-sequence crossover. Objectives: Investigation of the PK, safety and tolerability of macitentan in healthy Japanese and Caucasian subjects. Enrolled and Evaluable (PK & safety): 20 healthy subjects. Demographics: Japanese (10 subjects); 5 male, 5 female; Age: 21-32 years; Weight: 49.4-62.9 kg; BMI: 19.4-23.6 kg/m2. Caucasian (10 subjects); 5 male, 5 female; Age: 19-44 years; Weight: 50.9-66.7 kg; BMI: 19.1-22.5 kg/m2. Treatments: Single oral, macitentan 10 mg tablet. Design: Open-label, parallel group.                                                                                                                                                                                            |
| Hepatic impairment AC-055-110                                                      | Objectives: Investigation of the PK, safety and tolerability of macitentan in subjects with mild, moderate, or severe hepatic impairment due to liver cirrhosis. Enrolled: 32 subjects; Evaluable PK: 31 subjects; Evaluable safety: 32 subjects. 24 subjects with hepatic impairment [8 mild (Child-Pugh A), 8 moderate (Child-Pugh B), 8 severe (Child-Pugh C)] and 8 healthy subjects. Demographics: Sex: 20 male; 12 female; Ethnicity: Caucasian; Age range: 34-66 years; Weight range: 62.0-106.0 kg; BMI range: 20.0-31.9 kg/m2. Treatments: Single oral macitentan 10 mg tablet.                                                                                                                                                            |
| Renal impairment AC-055-112                                                        | Design: Open-label, parallel group. Objectives: Investigation of the PK in patients with impaired renal function. Safety and tolerability. Enrolled and Evaluable (PK and safety): 8 patients with severe renal impairment, 8 healthy subjects. Demographics: 8 subjects with severe renal impairment (creatinine clearance range: 16.1-29.0 mL/min), 8 healthy subjects (creatinine clearance range: 89.9-107.4 mL/min); 8 male, 8 female; Caucasian; Age: 36-60 years; Weight: 63.0-90.4 kg; BMI: 22.2-31.1 kg/m2. Treatments: Single oral macitentan 10 mg tablet. Design: Open-label, parallel group                                                                                                                                            |
| Spermatogenesis AC-055-113                                                         | Objectives: Investigation of the effect of macitentan on spermatogenesis, sperm quality and serum hormone concentrations of the hypothalamus-pituitary-adrenal and gonadal axes. PK, safety and tolerability. Enrolled: 84 healthy subjects. Evaluable testicular safety & other safety variables: All 84 subjects. Evaluable PK: 65 subjects. Demographics: Male; Caucasian (56), Black (25), other (3); Age: 18-44 years; Weight: 51.0-110.2 kg; BMI: 18.3-30.0                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

b.i.d. = twice daily; BMI = body mass index; o.d. = once daily; PD = pharmacodynamic; PK = pharmacokinetic; t.i.d. = three times daily.

| Study                        | Characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | Treatments: Once daily oral macitentan 10 mg tablet or placebo for 12 weeks. Design: Double-blind, placebo-controlled, parallel group.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Thorough QT study AC-055-114 | Objectives: Investigation of the effect of repeated daily doses of 10 mg and 30 mg macitentan on the QT/QTc interval in healthy male and female subjects. Enrolled: 64 healthy subjects. Evaluable PK: 62 subjects (Treatments A-D). Evaluable safety (cardiodynamic): 64 subjects (Treatments A-B), 63 subjects (Treatments C-D). Evaluable PK/cardiodynamic: 62 subjects (Treatments A-D). Demographics: 26 male, 38 female; Caucasian, 63 subjects; Hispanic, 1 subject; Age: 23-55 years; Weight: 50.1-98.5 kg; BMI: 19.1-28.0 kg/m2. Treatments: Oral macitentan tablet. Treatment A: 8-day o.d. placebo, matching macitentan with single (open-label) moxifloxacin 400 mg (Day 8). Treatment B: 8-day o.d. macitentan 10 mg. Treatment C: 8-day o.d. macitentan 30 mg. Treatment D: 8-day o.d. placebo matching macitentan. Design: Double-blind, double-dummy, placebo-controlled, 4-way crossover, with open-label. Active comparator. |

b = Study conducted in patients.

a = Ongoing study, will not be completed at data cut-off for regulatory filing

Macitentan has been studied in an adequate program of pharmacology studies, which provide comprehensive information on pharmacokinetic (PK) and metabolism, effects of intrinsic factors and  concomitant  use  of  other  drugs,  and  important  pharmacodynamic  (PD)  characteristics.  A total  of  14  completed  clinical  pharmacology  studies  are  included  in  the  application.  A brief summary is provided in Table O-PK-01. Additional relevant PK/PD information that is discussed in this section was generated in study AC-055-201 in patients with essential hypertension (Study AC-055-201) and in a PK/PD sub-studies to the pivotal Phase 3 study AC-055-302 SERAPHIN (study AC-055-302) and its open-label extension AC-055-303 SERAPHIN OL.

Two  formulations  of  macitentan  were  used  in  clinical  studies,  a  capsule  formulation  for  early clinical development and a film-coated tablet formulation, which was used in a number of Phase 1 studies, in the Phase 2 study in IPF, and in the pivotal Phase 3 study in PAH. The film-coated tablet formulation used in the confirmatory clinical study (SERAPHIN) is identical to the to-bemarketed formulation.

## 2.4.2. Pharmacokinetics

Macitentan has been studied in a total of 14 completed clinical pharmacology studies. Additional relevant  PK/PD  information  was  generated  in  study  AC-055-201  in  patients  with  essential hypertension and in a PK/PD sub-studies of the pivotal Phase 3 study AC-055-302 SERAPHIN and its open-label extension AC-055-303 SERAPHIN OL .

Concentrations  of  macitentan  and  its  active  metabolite  ACT-132577  in  human  plasma  were determined  using  liquid  chromatography  coupled  to  tandem  mass  spectrometry  method  (LCMS/MS). All analyses  were performed in the same laboratory and during the studies a partial validation  was  performed,  mainly  by  analysing  quality  samples.  In  the  studies  after  2009 incurred samples analysis was performed. The studied PK parameters (Cmax, tmax, t1/2, AUC0-t, and AUC0-∞) as well as statistical methods are the usual ones in PK studies and are considered appropriate.

<div style=\"page-break-after: always\"></div>

## Bioequivalence between tablets and capsules (study AC-055-108)

The MAH performed an open label two-way cross-over tablet-capsule biocomparison study (AC055-108)  aiming  at  comparing  the  film-coated  tablets  (intended  to-be-marketed  formulation) and  capsule  formulations  (used  in  early  clinical  development  and  the  Phase  II  study  in hypertension) in 12 healthy subjects.

Maximum plasma concentrations of the film-coated tablets (intended to-be-marketed formulation, used in a number of Phase 1 studies, in the Phase 2 study in IPF, and in the pivotal Phase 3 SERAPHIN study in PAH) were slightly lower (19%)  than capsules (used in early clinical development and the Phase II study in hypertension). However, the relative difference in AUC is small  (ranging  between  5%  to7%),  and  the  corresponding  90%  CI  for  AUC  falls  within bioequivalence  limits. Therefore, results  of  PK  studies  conducted  with  capsules  may  be extrapolated to tablets.

## Absorption

## Bioavailability

The absolute bioavailability of macitentan could not be established, as the development of an i.v. formulation  was  not  technically  feasible.  Maximum  plasma  concentrations  of  macitentan  are achieved about 8 hours after oral administration. Thereafter, plasma concentrations of macitentan  and  its  active  metabolite  decrease  slowly,  with  apparent  elimination  half-lives  of approximately 16 hours and 48 hours, respectively (Table O-PK-02 and Figure O-PK-01).

Table  O-PK-02.  Study  AC-055-101:  Plasma  PK  parameters  of  macitentan  in  healthy subjects after administration of a single dose of 0.2, 1, 5, 25, 100, 300, or 600 mg

| Treatment   | N   | Cmax (mg/ml)      | tmax (E)   | AUC0-48 (mg.h/ml)        | AUCo-t (ng.h/ml)                        | AUC0-∞ (ng.h/ml)          | tn (h)            |
|-------------|-----|-------------------|------------|--------------------------|-----------------------------------------|---------------------------|-------------------|
| 0.2mg       | 6   | 4.0 (2.6, 6.2)    | 8 (8-12)   | 85.9 (52.4, 141)         | NC*                                     | NC                        | NC                |
| 1mg         | 6   | 17.9 (12.4, 25.9) | 8 (4-10)   | 439 (271, 711)           | NC*                                     | NC                        | NC                |
| 5 mg        | 6   | 93.4 (79.1, 110)  | 8 (4-8)    | 2056 (1855,2278)         | NC*                                     | NC                        | NC                |
| 25mg        | 6   | 335 (264, 425)    | 8 (430)    | 8810 (7412, 10,472)      | NC*                                     | NC                        | NC                |
| 100mg       | 6   | 666 (643, 1552)   | 8 (4-12)   | 25,281 (18,775,34,040)   | NC*                                     | NC                        | NC                |
| 300 mg      | 6   | (1409, 2422) 1847 | (10-48) 30 | 67,109                   | (48,751,92,380)(76,088,136,783) 102,017 | (76,650, 103,007 138,428) | (14.1, 21.8) 17.5 |
| 600 mg      | 5** | 2967 (2233,3943)  | 12 (8-30)  | (70,006, 96,530 133,102) | 126,882 (82.617,194.865)                | (82,657, 127,104 195,450) | 13.4 (11.3, 15.9) |

AUCo-4s = area under plasma concentration-time curve from 0 to 48 h after drug administration; AUCo- = area under plasmaconcentration-timecurvefromzerototimetofthelastmeasuredconcentrationabovethelimitofquanification; AUCo-. = area undertheplasmaconcentration-timecurvef from zero to infinity; CI = confidence interval; Cmax = maximum plasma concentration; N = number of subjects; NC = not calculated; ti/2 = terminal half-life; tmax = time to reach maximum plasma concentration.

Data are geometric means (and 95% CI) or for tmax the median (and range).

*AUCo-t equals AUCo-4s for these dose groups.

** For 1 subject, no reliable estimate of ti/2 could be determined. Source:vanGiersbergen2005aTable6.

<div style=\"page-break-after: always\"></div>

Figure O-PK-01. Study AC-055-101: Mean plasma concentration versus time profiles of macitentan and ACT-132577 in healthy subjects (n = 6 per group) after administration of a single macitentan dose of 0.2, 1, 5, 25, 100, 300, or 600 mg

<!-- image -->

Source:vanGiersbergen2005aFigure1

## Influence of food (study AC-055-103)

In healthy subjects, the exposure to macitentan and its active metabolite was unchanged in the presence of food and, therefore, macitentan is proposed to be taken with or without food. The breakfast  that  was  provided  followed  the  FDA  guidance  for  Food-Effect  Bioavailability  and  Fed Bioequivalence Studies.

## Distribution

Macitentan and ACT-132577 are well distributed into tissues as indicated by an apparent volume of  distribution  (Vss/F)  of  approximately  50  L  and  40  L  for  macitentan  and  ACT-132577, respectively  (Study  AD-055-101).  Macitentan  and  its  active  metabolite  are  highly  bound  to plasma proteins (&gt;99%), primarily to albumin (Study B-04.025).

## Metabolism

Macitentan  undergoes  biotransformation  by  hydroxylation,  with  the  CYP3A4  isoenzyme  as  the major  contributor  (Studies  B-04.022,  B-04.093  and  B-04.099).  Two  circulating  macitentan metabolites have been identified in humans: ACT-132577 (active metabolite) and ACT-373898 (inactive metabolite). ACT-132577 is approximately 8-fold less potent than macitentan on ETA and  2-fold  less  potent  on  ETB.  The  main  metabolite  is  ACT-132577  (active  M6),  present  at approximately 71% of total drug exposure in plasma. No particularly relevant consequences of polymorphism in CYP3A4 are expected.

## Elimination

The  major  excretion  route  of  macitentan  in  humans,  in  the  form  of  metabolites,  is  via  urine, accounting for about 50% of the dose (four metabolites, with the metabolite M323u as the most abundant one), while approximately 24% of the administered dose was recovered in faeces (five metabolites, with the metabolite ACT-080803 M5 the most abundant one) (study AC-055-104). Neither unchanged macitentan nor the active metabolite ACT-132577 were recovered in urine.

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

After  repeated administration, the pharmacokinetics of macitentan are dose-proportional up to and  including  30 mg  (study  AC-055-102).  In  healthy  subjects,  the  accumulation  factor  for macitentan  was  1.4-1.7  when  comparing  the  AUC0-24  on  Days  1  and  10.  The  expected accumulation of the active metabolite ACT-132577 based on the half-life was approximately 3.5. However, the accumulation found in healthy subjects after repeated dosing was relatively large, 7-10 times (study AC-055-102). The applicant has clarified that the differences in accumulation ratio of the metabolite ACT132577 based on half-life and the accumulation found in  vivo after repeated  dosing  are  due  to  differences  in  equations  applied.  In  patients,  no  trend  for  timedependency was noted (study AC-055-302). Inter-subject variability was low in healthy subjects and moderate in patients.

## PK in the target population

Based on trough concentrations, exposure to macitentan in patients with PAH (study  AC-055302) was approximately 2-fold greater than in healthy subjects ((study AC-055-102) or patients with  essential  hypertension  (Table  O-PK-03).  ACT-132577  trough  plasma  concentrations  were higher in patients with PAH and essential hypertension (Study AC-055-201) when compared to healthy subjects treated with 10 mg macitentan (study AC-055-102).

Table  O-PK-03.  Studies  AC-055-302,  AC-055-201:  Summary  statistics  of  macitentan and ACT-132577 trough plasma concentrations (ng/mL)

|            | AC-055-302(PAH)   | AC-055-302(PAH)   | AC-055-302(PAH)   | AC-055-302(PAH)   | AC-055-201 (essential hypertension)   | AC-055-201 (essential hypertension)   | AC-055-201 (essential hypertension)   | AC-055-201 (essential hypertension)   |
|------------|-------------------|-------------------|-------------------|-------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|            | Mfacitentan       | Mfacitentan       | AC T-132577       | AC T-132577       | Nfacitentan                           | Nfacitentan                           | ACT-132577                            | ACT-132577                            |
| Dose group | Mfonth 6          | EOT               | Mfonth 6          | EOT               | Week 4                                | WWeelk 8                              | Week 4                                | Week 8                                |
| 3mg n.     | 49                | 142               | 49                | 142               | 46                                    | 39                                    | 46                                    | 39                                    |
| mean.      | 92.1              | 76.4              | 253.0             | 309.6             | 65.3                                  | 67.3                                  | 237.9                                 | 246.5                                 |
| SD         | 52.6              | 61.4              | 103.8             | 175.3             | 39.1                                  | 34.8                                  | 128.4                                 | 122.0                                 |
| CV96       | 57.1              | 80.4              | 41.0              | 56.6              |                                       |                                       |                                       |                                       |
| median     | 068               | 61.0              | 251.0             | 294.0             |                                       |                                       |                                       |                                       |
| min        |                   |                   |                   |                   | 0.0                                   | 0.0                                   | 0.0                                   | 00                                    |
| max        |                   |                   |                   |                   | 176                                   | 132                                   | 762                                   | 509                                   |
| 10mg       | 41                | 154               | 41                | 154               | 48                                    | 44                                    | 48                                    | 44                                    |
| mean       | 291.5             | 208.2             | 837.4             | 842.6             | 164.3                                 | 170.9                                 | 727.9                                 | 805.0                                 |
| SD         | 155.2             | 138.7             | 328.2             | 413.1             | 108.4                                 | 85.6                                  | 383.1                                 | 273.9                                 |
| CV%        | 53.3              | 66.6              | 39.2              | 49.0              |                                       |                                       |                                       |                                       |
| median     | 276.0             | 200.0             | 822.0             | 857.5             |                                       |                                       |                                       |                                       |
| min        |                   |                   |                   |                   | 0.0                                   | 0.0                                   | 0.0                                   | 2.3                                   |
| max        |                   |                   |                   |                   | 462                                   | 384                                   | 1600                                  | 1330                                  |

CT = Coefficientof vanatiom: EOT end-of-treatment, mumber 10 patients: PAH = pulmonary arterial hypertension; SD = standard deviation.

Source: D-12.473 Tables 5, 6, 9, and 10.

Table O-PK-04. Study AC-055-102: Summary statistics of macitentan and ACT-132577 trough plasma concentrations (ng/ml) on Day 10

|            | Healthy subjects   | Healthy subjects   |
|------------|--------------------|--------------------|
| Dose group | MIacitentan        | ACT-132577         |
| 3mg        |                    |                    |
| n          | 6                  | 6                  |
| meam       | 51.8               | 214                |
| SD         | 22.2               | 92.7               |
| mmin.      | 25.6               | 151                |
| max        | 87.9               | 399                |
| 10 mg      |                    |                    |
|            | 6                  | 6                  |
| meam       | 131                | 585                |
| SD         | 34.3               | 132                |
| mmin.      | 96.7               | 412                |
|            | 184                | 747                |

n=mumberofsubjects;SD=standarddeviation

Souuce:D-06.044 Tables21and22

<div style=\"page-break-after: always\"></div>

A  PK  sub-study  within  study  AC-055-303  (SERAPHIN-OL),  the  open-label  extension  to  the SERAPHIN  study,  was  undertaken  to  allow  a  more  precise  dose  selection  for  clinical  trials  in children and was recently clinically completed. For this, 20 patients from the SERAPHIN-OL study were confined to the clinic for 24 hours, during which samples for a PK profile evaluation were taken, thus allowing for determination of Cmax and AUCτ of macitentan and ACT-132577. The findings  indicated  that  plasma  exposure  to  macitentan  and  its  active  metabolite  ACT-132577, measured over a 24 h dosing interval, were increased by approximately 10-30% between PAH patients and healthy subjects. These findings are reflected in the SmPC.

## Special populations

## Renal impairment (Study AC-055-112)

The relative increase in exposure to macitentan and the active metabolite observed in patients with severely impaired renal function (24% and 58% higher than those in healthy subjects) was below that achieved at the highest well-tolerated macitentan dose of 300 mg reported in the SAD study  (AC-055-101).  There  was  an  8-fold  increase  in  the  exposure  to  the  inactive  metabolite ACT-373898,  which  is  expected  not  to  be  of  clinical  relevance,  based  on  available  data  in animals.  However,  the  clinical  significance  in  humans  is  unknown.  In  addition,  no  data  are available in PAH patients with severe renal impairment.

## Hepatic impairment (Study AC-055-110)

Overall, the exposure to macitentan and its active metabolite is decreased by 20% in patients with  hepatic  impairment,  without  differences  according  to  the  degree  of  impairment.  The differences in other PK parameters between hepatically impaired and normal subjects are even more irrelevant. Therefore, no dose-adjustment in hepatic impairment is deemed necessary. It is possible that the PK of a drug differs between a hepatically impaired subject population and a healthy  population  treated  concomitantly  with  a  strong  CYP3A4  inhibitor.  On  the  basis  of  the hepatic impairment study AC-055-110, the applicant hypothesises that the decrease in intrinsic hepatic clearance due to a decrease in enzyme-capacity is compensated by the increase in the unbound fraction leading to an unchanged hepatic drug clearance.

## Gender

Females tend to have a longer t1/2 and higher plasma through concentration for both macitentan and ACT-132577, leading to differences in exposure when compared to males (Study AC-055109). However, the small difference observed could be confounded by body-weight differences (female subjects had a body weight 12% lower than that of the male subjects).

## Race

There  were  no  large  differences  between  the  races  involved  in  the  studies  with  this  product. Japanese subjects tend to have lower exposures to macitentan  and  ACT-132577  than Caucasians, although the 15% relative difference seems not to be of clinical relevance (Study AC-055-109).  Therefore,  it  can  be  concluded  that  the  different  races  do  not  show  clinically relevant differences in the pharmacokinetics of macitentan.

<div style=\"page-break-after: always\"></div>

## Weight

Analysis  by  weight  category  (&lt;  50  kg,  50-99  kg,  and  &gt;  100  kg)  did  not  indicate  a  clinically relevant effect of weight on exposure to macitentan at Month 6 or EOT. A decrease of trough plasma concentrations of ACT-132577 with weight was suggested in the 10 mg dose group at Month 6, but this observation could have been driven by the limited number of patients with a weight above 100 kg.

## Elderly

The number of elderly patients included in the clinical development of macitentan is provided in table  below.  In  the  14  dedicated  PK  studies,  no  subjects  &gt;  65  were  included.  The  PK  studies were  performed  in  a  healthy  subject  population  and  the  upper  allowed  age  limit  for  inclusion varied  between  45  and  65  years  of  age.  The  SmPC  reflects  that  there  is  limited  clinical experience in patients over the age of 75 years, and therefore macitentan should be used with caution in this population (see also 'PK in the target population').

Table  O-PK-05.  Number  of  elderly  patients  included  in  the  clinical  development programme of macitentan

|                                 |   Age 65-74 |   75-84 |   Age 85+ |
|---------------------------------|-------------|---------|-----------|
| PK Trials                       |           0 |       0 |         0 |
| ControlledTrials AC-055-201     |          44 |      10 |         0 |
| AC-055A201                      |          57 |      11 |         0 |
| AC-055-302                      |          48 |      12 |         0 |
| Non-controlledTrials AC-055-303 |          60 |      24 |         1 |

## Children:

Twenty  patients  between  the  ages  of  12  and  &lt;  18  years  were  enrolled  in  SERAPHIN study. Characterisation  of  PK  could  not  be  performed.  Additional  data  would  be  needed  in  order  to support paediatric use (Refer to the clinical efficacy and safety part).

## Pharmacokinetic interaction studies

## Drug-drug interactions

in vitro studies showed that the metabolism of macitentan to its active metabolite is catalysed by CYP3A4  and  to  a  minor  extent  by  CYP2C19  (Studies  B-04.022,  B-04.093  and  B-04.099). Macitentan and its active metabolite were neither a substrate nor an inhibitor of CYP isoenzymes, multi-drug resistance protein (P-gp, MDR-1),  or  organic anion transporting polypeptides (OATP1B1 and OATP1B3), and did not interact with proteins involved in hepatic bile salt transport (i.e. BSEP, NTCP). In vivo DDI studies with warfarin (study AC-055-105), sildenafil (study AC055-106)  and  cyclosporine  (study AC-055-111)  showed  no  relevant  PK  interaction  with macitentan. In addition, there was a 2-fold increase in macitentan exposure with concomitant ketoconazole,  a  strong  CYP3A4  inhibitor  (Study  AC-055-107)  and  a  decrease  by  79%  in macitentan exposure with concomitant rifampicin, a potent inducer of CYP3A4 (Study AC-055111). However, ketoconazole was only administered once daily dose and therefore the inhibitory effect  is  not  considered  to  represent  a  worst-case  scenario  due  to  the  short  half-life  of ketoconazole  in  comparison  to  macitentan.  In  post-hoc  analyses,  the  predicted  increase  was

<div style=\"page-break-after: always\"></div>

approximately 3.0-fold in the presence of ketoconazole 200 mg twice daily using physiologically based pharmacokinetic (PBPK) modelling.

No  specific  drug-drug  interaction  studies  with  hormonal  contraceptives  have  been  conducted. However, the lack of interaction with sildenafil indicates that no clinically relevant pharmacokinetic  interactions  between  macitentan  and  other  CYP3A4  substrates  would  occur. Overall, macitentan seems to have a low potential for interactions with other medicinal products.

## Exposure relevant for safety information

In dose-ascending studies conducted in healthy subjects (Studies AC-055-101 and 102), dosedependent increases in the incidence of AEs were observed, with headache the most frequently reported adverse event.

The relationship  between exposure (trough plasma concentrations) and safety in PAH patients was characterized using a logistic regression model (PK/PD Modelling Report AC-055-302) based on  the  data  from  study  AC-055-302  (SERAPHIN).  However,  for  adverse  events,  only  the relationship between exposure and AEs leading to study drug discontinuation was explored. Only a  small  number  of  patients  had  an  AE  leading  to  study  drug  discontinuation  (n  =  26)  in  this analysis.  On  the  other  hand,  there  was  an  inverse  relationship  between  macitentan  trough plasma concentrations and changes in hematocrit and haemoglobin levels, but no concentrationdependent  impact  on  changes  in  liver  function  tests  could  be  established.  Post-hoc  logistic regression  models  were  applied  to  explore  the  relationship  between  exposure  and  treatmentrelated AEs. The median macitentan trough concentrations in the 3 mg and 10 mg dose groups (89 and 276 ng/mL) predicted increases in the probability to have an AE of anaemia from 1.77% (placebo subjects) to 2.09% and 2.96%, respectively. No trend was observed for infrequent AEs (n&lt;30  for  the  SMQs  teratogenicity,  thrombocytopenia,  leucopenia,  menstrual  disorder,  and ovarian cysts) or for hepatic events (n = 86).

## 2.4.3. Pharmacodynamics

## Mechanism of action

Macitentan  is  an  orally  active  potent  endothelin  receptor  antagonist,  approximately  100-fold more selective for ETA as compared to ETB (refer to the non-clinical part).

## Primary and Secondary pharmacology

## Primary pharmacology

Binding of an ERA to ETB receptors causes an increase in plasma ET-1 levels, which can be used as a marker of pharmacological effect and potency on the ETB receptor. This effect of ERAs is of rapid onset. A dose-related effect of macitentan to increase plasma ET-1 levels was demonstrated in nonclinical in vivo studies, as well as after a single dose in humans (study AC055-101) (Figure O-PD-01).

<div style=\"page-break-after: always\"></div>

Figure PD-01. Study AC-055-101: Effect of macitentan on plasma ET-1 concentrations.

225

<!-- image -->

EachbarrepresentsthearithmeticmeanandSD.N=6forthedifferentmacitentandosesand14fortheplacebogroup.

*p&lt;0.o5whencomparedtoplacebo. AUC0-4S= areaundertheplasmaconcentration-time curvefromtime 0to48hafterdrugadministration; ET-1=endothelin-1;SD=standarddeviation Source:vanGiersbergen2o05aFigure3.

In  the  multiple-ascending  dose  study  in  healthy  subjects  (study  AC-055-102),  plasma  ET-1 concentrations  at  steady-state  showed  a  dose-dependent  increase,  with  no  further  increase beyond the 10 mg OD dose (Figure O-PD-02), indicating full receptor blockade at this dose level.

Figure O-PD-02. Study AC-055-102: Effect of macitentan on plasma ET-1 concentrations

<!-- image -->

Eachbar andSD.N=6forthedifferent andN=8fortheplacebo group

0.05whencom toplacebo (derivedbyexploratorystatisticalanalyses) AUC0-24 area under the cuve from tine to 24hafterdrug ET-1=endothelin-1;SD standarddeviation Source:D-06.044Figure5

Macitentan  has  a  circulating  active  metabolite  (ACT-132577)  that  is  also  a  dual  ERA,  is  on average  approximately  5-fold  less  potent  than  macitentan,  and  may  contribute  to  the  clinical effect.

## Secondary pharmacology

## Thorough TQT study (AC-055-114)

A Thorough QT study AC-055-114 was conducted to investigate the effect of repeated daily doses of  10  mg and 30 mg macitentan on the QT/QTc interval in healthy male and female subjects. This  was  a  double-blind,  double-dummy,  placebo-controlled,  4-way  crossover,  with  open-label with moxifloxacin as active comparator. 64 healthy subjects were enrolled.

The  results  demonstrate  that  macitentan  did  not  affect  cardiac  repolarization  in  nonclinical studies or in a thorough TQT study.

<div style=\"page-break-after: always\"></div>

Figure  O-PD-03.  Study  AC-055-114:  Baseline-adjusted,  placebo-corrected  mean  QTcF and 90% CI over time, 30 mg macitentan.

<!-- image -->

TreatmentC:30mgmacitentan;CI=confidenceinterval

Baselinedefinedastime-matchedvalueonDay1pre-dose.

Source:D-12.322Figure4.

## Testicular safety (study AC-055-113)

The  results  of  a  dedicated  study  in  healthy  subjects,  as  well  as  evidence  from  non-clinical studies, cannot exclude with reasonable confidence the possibility that macitentan would have any major effect on sperm concentration or sperm motility and morphology.

## Relationship between plasma concentrations and effect

In the PK/PD model, increasing macitentan concentrations were associated with longer time from baseline to morbidity/mortality event and with an increase in 6 minute walk distance (6MWD).

However, no clear separation between the macitentan 3 mg and 10 mg doses could be observed. The  proportion  of  subjects  with  an  event  who  provided  PK  data  at  EOT  was  small.  Thus,  the results  should  be  interpreted  cautiously  and  no  firm  conclusion  should  be  drawn.  Increasing macitentan  concentrations  were  associated  with  reductions  in  PVR,  mPAP,  and  TPR  and  an increase in cardiac index. However, no relationship was established for mRAP and mixed venous oxygen  saturation  (SvO2).  The  most  important  dose-related  AE  was  anaemia/  haemoglobin decrease.

In conclusion, based on the results from the pivotal SERAPHIN study, no population/population subset has been identified for which a dose below 10 mg could be recommended, without the risk of compromising the benefit that can be obtained with macitentan 10 mg.

## Pharmacodynamic interactions

In healthy volunteers (study AC-055-106), the administration of macitentan and sildenafil led to an  increase  in  headache  and  hypotension  as  compared  with  each  of  the  drugs  administered alone. In the double-blind PAH population, headache was reported at an incidence of 13.2% and 13.6% in  the  macitentan  3  mg  and  10  mg  groups,  respectively,  and  at  8.8%  in  the  placebo group. The incidence of headache in patients with concurrent PAH therapy was 14.0% (23/164) and  13.6%  (21/154)  on  macitentan  3  and  10  mg,  respectively,  versus  10.5%  (16/153)  on placebo.  These  data  do  not  indicate  a  higher  incidence  of  headache  associated  with  the administration of macitentan in patients receiving concurrent PAH therapy. Subgroup evaluation of  the  PT  'hypotension'  in  the  double-blind  PAH  population  showed  that  the  incidence  of hypotension in patients with concurrent PAH therapy was 6.1% (10/164) and 4.5% (7/154) on macitentan 3 and 10 mg, respectively, versus 3.3% (5/153) on placebo. In the subgroup not treated with a specific PAH therapy, the incidence of hypotension was 4.7% (4/86) and 9.1%

<div style=\"page-break-after: always\"></div>

(8/88) in macitentan 3 and 10 mg, respectively, versus 6.3% (6/96) on placebo. These data do not  suggest  a  higher  incidence  of  hypotension  AEs  associated  with  the  administration  of macitentan in patients receiving concurrent PAH therapy.

## 2.4.4. Discussion on clinical pharmacology

Macitentan has been studied in a total of 14 completed clinical pharmacology studies. Additional relevant  PK/PD  information  was  generated  in  study  AC-055-201  in  patients  with  essential hypertension and in a PK/PD sub-study to the pivotal Phase 3 study AC-055-302 SERAPHIN.

## Pharmacokinetics

Concentrations  of  macitentan  and  its  active  metabolite  ACT-132577  in  human  plasma  were determined  using  a  validated  liquid  chromatography  coupled  to  tandem  mass  spectrometry method (LC-MS/MS). The analytical method was demonstrated to be precise and accurate. The studied PK parameters (Cmax, tmax, t1/2, AUC0-t, and AUC0-∞) as well as statistical methods are the usual ones in PK studies and are considered appropriate. It is considered that results of PK studies conducted with capsules (used in early clinical development and the Phase 2 study in hypertension) may be extrapolated to film coated tablets (intended to-be-marketed formulation, used in a number of Phase 1 studies, in the Phase 2 study in IPF, and in the pivotal Phase 3 SERAPHIN study in PAH).

## Absorption

The absolute bioavailability of macitentan could not be established, as the development of an i.v. formulation  was  not  technically  feasible.  Maximum  plasma  concentrations  of  macitentan  are achieved  about  8 hours  after  administration.  Thereafter,  plasma  concentrations  of  macitentan and its active metabolite decrease slowly, with an apparent elimination half-life of approximately 16 hours  and  48 hours,  respectively.  In  healthy  subjects,  the  exposure  to  macitentan  and  its active  metabolite  was  unchanged  in  the  presence  of  food  and,  therefore,  macitentan  may  be taken with or without food. This information is adequately reflected in the SmPC section 5.2.

## Distribution

Macitentan and ACT-132577 are well distributed into tissues as indicated by an apparent volume of distribution (Vss/F) of  approximately  50L  and  40L  for  macitentan  and  ACT-132577, respectively. Macitentan and its active metabolite are highly bound to plasma proteins (&gt;99%), primarily to albumin.

## Biotransformation/metabolism

Macitentan undergoes biotransformation by hydroxylation, with CYP3A4 isoenzyme as the major contributor. The main metabolite is ACT-132577 (active M6), present at approximately 71% of total drug exposure in plasma. No particularly relevant consequences of polymorphism in CYP3A4 are expected. In vitro studies showed that the metabolism of macitentan to its active metabolite is  catalysed  by  CYP3A4  and  to  a  much  minor  extent  by  CYP2C19.  Macitentan  and  its  active metabolite were neither a substrate nor an inhibitor of CYP isoenzymes, multi-drug resistance protein (P-gp, MDR-1), or organic anion transporting polypeptides (OATP1B1 and OATP1B3), and did not interact with proteins involved in hepatic bile salt transport (i.e. BSEP, NTCP).

<div style=\"page-break-after: always\"></div>

## Exposure

Plasma exposure to macitentan and its active metabolite  ACT-132577,  measured  over  a  24  h dosing  interval,  were  increased  by  approximately  10-30%  between  PAH  patients  and  healthy subjects. As the total daily exposure expressed in AUC is a more relevant reflection of exposure during chronic use than the Ctrough, the applicant proposed to reflect this information in section 5.2 of the SmPC as follows:

'The pharmacokinetics of macitentan and its active metabolite have mainly been documented in healthy  subjects.  Exposure  to  macitentan  in  patients  with  PAH  was  approximately  1.2-fold greater  than  in  healthy  subjects.  The  exposure  to  the  active  metabolite  in  patients,  which  is approximately  5-fold  less  potent  than  macitentan,  was  approximately  1.3-fold  higher  than  in healthy subjects. The pharmacokinetics of macitentan in PAH patients were not influenced by the severity of the disease.'

The proposed SPC amendments are considered appropriate by the CHMP.

After  repeated administration, the pharmacokinetics of macitentan are dose-proportional up to and  including  30 mg.  In  patients,  no  trend  for  time-dependency  was  noted.  Inter-subject variability was low in healthy subjects and moderate in patients.

In conclusion, this information is appropriately reflected in the SmPC as follows:

## After  repeated administration, the pharmacokinetics of macitentan are dose proportional up to and including 30mg.

## Elimination

The  major  excretion  route  of  macitentan  in  humans,  in  the  form  of  metabolites,  is  via  urine, accounting for about 50% of the dose, while approximately 24% of the administered dose was recovered in faeces. Neither unchanged macitentan nor the active metabolite ACT-132577 were recovered in urine.

## Pharmacodynamics

Macitentan  is  an  orally  potent  endothelin  receptor  antagonist,  active  on  both  ETA  and  ETB receptors and approximately 100-fold more for selective for ETA than ETB in vitro. Macitentan has a circulating active metabolite (ACT-132577) that is also a dual ERA, is on average approximately 5-fold less potent than macitentan, and may contribute to the clinical effect.

In the PK/PD model, increasing macitentan concentrations were associated with longer time from baseline  to  morbidity/mortality  event  and  with  an  increase  in  6MWD.  However,  no  clear separation between the 2 macitentan doses could be observed. The proportion of subjects with an  event  who  provided  PK  data  at  EOT  was  small.  Thus,  the  results  should  be  interpreted cautiously and no firm conclusion should be drawn. Increasing macitentan concentrations were associated with reductions in PVR, mPAP, and TPR and an increase in cardiac index. However, no relationship was established for mRAP and SvO2.

<div style=\"page-break-after: always\"></div>

Data  from  ET  receptor  antagonism  in  clinical  pharmacology  studies  and  from  decreased  blood pressure  in  a  phase  II  study  in  patients  with  essential  hypertension  provides  an  adequate rationale for dose selection for the pivotal study in patients with PAH.

Macitentan did not affect cardiac repolarization in nonclinical studies or in a thorough TQT study.

In healthy volunteers (study AC-055-106), the administration of macitentan and sildenafil led to an  increase  in  headache  and  hypotension  as  compared  with  each  of  the  drugs  administered alone. In the double-blind PAH population, headache was reported at an incidence of 13.2% and 13.6% in  the  macitentan  3  mg  and  10  mg  groups,  respectively,  and  at  8.8%  in  the  placebo group. The incidence of headache in patients with concurrent PAH therapy was 14.0% (23/164) and  13.6%  (21/154)  on  macitentan  3  and  10  mg,  respectively,  versus  10.5%  (16/153)  on placebo.  These  data  do  not  indicate  a  higher  incidence  of  headache  associated  with  the administration of macitentan in patients receiving concurrent PAH therapy. Subgroup evaluation of  the  PT  'hypotension'  in  the  double-blind  PAH  population  showed  that  the  incidence  of hypotension in patients with concurrent PAH therapy was 6.1% (10/164) and 4.5% (7/154) on macitentan 3 and 10 mg, respectively, versus 3.3% (5/153) on placebo. In the subgroup not treated with a specific PAH therapy, the incidence of hypotension was 4.7% (4/86) and 9.1% (8/88) in macitentan 3 and 10 mg, respectively, versus 6.3% (6/96) on placebo. These data do not  suggest  a  higher  incidence  of  hypotension  AEs  associated  with  the  administration  of macitentan  in  patients  receiving  concurrent  PAH  therapy.  The  median  macitentan  trough concentrations in the 3 mg and 10 mg dose groups (89 and 276 ng/mL) predicted increases in the probability to have an AE of anaemia from 1.77% (placebo subjects) to 2.09% and 2.96%, respectively.  No  trend  was  observed  for  infrequent  AEs  (n&lt;30  for  the  SMQs  teratogenicity, thrombocytopenia, leucopenia, menstrual disorder, and ovarian cysts) or for hepatic events (n = 86). Appropriate information has been included in the SmPC.

## Special populations

## Renal impairment:

The relative increase in exposure to macitentan and the active metabolite observed in patients with severely impaired renal function (24% and 58% higher than those in healthy subjects) was below that achieved at the highest well-tolerated macitentan dose of 300 mg reported in the SAD study. No data are available in PAH patients with severe renal impairment.

In  conclusion,  as  a  precautionary  measure,  additional  warnings  are  required  for  patients  with severe renal impairment and in patients undergoing dialysis. (see SmPC).

## Hepatic impairment

Overall, the exposure to macitentan and its active metabolite is decreased by 20% in patients with  hepatic  impairment,  without  differences  according  to  the  degree  of  impairment.  The differences in other PK parameters between hepatically impaired and normal subjects are even more irrelevant. Therefore, no dose-adjustment in hepatic impairment is deemed necessary. It is possible that the PK of a drug differs between a hepatically impaired subject population and a healthy  population  treated  concomitantly  with  a  strong  CYP3A4  inhibitor.  On  the  basis  of  the hepatic impairment study AC-055-110, the applicant hypothesises that the decrease in intrinsic hepatic clearance due to a decrease in enzyme-capacity is compensated by the increase in the

<div style=\"page-break-after: always\"></div>

unbound fraction leading to an unchanged hepatic drug clearance. Hepatic and liver function are further discussed in the clinical safety part. In summary, information related to hepatic function is  appropriately  reflected  in  the  SmPC  (see  contra  indication,  warnings,  undesirable  effects sections)and in the RMP.

## Gender/race/weight

Females tend to have a longer t1/2 and plasma through concentration for both macitentan and ACT-132577, leading to differences in exposure when compared to males. However, the small difference  observed  could  be  confounded  by  body-weight  (female  subjects  had  a  body  weight 12% lower than that of the male subjects). In conclusion, no specific information is warranted in the SmPC.

There  were  no  large  differences  between  the  races  involved  in  the  studies  with  this  product. Therefore,  it  can  be  concluded  that,  in  the  different  races,  macitentan  does  not  show  clinical relevant pharmacokinetics differences.

Analysis  by  weight  category  (&lt;50  kg,  50-99  kg,  and  &gt;100  kg)  did  not  indicate  a  clinically relevant  effect  of  weight  on  macitentan  exposure  at  Month  6  or  EOT.  .  A  decrease  of  trough plasma concentrations of ACT-132577 with weight was suggested in the 10 mg dose group at Month 6, but this observation could have been driven by the limited number of patients with a weight above 100 kg.

## Elderly population

In the 14 dedicated PK studies, no subjects &gt;65 were included. The PK studies were performed in a healthy subject population and the upper allowed age limit for inclusion varied between 45 and 65 years of age. The SmPC adequately reflects that there is limited clinical experience in patients over the age of 75 years, and therefore macitentan should be used with caution in this population.

## Paediatric population

Twenty  patients  between  the  ages  of  12  and  &lt;18  years  were  enrolled  in  SERAPHIN study. Characterisation  of  PK  could  not  be  performed.  Therefore,  no  conclusion  can  be  drawn  and additional data are needed to support any paediatric indication.

## Interaction studies

In vivo DDI studies with warfarin, sildenafil and cyclosporine showed no relevant interaction with macitentan. In addition, there was a 2-fold increase in macitentan exposure with concomitant ketoconazole  once  daily  (a  strong  CYP3A4  inhibitor)  and  a  decrease  by  79%  in  macitentan exposure with concomitant rifampicin (a potent inducer of CYP3A4). In post-hoc analyses, the predicted  increase  was  approximately  3.0-fold  in  the  presence  of  ketoconazole  200  mg  twice daily, using physiologically based pharmacokinetic (PBPK) modelling.

In conclusion, a potential increase in macitentan exposure when using strong CYP3A4 inhibitors could  be  of  clinical  relevance.  In  view  of  the  non-clinical  and  clinical  data,  it  is  therefore acceptable to reflect this information in the SmPC in sections 4.4, and 4.5 accordingly.

<div style=\"page-break-after: always\"></div>

In sections 4.4 and 4.5 the following warnings are mentioned:

'Caution should be exercised when macitentan is administered concomitantly with strong CYP3A4 inhibitors'. A warning is also added in case of concomitant use with strong CYP3A4 inducers, to mention that reduced efficacy of macitentan could occur.

No  specific  drug-drug  interaction  studies  with  hormonal  contraceptives  have  been  conducted. However, the lack of interaction with sildenafil indicates that no clinically relevant pharmacokinetic  interactions  between  macitentan  and  other  CYP3A4  substrates  would  occur. Overall, macitentan seems to have a low potential for interactions with other medicinal products.

In dose-ascending studies conducted in healthy subjects (Studies AC-055-101 and 102), dosedependent increases in the incidence of AEs were observed, headache being the more frequently reported adverse event. The relationship between exposure (trough plasma concentrations) and safety  in  PAH  patients  was  characterized  using  a  logistic  regression  model  based  on  the  data from study AC-055-302 (SERAPHIN). However, for adverse events, only the relationship between exposure and AEs leading to study drug discontinuation was explored. Only a small number of patients had an AE leading to study drug discontinuation (n = 26) in this analysis. On the other hand, there was an inverse relationship between macitentan trough plasma concentrations and changes in haematocrit and haemoglobin levels; anaemia/haemoglobin decrease being the most important dose-related AE.

No  concentration-dependent  impact  on  changes  in  liver  function  tests  could  be  established. Based on the results from the pivotal SERAPHIN study, no population/population subset has been identified for which a dose below 10 mg could be recommended, without risk of compromising the benefit that can be obtained with macitentan 10 mg.

## 2.4.5. Conclusions on clinical pharmacology

The clinical pharmacology of macitentan has generally been well characterized. However, some additional  clarifications  and  SmPC  amendments  were  considered  necessary  in  some  particular subpopulations  (lack  of  appropriate  PK  data  in  children)  and  situations  (PK  interaction  with ketoconazole ; uncertainty about testicular safety; and hepatic impairment/toxicity). The agreed SmPC  adequately  reflects  the  current  knowledge  of  the  product  from  a  pharmacological perspective (see product information).

## 2.5. Clinical efficacy

This application is based on a single, long-term, pivotal Phase 3 study, AC-055-302/SERAPHIN. There  are  no  other  ongoing  Phase  3  studies  in  the  sought  indication.  Study  AC-055-201  in patients  with  essential  hypertension  contributed  data  on  the  dose-response  for  hemodynamic efficacy of macitentan and, thus, to the dose selection for the Phase 3 study in PAH (Table O-E01), and will be discussed under 'Dose response study' section of this report. Studies SERAPHIN OL (AC-055-303) and MUSIC (AC-055B201) in patients with idiopathic pulmonary fibrosis (IPF) contributed  long-term  safety  and  tolerability  data  for  the  proposed  dose  of  10  mg  macitentan OD, and will be discussed only in the 'Clinical safety' section of this report.

<div style=\"page-break-after: always\"></div>

Table O-E-01. Overview of phase 2 and 3 clinical trials with macitentan

| Study [Doc No]                        | Study objectives                                                                               | Patients enrolled            | Treatment/dose (mg)                                                                                | Treatment duration                                  | Type of control/blinding                                                                   |
|---------------------------------------|------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------------------------------------|
| Main studies                          | Main studies                                                                                   | Main studies                 | Main studies                                                                                       | Main studies                                        | Main studies                                                                               |
| AC-055-201 ( Phase study)             | II Efficacy and safety of macitentan in patients with mild to moderate essential hypertension. | 466 enrolled, 379 randomized | Placebo run-in                                                                                     | 3-4 weeks                                           | Placebo single-blind run- in Placebo and active controlled (enalapril 20 mg), double-blind |
| AC-055-201 ( Phase study)             | II Efficacy and safety of macitentan in patients with mild to moderate essential hypertension. | 466 enrolled, 379 randomized | Macitentan 0.3 mg Macitentan 1 mg Macitentan 3 mg Macitentan 10 mg Enalapril 20 mg Placebo Placebo | 8 weeks                                             | treatment.                                                                                 |
| AC-055-302 SERAPHIN (Phase III study) | Efficacy and safety of macitentan in patients with PAH                                         | 742                          | Macitentan 3 mg Macitentan 10 mg Placebo                                                           | Up to 3.6 years                                     | Placebo, double-blind.                                                                     |
| Supportive studies                    | Supportive studies                                                                             | Supportive studies           | Supportive studies                                                                                 | Supportive studies                                  | Supportive studies                                                                         |
| AC-055-303 a (SERAPHIN OL)            | Long-term safety of macitentan in patients with PAH                                            | 550                          | Macitentan 10 mg                                                                                   | N/A                                                 | Uncontrolled.                                                                              |
| AC-055B201 (MUSIC)                    | Efficacy and safety of macitentan in patients with IPF.                                        | 178 randomized               | Macitentan 10 mg                                                                                   | 12 months (Period 1) + variable duration (Period 2) | Placebo-controlled, double-blind.                                                          |

N/A = not applicable; IPF = idiopathic pulmonary fibrosis; OL = open-label; PAH = pulmonary arterial hypertension.

a  Ongoing study.

## 2.5.1. Dose response studies

No  dedicated  dose-finding  study  was  conducted  in  patients  with  PAH.  Instead,  the  applicant's strategy  was  to  employ  PD  data  on  ET-1  levels  (see  'pharmacodynamics'  section)  and hemodynamic efficacy data on blood pressure (BP) reduction in patients with mild to moderate essential hypertension to determine the doses to be tested in the Phase 3 clinical outcome study in  patients  with  PAH  (SERAPHIN).  The  underlying  assumption  was  that  a  dose  shown  to  be efficacious  in  systemic  hypertension  would  also  be  hemodynamically  effective  in  PAH,  as previously observed with the ERA bosentan (Krum, 1998).

Dose response study AC-055-201: A multi-center, double-blind, randomized, placeboand  active-controlled,  parallel  group,  dose-ranging  study  to  evaluate  the  efficacy, safety  and  tolerability  of  ACT-064992  in  subjects  with  mild-to-moderate  essential hypertension .

## Population and baseline characteristics

A total of 314 subjects were enrolled. The per-protocol set for evaluation of the primary endpoint included placebo (n = 54), macitentan doses 0.3 mg (n = 54), 1 mg (n = 60); 3 mg (n = 57); 10  mg  (n  =  56)  and  enalapril  (n  =  56).  Baseline  values  were  balanced  between  treatment groups; subjects with rather mild hypertension were included (SiDBP at randomization 97.6 ± 2.5 mmHg [mean ± SD]).

<div style=\"page-break-after: always\"></div>

## Efficacy

Treatment  with  the  10  mg  dose  of  macitentan  was  associated  with  a  statistically  significant reduction vs placebo in SiDBP at trough (Figure O-E-01). The response to macitentan seemed dose-dependent  and  most  of  the  BP  reduction  was  reached  within  4  weeks  of  treatment. Secondary  and  exploratory  analyses  of  control  and  response  rates  showed  similar  treatment effects and trends.

Figure  OE-01.  Study  AC-055-201:  Change  in  sitting  diastolic  blood  pressure  from baseline to end of double-blind period (placebo-adjusted).

<!-- image -->

|                                         | n 3                                     | n P                                     | Mean                                    | 95% CI Dunnett                          | -15 -10   | 0 5 10   |
|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------|----------|
| Sitting diastolic blood pressure (mmHg) | Sitting diastolic blood pressure (mmHg) | Sitting diastolic blood pressure (mmHg) | Sitting diastolic blood pressure (mmHg) | Sitting diastolic blood pressure (mmHg) |           |          |
| Macitentan O.3 mg                       | 53                                      | 54                                      | -0.9                                    | 4.6, 2.8                                |           |          |
| Macitentan 1 mg                         | 60                                      | 54                                      | -2.1                                    | -5.7,1.5                                |           |          |
| Macitentan 3 mg                         | 57                                      | 54                                      | -2.9                                    | -6.5 , 0.7                              |           |          |
| Macitentan 10 mg                        | 56                                      | 54                                      | -3.9                                    | -7.5, -0.2                              |           |          |
| Enalapril 20 mg                         | 56                                      | 54                                      | -1.0                                    | 4.6 , 2.7                               |           |          |

CI = confidence interval.

Source:D-06.142Figure3

## PK/PD results

Pharmacokinetic analysis showed that exposure in terms of Ctrough to both ACT-064992 and ACT132557 was dose-proportional over the dose range tested. Pharmacodynamic results showed a pronounced effect on endothelin-1 (ET-1) levels in the 3- and 10-mg ACT-064992 dose groups. When pharmacokinetic (PK) and SiDBP at trough data are included in a mathematical model, the 10 mg dose seemed to be close to the plateau of the pharmacological effect.

## Safety

In study AC-055-201 in patients with essential hypertension, there were five cases of increases in liver transaminases &gt;3×ULN, which led to the Sponsor's decision to end the study earlier than planned (see section 4 of current report for further discussion on hepatotoxicity).

## 2.5.2. Main study

Study  AC-055-302  (SERAPHIN;  Module  5.3.5.1):  Study  with  Endothelin  Receptor Antagonist in Pulmonary  arterial Hypertension to improve  cliNical outcome:  A multicenter, double-blind, randomized, placebo-controlled, parallel-group, eventdriven, Phase III study to assess the effects of macitentan on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension.

The  clinical  evidence  based  on  the  results  of  the  efficacy  and  safety  of  macitentan  in  the treatment  of  patients  with  PAH  is  derived  from  study  AC-055-302/SERAPHIN  (Table  O-E-01). This  was  a  pivotal  placebo-controlled,  global  Phase  3  study,  which  enrolled  742  patients  with symptomatic PAH, randomized in a 1:1:1 ratio to macitentan 3 mg OD, macitentan 10 mg OD, or placebo OD (Figure O-E-03).

<div style=\"page-break-after: always\"></div>

Figure O-E-03. SERAPHIN study design.

<!-- image -->

End of treatment (EoT)is the date of discontinuationfromtreatment.Patients could discontinue study treatmentatanytimefollowingrandomization.EoTcoincidedwiththeendofstudyforpatientswhowere ongoingonstudy drugon the dateof studycompletion(30January 2012announced byActelion).

Endofstudy(EoS)isthedateofdiscontinuationfromstudy.

Study completers are patients whowere stillin the study (alive and available for avisit/tobe contacted) on thedateof studycompletion,independent ofwhether ornotthepatientshaddiscontinuedthestudy treatmentprematurelyorhadbeenenrolledintotheSERAPHINopenlabelstudyfollowingamorbidity event.

The primary objective of the long-term, event-driven SERAPHIN study was to demonstrate that macitentan reduces the risk of morbidity and mortality events during treatment in patients with PAH.  The  study  was  conducted  in  158  centres  in  39  countries,  between  25  May  2008  (first patient enrolled) and 15 March 2012 (last patient last visit).

## Methods

The  study  included  a  screening  period  (up  to  28  days)  followed  by  a  treatment  period  from randomization to the EOT visit. EOS occurred when the target of 285 events confirmed by the Clinical  Event  Committee  (CEC)  was  expected  to  have  been  achieved.  The  EOT  visit  either coincided  with  the  EOS  visit  for  patients  who  were  still  on  double-blind  study  treatment  or occurred earlier in case of premature discontinuation of study drug. Patients were encouraged to remain in the study after EOT up to the EOS visit. Vital status follow-up at EOS was performed for  all  patients  who  had  not  prematurely  discontinued  from  the  study  (i.e.,  died,  withdrawn consent or had been declared lost to follow-up). Patients who prematurely discontinued study treatment (double-blind) due to worsening of PAH and obtained written approval from Actelion, and patients who completed the study as scheduled, could enter the open-label extension study, SERAPHIN  OL.  For  patients  who  had  opted  not  to  participate  or  who  were  not  eligible  to participate in the open-label extension study, SERAPHIN OL, a 28-day safety follow-up after EOT was performed.

## Study Participants

A  total  of  699  patients  were  planned  to  be  randomized  and  742  patients  were  actually randomized (1:1:1 ratio) to macitentan 3 mg (250 patients), macitentan 10 mg (242 patients) or placebo (250 patients).

<div style=\"page-break-after: always\"></div>

## Diagnosis and main criteria for inclusion

Patients aged 12 years or older at study entry, with a confirmed diagnosis of symptomatic PAH in modified WHO FC II to IV were eligible. The PAH aetiology was required to be within groups 1.1 to  1.3  of  the  Venice  classification,  i.e.,  idiopathic  PAH,  familial  PAH,  PAH  related  to  collagen vascular disease, PAH associated with simple congenital systemic-to-pulmonary shunts (at least 1 year post surgical repair), HIV infection, or drugs and toxins.

Randomization into the study required a PAH diagnosis confirmed by hemodynamic evaluation showing:

Mean pulmonary artery pressure (mPAP) &gt;25 mmHg

Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤15 mmHg

Pulmonary vascular resistance (PVR) at rest ≥ 320 dyn×sec/cm 5

Patients were required to have a 6-minute walk distance (6MWD) ≥ 50 m at baseline.

## Exclusion criteria

There were a total of 23 exclusion criteria. Of interest, patients with PAH associated with noncorrected simple congenital systemic-to-pulmonary shunts and, combined and complex systemicto-pulmonary  shunts, corrected or non-corrected, were  excluded. The  criterion of  'PAH associated with congenital heart disease' in the indication was amended to acknowledge that it was limited to 'PAH associated with corrected simple congenital heart disease.

## Study treatments

Altogether, 742 patients were randomized to macitentan 3 mg, macitentan 10 mg, or matching placebo in a 1:1:1 ratio. Patients received macitentan or placebo tablets OD, in addition to their usual PAH treatment (if applicable and allowed by the protocol).

Patients  randomized into  the  study  were  either  naïve  to  a  PAH-specific  treatment  or  could  be undergoing treatment with oral phosphodiesterase inhibitors, oral or inhaled prostanoids, calcium channel blockers, or L-arginine, provided that the dose had been stable for at least 3 months prior  to  randomization.  Any  change  of  dose  in  the  absence  of  PAH  worsening  was  strongly discouraged during the study. Concomitant treatment with oral diuretics was allowed, provided the patient had been on stable dose for at least 1 month prior to randomization. Optimization of the dose of oral diuretics was allowed during the treatment period.

## Prohibited concomitant medications

1) ERAs (e.g., bosentan and ambrisentan) unless they were initiated for clinical worsening of PAH and  after  study  drug  discontinuation;  2)  Intravenous  or  subcutaneous  prostanoids  (e.g., epoprostenol, treprostinil) unless they were  initiated for a morbidity event; 3) Specific immunosuppressants:  calcineurin  or  mTOR  inhibitors  (e.g.,  cyclosporine  A  and  tacrolimus, everolimus,  sirolimus);  4)  CYP3A  inducers  (carbamazepine,  rifampin,  rifabutin  and  St  John's wort); 5) Any investigational drug other than the study drug.

<div style=\"page-break-after: always\"></div>

## Objectives

The  primary  objective  of  the  study  was  to  demonstrate  that  either  dose  (3  mg  or  10  mg)  of macitentan reduces the risk of morbidity and mortality in patients with symptomatic PAH.

Secondary objectives of the study were:

To  demonstrate  that  either  dose  (3  mg  or  10  mg)  of  macitentan  improves  exercise  capacity, WHO functional class (FC), and reduces the risk of death due to PAH or hospitalization for PAH up to end-of-treatment (EOT) in patients with symptomatic PAH.

To demonstrate that either dose (3 mg or 10 mg) of macitentan reduces the risk of death of all causes up to EOT and up to end-of-study (EOS).

To evaluate the safety and tolerability of macitentan in patients with symptomatic PAH.

## Outcomes/endpoints

## Primary efficacy endpoint

The primary objective of reduction in the risk of a morbidity or mortality event was assessed as the time from start of treatment to the first morbidity or mortality event up to EOT, defined as follows:

Death,  or  onset  of  a  treatment-emergent  adverse  event  (AE)  with  a  fatal  outcome  occurring within 4 weeks of study treatment discontinuation, or

Atrial septostomy or hospitalization for atrial septostomy, or

Lung transplantation or hospitalization for lung transplantation, or

Initiation  of  intravenous  or  subcutaneous  prostanoids  (e.g.,  epoprostenol,  treprostinil)  or hospitalization for initiation of intravenous or subcutaneous prostanoids, or

Other  worsening of  PAH,  defined  by  the  combined  occurrence  in  a  patient  of  all  the  following three events:

At  least  15%  decrease  in  the  6MWD  from  baseline,  confirmed  by  two  6-minute  walk  tests (6MWT), performed on separate days, within 2 weeks of each other.

## AND

Worsening of PAH symptoms that included at least one of the following: Increase in WHO FC, or no change in patients in WHO FC IV at baseline; Appearance or worsening of signs/symptoms of right heart failure that did not respond to optimized oral diuretic therapy

## AND

Need for new treatment(s) for PAH that included the following: Oral or inhaled prostanoids (e.g., iloprost);  Oral  phosphodiesterase  inhibitors  (e.g.,  sildenafil);  Endothelin  receptor  antagonists (e.g.,  bosentan,  ambrisentan)  only  after  discontinuation  of  the  study  treatment;  Intravenous diuretics

<div style=\"page-break-after: always\"></div>

The observation period for the primary endpoint started with first drug intake and ended at EOT +  7  days.  Patients  who  prematurely  discontinued  study  treatment  without  a  morbidity  or mortality  event  were  censored  at  the  time  of  study  treatment  discontinuation  plus  7  days. Patients without an event at EOS (declared by the sponsor on 30 January 2012) were censored for the primary endpoint at their last visit in the study. An independent clinical event committee (CEC) reviewed all morbidity and mortality events in a blinded fashion and adjudicated (qualified or disqualified) these events for the main analysis of the primary endpoint. Furthermore, the CEC also  adjudicated  the  type  of  primary  endpoint  event  and  confirmed  whether  a  mortality  event was due to PAH.

## Secondary efficacy endpoints

- Change in 6MWD from baseline to Month 6
- Proportion of patients with improvement in modified WHO FC from baseline to Month 6
- Time  to  death  due  to  PAH  or  hospitalization  for  PAH  up  to  EOT  that  included  (The protocol-defined  endpoint  was  clarified  in  the  Statistical  Analysis  Plan  (SAP)  prior  to unblinding): Death due to PAH (as identified by CEC) up to EOT + 7 days, or onset of a treatment-emergent AE with a fatal outcome due to PAH occurring up to 4 weeks after EOT, or Hospitalization for PAH up to EOT + 7 days.
- Time to death of all causes up to EOT that included (The protocol-defined endpoint was clarified in the SAP prior to unblinding): Death of all causes up to EOT + 7 days, or onset of a treatment-emergent AE with a fatal outcome occurring up to 4 weeks after EOT (The protocol-defined  endpoint  was  clarified  in  the  Statistical  Analysis  Plan  (SAP)  prior  to unblinding).
- Time to death of all causes up to EOS (This protocol defined exploratory endpoint was changed to a secondary endpoint in the SAP).

Exploratory endpoints investigated the effects of macitentan on changes in 6MWD, Borg dyspnea index and WHO FC at each assessed time-point, quality of life (QoL), and N-terminal pro-B type natriuretic peptide (NT-pro-BNP) levels.

Pharmacodynamic  endpoints  investigated  the  effects  of  macitentan  on  changes  in  PVR,  mean right  atrial  pressure  (mRAP),  mean  pulmonary  pressure  (mPP),  cardiac  index  (CI),  total pulmonary resistance (TPR) and mixed venous oxygen saturation from baseline to Month 6 in a sub-study to the overall protocol.

Pharmacoeconomic endpoints:

Number per year of all-cause and PAH-related hospitalizations from baseline up to EOT; Number per year of in-patient hospital days for all causes and PAH-related causes from baseline up to EOT.

## Sample size

The  anticipated  sample  size  for  this  study  was  699  patients  randomized  to  treatment  using  a 1:1:1 ratio. A total of 285 events were needed to detect a hazard ratio for macitentan/placebo of 0.55 for at least one dose group over an estimated maximum study duration of 4.1 years (using

<div style=\"page-break-after: always\"></div>

a hazard rate of 0.43 in the placebo group, an expected hazard ratio of 0.05 per year for attrition and an accrual rate of 200 patients per year). For sample size calculations, type-I error was set to 0.005 (two-sided, Bonferroni correction to ensure an overall alpha level of 0.01) and power was set to 90% A planned blinded sample size re-estimation was performed 3 months before the end of expected recruitment which led to a revised expected hazard rate of 0.28 in the placebo group, resulting in the decision to increase the initial planned sample size (n = 525) to 699 to maintain the planned study duration. The planned sample re-sizing had no impact on the results in  the  primary endpoint and change in 6MWD, according to ancillary analyses provided by the applicant.

## Randomisation

Patients  who  satisfied  the  eligibility  criteria  were  randomized  in  a  1:1:1  ratio  to  receive macitentan (3 mg or 10 mg) or placebo using a centralized randomization system via Interactive Voice Response (IVR) or Interactive Web Response (IWR). An independent service provider was responsible for the central randomization services. A unique 4-digit randomization number was assigned to each patient. Randomization was stratified by centre and the block size used was a combination of 3 and 6. The randomization code was to be unblinded/broken by Actelion GQM and  made  available  for  data  analysis  only  after  study  closure,  i.e.,  when  the  study  was completed,  the  protocol  violations  were  determined,  and  the  clinical  database  was  declared complete, accurate and locked. The password was requested by an authorized person at Actelion GQM on 23 April 2012 and the randomization code was made available for analysis on 26 April 2012.

## Blinding (masking)

This study was performed in a double-blind fashion. The two dose strengths of macitentan and placebo were indistinguishable and all study drug kits were packaged in the same way. The SDAC (Statistical Data Analysis Center) had access to the randomization codes and was responsible for the overall preparation of the data for review by the DSMB and for preparing interim reports for review by the DSMB based on the data generated by Actelion. The investigator and study staff, the  patients,  the  monitors,  and  Actelion  employees  and  contractors  remained  blinded  to  the study drug allocation until the database closure on 26 April 2012.

## Statistical methods

The null hypothesis was that, independently for each dose group of macitentan (3 mg and 10 mg), there was no difference between macitentan and placebo for the risk of first occurrence of a morbidity or mortality event up to EOT (the primary endpoint). To keep the study-wise type-I error to a two-sided 0.01 'conclusive' (and highly statistically significant) level in the presence of multiple tests, each  comparison of active  dose  versus  placebo  was  tested  at a  nominal  type-I error level of 0.005 (two-sided) according to Bonferroni's approach, with testing starting from the primary endpoint. The study could also be declared 'positive' at a global significance level of 0.05 (statistically significant). According to Bonferroni's approach, the comparison of each active dose versus placebo was to be tested at a nominal type-I error level of 0.025 (two-sided), with testing starting  from  the  primary  endpoint.  The  secondary  endpoints  were  analyzed  hierarchically  for each dose group in the sequence of change in 6MWD (Wilcoxon rank sum test), change in WHO

<div style=\"page-break-after: always\"></div>

FC (Fisher's exact test), time to death or hospitalization due to PAH up to EOT, and time to death of all causes up to EOT and EOS (all logrank test). No further alpha adjustment was necessary for  the  secondary  endpoints  due  to  the  hierarchical  testing  procedure.  No  confirmatory  claims can  be  based  on  variables  that  have  a  rank  lower  than  or  equal  to  that  variable  whose  null hypothesis was the first that could not be rejected. Efficacy endpoints were analyzed using the All-randomized set (all randomized patients irrespective of whether or not they received study drug). The logrank test with no adjustment for covariates was used to compare the treatment effect of macitentan versus placebo for the primary endpoint. The treatment effect was estimated using  Cox's  proportional  hazard  model.  All  time  to  event  variables  were  estimated  using  the Kaplan-Meier method. The exploratory endpoints were analyzed descriptively. Safety data were analyzed  descriptively  using  the  All-treated  set  (all  randomized  patients  who  received  study drug).

## Participant flow

A total of 955 patients were screened from 158 centres in 39 countries and 742 patients from 151 centres in 39 countries were randomized in a 1:1:1 ratio to the macitentan 3 mg (n = 250), macitentan  10  mg  (n  =  242)  and  placebo  groups  (n  =  250)  (Figure  O-E-04).  A  total  of  590 patients (79.5%) completed the study as planned. The proportion of patients who prematurely discontinued the study was 22.4% in the macitentan 3 mg group, 16.9% in the macitentan 10 mg group, and 22.0% in the placebo group. Death was the main reason for patients not being able to complete the study in all three groups (18.8% macitentan 3 mg, 14.0% macitentan 10 mg,  17.6%  placebo).  Other  reasons  for  premature  discontinuation  from  the  study  included withdrawal of consent (2.4% macitentan 3 mg, 1.7% macitentan 10 mg, 1.2% placebo) and loss to follow up (1.2% macitentan 3 mg, 0.8% macitentan 10 mg, 2.8% placebo).

Figure O-E-04. Disposition of patients

<!-- image -->

<div style=\"page-break-after: always\"></div>

Premature  discontinuation  from  treatment  or  EOT is  the  date  of  discontinuation  from  treatment.  Patients  could discontinue  study  treatment  at  any  time  following  randomization.  EOT  coincided  with  EOS  for  patients  who  were  still  on study drug on the date of study completion (30 January 2012, announced by Actelion).

Premature  discontinuation  from  study: Patients  no  longer  alive/willing/available  to  provide  vital  status  following sponsor's announced EOS (30 January 2012, announced by Actelion).

Study completed : Patients from whom vital status could be collected following sponsor-announced EOS independent of an earlier discontinuation from the treatment.

## Recruitment

Russia and China were the only countries contributing more than 20 patients per group. There was  a  significant  difference  in  patient  recruitment  by  region  before  and  after  sample  size  resizing.  Most  patients  from  Asia  and  North-America  were  recruited  after  sample  size  re-sizing, while in the remaining regions most patients were recruited before sample size re-sizing.

## Conduct of the study

Four  protocol  amendments  were  made  and  the  most  important  was  amendment  3  related  to increase in sample size (See 'sample size' subsection).

## Baseline data

A summary of the demographic characteristics for the 'All-randomized set' is provided in Table OE-02. In general, the demographic characteristics across the three treatment groups were well matched.  There  was  a  predominance  of  females  and  the  median  age  was  approximately  45 years. Approximately 14% of the patients were elderly (age &gt; 65) and 3% were adolescents (1217 years). Average body mass index (BMI) was approximately 25 kg/m 2 . Ethnically, the patients were predominantly Caucasian or Asian, reflecting the fact that the majority were recruited at centres in Europe and Asia.

<div style=\"page-break-after: always\"></div>

Table O-E-02. Summary of patient demographics, All-randomized set

<!-- image -->

|                       | Placebo N=250   | Macitentan 3 .mg N=250   |                 | Macitentan 10 mg N=242   |             | All patients N=742   |            |
|-----------------------|-----------------|--------------------------|-----------------|--------------------------|-------------|----------------------|------------|
| SEX[n (&)]            |                 |                          |                 |                          |             |                      |            |
| n                     | 249             |                          | 248             | 242                      |             | 739                  |            |
| Males                 | 65 26.18        | 61                       | 24.68           | 48                       | 19.88       | 174                  | 23.5%      |
| Females               | 184 73.9%       | 187                      | 75.4%           | 194                      | 80.2%       | 565                  | 76.58      |
| AGE (years)           |                 |                          |                 |                          |             |                      |            |
| n                     | 249             | 248                      |                 | 242                      |             | 739                  |            |
| Mean                  | 46.7            | 44.5                     |                 |                          | 45.5        | 45.6                 |            |
| Standard deviation    | 17.03           |                          | 16.26           |                          | 14.99       | 16.13                |            |
| Standard error        | 1.08            |                          | 1.03            |                          | 0.96        | 0.59                 |            |
| Medlian               | 46.0            | 43.0                     |                 | 45.0                     |             | 45.0                 |            |
| Q1 Q3                 | 32.0            | 61.0                     | 31.0 57.0       | 34.0                     | 56.0        | 33.0                 | 58.0       |
| Min Max               | 13.0            | 85.0                     | 12.0 80.0       | 13.0                     | 76.0        | 12.0                 | 85.0       |
| AGE [n (%)]           |                 |                          |                 |                          |             |                      |            |
| n                     | 249             | 248                      |                 | 242                      |             | 739                  |            |
| < 18                  | 7               |                          | 7               | 6                        | 2.5%        | 20                   | 2.7%       |
| 18 一 64               | 2.8% 199 79.9%  | 208                      | 2.8% 83.9%      | 209                      | 86.48       | 616                  | 83.4%      |
| 65                    | 43              | 17.3%                    | 33 13.3         | 27                       | 11.2%       | 103                  | 13.9       |
| BMI (kg/m~2)          |                 |                          |                 |                          |             |                      |            |
| n                     | 249             | 248                      |                 | 242                      |             | 739                  |            |
| Mean                  | 25.2            |                          | 25.8            |                          | 25.6        | 25.5                 |            |
| Standard deviation    | 5.11            |                          | 6.36            |                          | 6.06        | 5.86                 |            |
| Standard error        | 0.32            |                          | 0.40            |                          | 0.39        | 0.22                 |            |
| Median                | 24.6            | 24.8                     |                 | 24.4                     |             | 24.6                 |            |
| Q1，Q3                 | 21.6            | 28.1 21                  |                 | 29.6 21.7                | 28.2        | 21.6                 | 28.7       |
| Min ， Max             | 14.9            | 49.0                     | 15.2            | 61.9 15.4                | 52.1        | 14.9                 | 61.9       |
| RACE [n (&)]          |                 |                          |                 |                          |             |                      |            |
| n                     | 249             |                          | 248             |                          | 242         | 739                  |            |
| Caucasian/white       | 131 52.6%       |                          | 137             | 135                      | 55.8        | 403                  | 54.5%      |
| Black                 | 8 3.2%          |                          | 5               | 55.2% 2.0%               | 6 2.58      | 19                   | 2.6%       |
| Asian                 | 71 28.5%        |                          | 69              | 27.8%                    | 65 26.98    | 205                  | 27.7%      |
| Hispanic Other        | 37 14.9% 2 0.8% |                          | 37 14.9%        | 35 1                     | 14.5% 0.4%  | 109 3                | 14.7% 0.4% |
| LOCATION u] (%)]      |                 |                          |                 |                          |             |                      |            |
| n                     | 249             |                          | 248             | 242                      |             | 739                  |            |
| US                    | 23              |                          | 25              |                          | 19 7.9%     | 67                   | 9.1%       |
| Non-US                | 226             | 9.2% 90.8%               | 10.1% 223 89.9% | 223                      | 92.1%       | 672                  | 90.9%      |
| REGION[n(&)]          |                 |                          |                 |                          |             |                      |            |
| n                     | 249             | 248                      |                 | 242                      |             | 739                  |            |
| North America         | 30 12.0%        |                          | 30              | 23                       | 9.5%        | 83                   | 11.2%      |
| Western Europe/Israel | 50 20.1%        |                          | 12.1 41 16.5%   | 48                       | 19.8%       | 139                  | 18.8%      |
| Eastern Europe/Turkey | 59 23.7%        |                          | 63 25.4%        | 62                       | 25.6%       | 184                  | 24.9%      |
| Asia                  | 68 27.3% 42     | 70                       | 28.2%           | 68                       | 28.18 16.98 | 206                  | 27.9%      |
| Latin America         | 16.9%           |                          | 44 17.7         |                          | 41          | 127                  | 17.2°      |

Source: Table 62

The  mean  time  from  PAH  diagnosis  to  randomization  in  the  study  population  was  2.7  years (Table O-E-03). Idiopathic PAH was the most common aetiology (55%) followed by PAH due to collagen vascular disease (30%) and PAH due to congenital shunts (8%). It is worth mentioning that the term 'congenital shunts' corresponds to PAH associated to corrected simple congenital systemic-to-pulmonary  shunts,  since  patients  with  PAH  associated  with  non-corrected  simple congenital  systemic-to-pulmonary  shunts  and  combined  and  complex  systemic-to-pulmonary shunts were excluded. . In the indication this subpopulation was limited to 'PAH associated with corrected simple congenital heart disease'. Familial (heritable) PAH and PAH due to HIV infection and drugs and toxins represented 3% or less.

<div style=\"page-break-after: always\"></div>

Table O-E-03. Summary of baseline characteristics, All-randomized set

<!-- image -->

|                                   | Placebo N=250   | Macitentan 3mg N=250   | Macitentan 10.mg N=242   | All patients N=742   |
|-----------------------------------|-----------------|------------------------|--------------------------|----------------------|
| Time from  PAH diagnosis (days)   |                 |                        |                          |                      |
| n                                 | 247             | 247                    | 241                      | 735                  |
| Mean                              | 942             | 1079                   | 951                      | 991                  |
| Standard deviation                | 1362.0          | 1659.1                 | 1325.1                   | 1456.9               |
| Standard error                    | 86.7            | 105.6                  |                          | 53.7                 |
| Median                            | 460             | 425                    | 476                      | 462                  |
| Q1 Q3                             | 180 1279        | 178 1230               | 174 1090                 | 178 1225             |
| Min1 Max                          | 6 13267         | 1 11957                | 2 10199                  | 1 13267              |
| EtiologyofPAH[n(&)]               |                 |                        |                          |                      |
| n                                 | 247             | 247                    | 241                      | 735 404              |
| Idiopathic                        | 126 51.0%       | 144 58.38              | 134 55.6%                | 55.0%                |
| Familial                          | 3 1.2%          | 8 3.2%                 | 2 0.8%                   | 13 1.88              |
| Collagen yascular disease         | 81 32.8%        | 70 28.38               | 73 30.3%                 | 224 30.5% 62         |
| Congenitalshunts                  | 26 10.53        | 15 6.1%                | 21 8.78                  | 8.4% 10              |
| HiVinfection                      | 3 1.2%          | 1 0.4%                 | 6 2.5%                   | 1.4%                 |
| Drugs and toxins                  | 8 3.2%          | 9 3.6%                 | 5 2.18                   | 22 3.0%              |
| 6mn Walk Test (m)(absolute)       |                 |                        |                          |                      |
| n                                 | 249             | 248                    | 242                      | 739                  |
| Mean                              | 352.4           | 364.1                  | 362.6                    | 359.6                |
| Standard deviation                | 110.62          |                        | 93.21                    | 100.15               |
| Standard error                    | 7.01            | 6.07                   | 66*5                     | 3.68                 |
| Medlian                           | 360.0           | 378.0                  | 378.0                    | 372.0                |
| Q1 Q3                             | 284.0 428.0     | 311.0 425.0            | 300.0 434.0              | 300.0 430.0          |
| Min1 Max                          | 65.0 650.0      | 80.0 610.0             | 90.0 578.0               | 65.0 650.0           |
| Sigms of right heartfailure [n()] |                 |                        |                          |                      |
| n                                 | 249             | 248                    | 242                      | 739                  |
| Patients with at leastonesigm     | 78 31.38        | 76 30.68               | 76 31.4%                 | 230 31.18 80         |
| Hepatomegaly                      | 25 10.0%        | 29 11.7%               | 26 10.73                 | 10.8%                |
| Ascites                           | 6 2.4%          | 2 0.8%                 | 3 1.2%                   | 11 1.5%              |
| Peripheral edema                  | 34 13.78        | 43 17.38               | 43 17.8%                 | 120 16.28            |
| s3 gallop                         | 12 4.8%         | 7 2.8号                 | 8 3.38                   | 27 3.7%              |
| Hepato-jugular reflux             | 12 4.8%         | 16 6.5%                | 15 6.2%                  | 43 5.8%              |
| Centralvenous pressure >8 mmHg    | 23 9.2%         | 27 10.98               | 23 9.58                  | 73 6'6 44            |
| Other                             | 16 6.4%         | 14 5.6%                | 14 5.8%                  | 0'9                  |
| WHO functional class [n （&)]      |                 |                        |                          |                      |
| n                                 | 249             | 248                    | 242                      | 739                  |
|                                   |                 |                        | 1 0.4%                   | 1 0.1%               |
|                                   | 129 51.8%       | 138 55.6%              | 120 49.6%                | 387 52.4%            |
| III                               | 116 46.6%       | 105 42.0               | 116 47.9%                | 337 45.6%            |
| IV                                | 4 1.6%          | 5                      | 5 2.1%                   | 14 1.9%              |
| Concomitant PAH therapy [n (&)]   |                 |                        |                          |                      |
| n                                 | 249             | 248                    | 242                      | 739                  |
| No                                | 95 38.28        | 85 34.38               | 88 36.4%                 | 268 36.38            |
|                                   | 154 61. 8号      | 163 65.78              | 154 63.6%                | 471 63.78 426        |
| Sildenafil Tadalafil              | 140             | 146 58.98              | 140 57.9% 0.8%           | 57.6% 7 0.9%         |
| Vardenafil                        | 234             | .0号                    | 3.3号                     | 88:2                 |
| Iloprost                          |                 | 2号                     | 18                       | 3.5%                 |
| Beraprost                         | 89              | 0号                     | 2:5%                     | 88:2 1               |
| Treprostinil                      |                 | 1 0.48                 |                          | 0.18                 |

Source:

Baseline mean 6MWD was approximately 360 m. The mean Borg dyspnoea index at baseline was approximately 3.5 across the groups (Table E-03). At baseline, approximately 52% of patients were in WHO FC II and 46% of patients were in WHO FC III, with only 14 patients (2%) in WHO FC  IV  (Table  O-E-03).  During  the  procedure,  patients  in  WHO  FC  IV  were  removed  from  the indication due to the very limited data available.

At  least  one  sign  of  right  heart  failure  was  reported  for  approximately  31%  of  patients  at baseline  (Table  E-03).  Ancillary  analyses  of  the  primary  and  main  secondary  outcome  in  the population with heart failure were consistent with the results in the overall study population.

## Results

All 742 patients were included in the 'All-randomized set'. One patient in the placebo group never received study treatment and therefore, a total of 741 patients were included in the 'All-treated set'.  The  'Per-protocol  set'  included  675  of  the  randomized  patients  (91%)  with  a  total  of  67 patients (9%) excluded from this set.

## Premature discontinuations from treatment

Of  the  741  patients  in  the  'All-treated  set',  373  (50.3%)  discontinued  study  treatment prematurely  (Table  E-05).  The  proportion  of  patients  who  discontinued  study  treatment  was 47.2% in the macitentan 3 mg group, 44.2% in the macitentan 10 mg group, and 59.4% in the

<div style=\"page-break-after: always\"></div>

placebo group. Disease progression followed by enrolment in the SERAPHIN OL was the most frequent reason for discontinuation of study treatment in all three groups (22.8% macitentan 3 mg, 20.7% macitentan 10 mg, 32.1% placebo). An AE led to discontinuation of study treatment in 13.6% macitentan 3 mg, 10.7% macitentan 10 mg, and 12.4% placebo. These AEs included disease  progression  (without  subsequent  enrolment  into  the  SERAPHIN  OL  study)  in  6.8%  of patients in the macitentan 3 mg group, 3.7% of patients in the macitentan 10 mg group, and 8.0% of patients in the placebo group. Other reasons included death, withdrawal from treatment (i.e.,  permanent  discontinuation  of  study  treatment,  but  with  the  patient's  agreement  to  be contacted at EOS to check vital status), withdrawal of consent and administrative reasons.

Table O-E-04. Summary of reasons for discontinuation of treatment, All-treated set.

| Preferred tem                            | Placebo N=249   | Macitentan 3 mg N=250   | Macitentan 10 mg N=242   | Macitentan 10 mg N=242   | Macitentan 10 mg N=242   |
|------------------------------------------|-----------------|-------------------------|--------------------------|--------------------------|--------------------------|
|                                          | No.             | No.                     | No.                      |                          |                          |
| Total patients with at least one reason  | 148 59.4        | 118 47.2                |                          | 107 44.2                 |                          |
| DISEASEPROGRESSIONLEADINGTO OL*          | 8032.1          | 57 22.8%                |                          | 50 20.7%                 |                          |
| ADVERSE EVENT                            | 31 12.4         | 34 13.6                 |                          | 26 10.78                 |                          |
| DISEASE PROGRESSION NOT LEADING TO OL*+l | 208.0号 4.8%     | 176.8%                  |                          | 93.7                     |                          |
| DEATH                                    | 12              | 10 4.0%                 | 10                       | 4.1                      |                          |
| WITHDRAWALFROM TREATMENT                 | 11 4.4%         | 7 2.8%                  | 12                       | 5.0%                     |                          |
| AIMINISTRATIVE/OIHER                     | 5 2.0号          | Nm 0.8%                 | 5                        | 2.1                      |                          |
| WITHDRAWALOFCONSENT                      | 1 0.4           | 1.28                    | 4                        | 1.7%                     |                          |
| LOST TO FOLLOW-UP                        | 3 1.2%          | 0.8%                    |                          |                          |                          |
| TREATMENT FAILURE                        | 3 1.2           | 0.8%                    |                          |                          |                          |
| AIMINISTRATION OF FORBIDDEN DRUG         | 2 0.8%          | NN- 0.4%                |                          |                          |                          |

Enrolment into the Open Label study following a morbidity event

iuana Aitptqtou/Aitteitou e oi anp iueuneaii aui peneututen oum sauatiedrr

Table PWIS\\_T - Produced by sturlor on 26APRl2 - Data dump of 26APR12

(Page 1/1)

## Missing data for mortality after EoT

A total of 27 patients did not complete the study and therefore vital status was missing at EOS, i.e., lost to follow-up, etc.). Missing data were well balanced by treatment group. The results of the sensitivity analyses using the Best-case, Base-case and Worst-case scenarios were similar to that of the primary analysis for the time to death up to EOS, with risk reductions ranging from 33% to 16% across all analyses (none of them statistically significant). The primary analysis risk reduction of 23% falls within that range.

## Protocol violations

A total of 67 randomized patients (9%) were excluded from the 'per-protocol set' due to major protocol deviations. Overall, the proportion of patients with major protocol deviations was similar across the groups (9.2% macitentan 3 mg, 9.1% macitentan 10 mg, 8.8% placebo). Introduction of  a  new  treatment  for  PAH  or  a  change  in  treatment  dose  without  documented  disease worsening  were  the  most  common  deviations  in  all  groups  (4.8%  macitentan  3  mg,  4.5% macitentan 10 mg, 3.6% placebo).

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary endpoint:

A  confirmed  primary  endpoint  event  was  recorded  for  95  patients  and  76  patients  in  the macitentan 3 mg and 10 mg groups, respectively, versus 116 patients in the placebo group (EOT + 7 days) (Figure E-05). In the time-to-event analysis, the hazard ratio versus placebo for the occurrence of the primary endpoint in the macitentan 3 mg group was 0.704 (97.5% CLs 0.516, 0.960,  logrank  p  =  0.0108)  (Figure  E-05).  In  the  macitentan  10  mg  dose  group,  the  effect versus  placebo  was  highly  statistically  significant  as  measured  by  the  hazard  ratio  of  0.547 (97.5% CLs 0.392, 0.762, logrank p &lt; 0.0001). For the 10 mg dose it corresponded to an overall relative risk reduction of 45% and a number-needed-to-treat (NNT) of 6 patients (95% CLs 4.48, 10.80)  to  avoid  one  event  at  2  years.  The  Kaplan-Meier  curves  of  the  first  event  in  the  'Allrandomized set' are shown in Figure 3. The separation between macitentan groups and placebo appeared  early  and  was  clearly  established  at  6  months  (Kaplan-Meier  estimates  of  primary endpoint event-free rate 89.3% macitentan 3 mg group, 92.7% macitentan 10 mg group, 80.1% placebo group). The treatment effect of macitentan was sustained for the duration of the study: at all time-points, the proportion of patients who had not experienced a morbidity or mortality event was greater in the macitentan 3 mg and 10 mg groups than in the placebo group.

Figure O-E-05. Kaplan-Meier curves of the CEC-confirmed morbidity or mortality events for patients without concomitant PAH therapy at baseline, All-randomized set

ACT-064992,Protocol:AC-055-302

Timetofirstconfirmedmorbidity/mortalityeventuptoEOT+7days(CEC)(Kaplan-Meierestimate withstandarderrorbars) Analysisset:All-randomized monthsfrom

treatmentstart

Placebo

Macitentan 10 mg

<!-- image -->

Macitentan 3 mg

CEC=ClinicalEventCommittee,EOT=Endoftreatment.EventsconfirmedbyIndependentCEC. Survival plots are presentedup to36months,time at whichmore than10%of the patientsare still in follow-up.

<div style=\"page-break-after: always\"></div>

| Treatment difference vs. placebo   | Macitentan 3 mg   | Macitentan 10 mg   |
|------------------------------------|-------------------|--------------------|
| Hazard ratio                       | 0.704             | 0.547              |
| 97.5% CL of hazard ratio           | 0.516, 0.960      | 0.392, 0.762       |
| Logrank p-value                    | 0.0108            | <.0001             |

## Components of the primary endpoint events

The  most  frequently  first-reported  CEC-confirmed  event  was  'Other  worsening  of  PAH'  (Table OE-06). The proportion of patients with 'Other worsening of PAH' was 28.8% in the macitentan 3  mg  group  and  24.4%  in  the  macitentan  10  mg  group,  compared  to  37.2%  in  the  placebo group. The proportion of patients with death as the first event was 8.4% (21 patients) in the macitentan  3  mg  group,  6.6%  (16  patients)  in  the  macitentan  10  mg  group,  and  6.8%  (17 patients)  in  the  placebo  group,  questioning  any  claim  for  a  mortality  benefit  with  macitentan. This is further confirmed in the competing risk analysis (fig OE-06).

|                                                  | Placebo N=250   | Macitentan 3 mg N=250   | Macitentan 3 mg N=250   | Macitentan 10 mg N=242   | Macitentan 10 mg N=242   |
|--------------------------------------------------|-----------------|-------------------------|-------------------------|--------------------------|--------------------------|
|                                                  | No.             | No.                     |                         | No.                      | 号                        |
| Total PATIENlS with at least one confirmed event | 116 46.4%       |                         | 9538.0%                 | 76 31.48                 | 76 31.48                 |
| First confirmed event                            |                 |                         |                         |                          |                          |
| WORSENING OF PAH*                                | 9337.28 6.8号    |                         | 72 28.8%                |                          | 5924.4%                  |
|                                                  | 17              | 21                      | 8.4%                    | 16                       | 6.6                      |
| IV/SC PROSTANOID INITIATION                      | 6 2.4%          | 1                       | 0.4%                    | 1                        | 0.4号                     |
| LUNG TRANSPLANIATION                             |                 | 1                       | 0.4号                    |                          |                          |

Table O-E-06. Summary of components of primary endpoint events (CEC-confirmed), All-randomized set

<!-- image -->

Figure  OE-06.  Cumulative  incidence  functions  for  the  first  confirmed  morbidity  or mortality event up to EOT+7 d (CEC), All-randomized set

<!-- image -->

Timetofirstevent(monthsfromtreatmentstart)

Results  of  sensitivity  analyses  for  the  primary  endpoint,  based  on  variation  of  the  endpoint definition and/or population analyzed, supported those of the main analysis. In particular, results

<div style=\"page-break-after: always\"></div>

of the analyses for time to first event and the risk reduction with macitentan, using the CHMPdefined morbidity/mortality event, were consistent with the results of the primary analysis of the SERAPHIN study. In the time-to-event analysis, the HR versus placebo for the occurrence of a CHMP-defined event in the macitentan 10 mg dose group was 0.550 (97.5%CI: 0.417, 0.725; logrank  p&lt;0.0001).  In  the  macitentan  3  mg  group  was  0.737  (97.5%  CI:  0.568,  0.956; p=0.0083).  The  corresponding  relative  risk  reductions  versus  placebo  were  45%  and  26%, respectively.

Table  OE-07.  Summary  of  causes  of  CHMP  defined  events  up  to  EOT+7  d,  Allrandomised set

|                                                | Placebo =250   | Placebo =250   | Macitentan3mg =250   | Macitentan3mg =250   | MIacitentan l0 mg n=242   | MIacitentan l0 mg n=242   |
|------------------------------------------------|----------------|----------------|----------------------|----------------------|---------------------------|---------------------------|
|                                                |                | 96             |                      | 96                   |                           | 96                        |
| TotalPATIENTSmith≥1CHlPdefined event           | 163            | 65.2           | 137                  | 54.8                 | 113                       | 46.7                      |
| FirstCHlliPdefinedevent                        |                |                |                      |                      |                           |                           |
| PAHrelatedhospitalisation                      | 26             | #01            | 20                   | 8.0                  | 19                        | 7.9                       |
| Death                                          | EL             | 5.2            | 14                   | 5.6                  | 9                         | 3.7                       |
| Decreaseof2:15%6in6lMW'Tfombaselime            | 28             | 11.2           | 24                   | 9.6                  | 20                        | 8.3                       |
| WorseningofWHoFCfinom baseline                 | 21             | 8.4            | 12                   | 4.8                  | 13                        | 5.4                       |
| Sigus or symptoms of right-sided heant failure | 75             | 30.0           | 67                   | 26.8                 | 52                        | 21.5                      |
| TotalNUiBERofCHMiPdefinedeventst               | 472            |                | 369                  |                      | 301                       |                           |
| PAHrelatedhospitalisation                      | t6             | 19.9           | 67                   | 18.2                 | 57                        | 18.9                      |
| Death                                          | 19             | 4.0            | 21                   | 5.7                  | 14                        | 4.7                       |
| Decreaseof215%6in6lmWTfombaselime              | 121            | 25.6           | 101                  | 27.4                 | 82                        |                           |
| WorseningofWHoFCfombaseline                    | 112            | L'E7           | 79                   | 21.4                 | 68                        | 22.6                      |
| Sigusorsymptomsof right-sided heant failue     | 126            | 26.7           | 101                  |                      | 08                        | 26.6                      |

Figure  OE-07.  K-M  curves  of  the  first  CHMP  defined  event  up  to  EOT+7  d,  Allrandomised set

<!-- image -->

The treatment effects adjusted for covariates (sex, region, race, PAH therapy at baseline, PAH etiology  and  WHO  FC  at  baseline)  of  both  macitentan  dose  groups  were  consistent  with  the unadjusted results of the main analysis.

## Subgroup analyses

The  p-values  for  the  statistical  test  of  interaction  did  not  formally  show  heterogeneity  of  the treatment  effect  (macitentan  versus  placebo)  for  any  of  the  subgroup  analyses.  The  point estimate was above 1 only in North-America, but the confidence limits were wide due to the low sample size in that region.

<div style=\"page-break-after: always\"></div>

Figure O-E-08. Occurrence of the first morbidity or mortality event (CEC-confirmed) up to EOT + 7 days by subgroups (macitentan 10 mg versus placebo), All-randomized set

<!-- image -->

## Paediatric patients

There  was  limited  recruitment  of  paediatric  patients  in  SERAPHIN  (n=20),  which  could  be expected  in  an  orphan  indication.  However,  unlike  the  adult  population,  70%  of  the  patients discontinued the medication because of disease progression. It is difficult to comment further on the efficacy data considering this high drop-out rate, but the results do not point to any benefit compared to the placebo. In line with the efficacy data, reported safety data concern worsening of PAH and right ventricular failure. The SmPC has been amended to acknowledge that the safety and efficacy of macitentan in children have not yet been established.

## Right heart failure

A 43.7% of the patients enrolled in the SERAPHIN study met the criteria of right heart failure at baseline. Post-hoc analyses in this subgroup are consistent with those in the overall SERAPHIN population. The findings do not indicate that a potential increase in fluid retention would offset or impact negatively on the benefit of macitentan on morbidity/mortality in this population.

## Main secondary endpoint: change in 6MWD from baseline to month 6.

The  placebo-corrected  median  change  in  6MWD  from  baseline  to  Month  6  showed  similar treatment  effects  versus  placebo  in  the  macitentan  3  mg  (14.0  m,  97.5%  CLs  2.0,  27.0, Wilcoxon rank sum p = 0.0122) and macitentan 10 mg groups (15.0 m, 97.5% CLs 2.0, 28.0, Wilcoxon rank sum p = 0.0078) (Table OE-07). The corresponding mean (± standard deviation [SD])  treatment  effect  was  16.8  m  (±  96.95)  in  the  macitentan  3  mg  group  and  22.0  m  (± 92.58) in the macitentan 10 mg group.

<div style=\"page-break-after: always\"></div>

Table OE-08. Change from baseline in walk distance to Month 6, All-randomized set

<!-- image -->

|                                                     | Placebo    | Placebo    | Macitentan 3.mg   | Macitentan 3.mg   | Macitentan 10.mg   | Macitentan 10.mg   |
|-----------------------------------------------------|------------|------------|-------------------|-------------------|--------------------|--------------------|
|                                                     | N=250      | N=250      | N=250             | N=250             | N=242              | N=242              |
| Use of supplemental. oxygen                         |            |            |                   |                   |                    |                    |
| during baseline walk test                           |            |            |                   |                   |                    |                    |
|                                                     | 249        |            | 248               |                   | 242                |                    |
| Yes                                                 | 18         | 7.2%       | 21                | 8.5%              | 8                  | 3.3%               |
| No                                                  | 231        | 92.8号      | 227               | 91.5%             | 234                | 96.7%              |
| Baseline                                            |            |            |                   |                   |                    |                    |
| n                                                   | 249        |            | 248               |                   | 242                |                    |
| Mean                                                | 352        |            | 364               |                   | 363                |                    |
| Standard Ideviation                                 | 110.6      |            | 95.5              |                   | 93.2               |                    |
| Median                                              | 360        |            | 378               |                   | 378                |                    |
| 01 Q3                                               | 284        | 428        | 311               | 425               | 300                | 434                |
| Min1 Max                                            | 65         | 650        | 80                | 610               | 06                 | 578                |
| Month 6                                             |            |            |                   |                   |                    |                    |
| n                                                   | 249        |            | 248               |                   | 342                |                    |
| Mean                                                | 343        |            | 371               |                   | 375                |                    |
| Standard I deviation                                | 146.5      |            | 124.1             |                   | 114.7              |                    |
| Medlian                                             | 365        |            | 394               |                   | 390                |                    |
| 01 Q3                                               | 268        | 447        | 317               | 450               | 333                | 445                |
| Min Max                                             | 0          | 657        | 0                 | 615               | 0                  | 595                |
| Imputations for missing walues                      |            |            |                   |                   |                    |                    |
| n                                                   | 249        |            | 248               |                   | 242                |                    |
| Total imputed                                       | 52         | 20.9%      | 32                | 12.9%             | 30                 | 12.4%              |
| With an event. (not death) Worst value              | 5          | 2.0号       |                   | 号8*0              |                    |                    |
| Carry- forward                                      | 23         | 9.2%       | 12                | 4.8%              | 10                 | 4.1%               |
| With an event (death only) Worst value              | 9          | 3.6%       | 6                 | 2.4%              | 4                  | 1.7%               |
| Without am event Carry- forward (baseline)          | 7          | 2.8号       | 2                 | 号8*0              | 10                 | 4.1%               |
| Carry-forward (mot baseline)                        | 8          | 3.2号       | 10                | 4.0号              | 6                  | 2.5%               |
| Changefrombaseline                                  |            |            |                   |                   |                    |                    |
| n                                                   | 249        |            | 248               |                   | 242                |                    |
| Mean                                                | 9.4        |            | 7.4               |                   | 1 2.5              |                    |
| Standard deviation                                  | 100.59     |            | 93.15             |                   | 83 . 54            |                    |
| Median                                              | 1.0        |            | 17.0              |                   | 1 5 5              |                    |
| Min Q1 Q3 Max                                       | 380 42 0 0 | 292 44.0 0 | 4.65 15 0 0       | 258.0 50.0        | 423 1 4 .0 0       | 247. 51 0          |
| TREATMENTEFEECT                                     |            |            |                   |                   |                    |                    |
| Mean                                                |            |            | 16.8              |                   | 32 0               |                    |
| Standard deviation                                  |            |            | 96.95             |                   | 92.58              |                    |
| Standard error                                      |            |            | 8.70              |                   | 8.36               |                    |
| 97.58 CL ofmean                                     |            |            | 2.7               | 36.4              | 3.2                | 40.8               |
| Median 97.5% CL of median p-value Wilcoxon rank sum |            |            | 14.0 2.0 0.0122   | 27.0              | 15.0 2.0 0.0078    | 28.0               |
| Iable WIS_A - Produced by sturlor                   | On 26APR12 |            | Data dump of      | 26AFR12,          | (Fage l/1)         |                    |

CL=

Confidencelimit.

## Change in 6MWD across subgroups

Examination  of  6MWD  in  WHO  FC  I/II  and  WHO  FC  III/IV  patients  shows  that  the  treatment effects  with  macitentan  were  comparable  to  those  observed  in  other  studies  with  WHO  FC  II patient  population  [Galiè  2008]  or  a  WHO  FC  III/IV  patient  population  [Rubin  2002].  It  also appears  that  macitentan  provides  symptomatic  benefit  when  used  concomitantly  with  PAH background medications. These findings  differ  from  the  experience  gained  from  earlier  clinical trials  (PHIRST,  EARLY,  PACES  and  TRIUMPH),  but  are  similar  to  those  recently  published PATENT-1 study (riociguat). Some imbalances in the geographic areas and aetiologies between the treatment naïve patients and patients on background PAH therapy could be the cause of such observation, but no definitive conclusions can be drawn.

## Death-related secondary and exploratory analyses

Results of the secondary and exploratory analyses of SERAPHIN in which mortality was either a component of the endpoint or the endpoint itself are presented in Table O-E-08. With macitentan 10 mg, the risk reductions versus placebo in death or hospitalization due to PAH up to EOT + 7 days were up to 50% and statistically significant, while the reduction with macitentan 3 mg was 33%. A similar trend was seen for all cause death and death due to PAH for the 10 mg dose, but none of the comparisons was statistically significant. There was a neutral effect of the macitentan

<div style=\"page-break-after: always\"></div>

3  mg  dose  versus  placebo  on  mortality  (Table  O-E-09).  The  relative  risk  reduction  in  deathrelated endpoints was generally smaller for the entire study period compared to the period of analysis for the primary endpoint that covers the treatment phase only. This can be explained by the transition of the majority of placebo patients who experienced a non-fatal primary endpoint event in SERAPHIN to alternative therapies, including treatment with macitentan 10 mg in the SERAPHIN OL study. However, despite the small overall number of deaths irrespective  of  the length of the observation period, the observed positive effect of macitentan 10 mg on survival was consistent. These findings also illustrate the difficulties in conducting survival studies in PAH, as  patients  experiencing  a  worsening  of  PAH  primary  events  cannot  be  left  untreated.  With  a median  post-event  survival  of  over  two  years,  an  adequately  powered  survival  study  would require more than 3500 patients, which is not feasible in rare disease like PAH.

Table O-E-09. Results of the death-related endpoints of SERAPHIN, All-randomized set

| Endpoint                                   | Periodofassessment   | Placebo   | Macitentan3mg        | Macitentan10mg       |
|--------------------------------------------|----------------------|-----------|----------------------|----------------------|
| Death due to PAH 01 hospitalization forPAH | up toEOT+7days       | 8=u       | n=65                 | n=50                 |
| Hazard ratio VS placebo (97.5% CLs),       |                      |           | 0.669 (0.462, 0.970) | 0.500 (0.335, 0.747) |
| 1ogrank p-value                            |                      |           | p=0.0146             | p<0.0001             |
| Relativeriskreduction                      |                      |           | 33%                  | 50%                  |
| DeathduetoPAH                              | up toEOT+7days       | n = 14    | n=14                 | n=7                  |
| Hazard ratio (97.5% CLs).                  |                      |           | 0.872 (0.373, 2.037) | 0.441 (0.156, 1.248) |
| 1ogrankp-value                             |                      |           | p=0.7180             | p=0.0699             |
| Relativeriskreduction                      |                      |           | 13%                  | 56%                  |
| DeathduetoPAH                              | up to EoS            | n=28      | n=30                 | n=26                 |
| Hazard ratio (97.5% CLs),                  |                      |           | 1.050 (0.583, 1.893) | 0.901 (0.489, 1.660) |
| 1ogrankp-value                             |                      |           | p=0.8514             | p=0.7027             |
| Relativeriskreduction                      |                      |           | 0%                   | 10%                  |
| Death (all causes)                         | up to EOT + 7 days   | n=19      | n=21                 | n =14                |
| Hazard ratio (97.5% CLs).                  |                      |           | 0.971 (0.477, 1.976) | 0.638 (0.287, 1.418) |
| logrank p-value                            |                      |           | p =0.9249            | p=0.2037             |
| Relativeriskreduction                      |                      |           | 3%                   | 36%                  |
| Death (all causes)                         | up toEOS             | n=44      | n =47                | n=35                 |
| Hazard ratio (97.5% CLs),                  |                      |           | 1.046 (0.653, 1.673) | 0.771 (0.464, 1.282) |
| 1ogrankp-value                             |                      |           | p=0.8312             | p=0.2509             |
| Relativeriskreduction                      |                      |           | 0%                   | 23%                  |

Source: Appendix 2,table 15; Appendix 2,table 16;Appendix 2,figure 3;Appendix 2, table 17; Appendix 2,figure 4; Appendix 2, table 22; Appendix 2, figure 6; Appendix 2, table 23; and Figure 10.

CL=confidencelimit;EOS=endof study;EOT=end of treatment;PAH=pulmonary arterial hypertension.

The applicant also conducted landmark analyses to show that in SERAPHIN, a morbidity event, as defined  in  the  SERAPHIN  study  protocol,  was  a  significant  risk  factor  for  subsequent  death. Although the mortality results are not inconsistent with those of the main composite endpoint, the point estimate tends to be of a lesser magnitude than that of the composite endpoint (mainly driven by worsening of PAH), and statistical significance is not achieved for mortality.

## Other endpoints of clinical relevance

## Change in WHO FC

Improvements in WHO FC from baseline to Month 6 were reported for 19.8% of patients in the macitentan  3  mg  group  and  22.3%  of  patients  in  the  macitentan  10  mg  group,  compared  to

<div style=\"page-break-after: always\"></div>

12.9% of patients in the placebo group. This translates into a 54% higher chance of WHO FC improvement relative to placebo for patients in the 3 mg dose group (relative risk 1.54, 97.5% CLs  0.96,  2.46,  p  =  0.0395)  and  a  74%  higher  chance  of  WHO  FC  improvement  relative  to placebo  in  patients  in  the  10  mg  dose  group  (relative  risk  1.74,  97.5%  CLs  1.10,  2.74,  p  = 0.0063).

Borg dyspnoea index The estimated treatment effect over 12 months compared to placebo was - 0.47 (95% CLs - 0.72, - 0.22, p = 0.0002) for macitentan 3 mg and - 0.38 (95% CLs -0.63, 0.13, p = 0.0029) for macitentan 10 mg (a negative difference favours macitentan).

## Change  in  N-terminal  pro-B  type  natriuretic  peptide  (NT-pro-BNP)  from  baseline  to Month 6

The  median  change  versus  placebo  in  NT-pro-BNP  (a  biomarker  predicting  right  ventricular overload) from baseline to Month 6 was -130 fmol/mL (97.5% CLs -202, -65) with macitentan 3 mg and -160 fmol/mL (97.5% CLs -235, -95) with macitentan 10 mg. The applicant compared NT-proBNP  levels  within  the  SERAPHIN  study.  Higher  baseline  and  higher  absolute  values  at Month 6 were associated with a higher risk of morbidity and mortality, however no prognostic value of change from baseline was observed.

## Effect on quality of life

The normalized treatment effect (vs placebo) on the mean change from baseline to Month 6 was significantly in favour of macitentan (both doses) in the scores of the individual domains (normbased)  of  physical  functioning,  role  physical,  pain  index,  vitality,  social functioning,  role emotional,  mental  health  index,  physical  and  mental  component  summary  scores,  with  mean score improvements ranging between 2.6 to 3.8.

## Effect of macitentan on hospitalizations

Treatment  with  macitentan  reduces  the  number  of  hospitalizations  and  days  in  hospital  by approximately 50%.

Effect  of  macitentan  on  hemodynamics: Hemodynamic  endpoints  (change  in  PVR  and  CI from  baseline  to  Month  6)  were  analyzed  in  a  sub-set  of  the  SERAPHIN  population  who participated  in  the  PK/PD  sub-study  (n  =  187).  Macitentan  was  associated  with  a  treatment effect on pulmonary hemodynamics compared to placebo, which was of a magnitude similar to that observed with other ERAs treatments for PAH. There was no clear difference between the 3 mg and 10 mg doses on any of the hemodynamic variables collected in the overall population. The  applicant  explained  that  in  treatment-naïve  patients  administered  macitentan,  a  dose response  can  be  demonstrated  on  PVR  and  to  a  lesser  extent  on  CI.  This  is  in  line  with observations made with ambrisentan and sildenafil. However such dose response is not observed in patients already on PAH therapy.

## Summary of main efficacy results

The following table summarises the efficacy results from the main studies supporting the present application.  These  summaries  should  be  read  in  conjunction  with  the  discussion  on  clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Table O-E-10. Summary of efficacy for SERAPHIN trial

| Title: S tudy with E ndothelin R eceptor A ntagonist in P ulmonary arterial Hy pertension to improve cli N ical outcome: A multicenter, double-blind, randomized, placebo-controlled, parallel-group, event-driven, Phase III study to assess the   | Title: S tudy with E ndothelin R eceptor A ntagonist in P ulmonary arterial Hy pertension to improve cli N ical outcome: A multicenter, double-blind, randomized, placebo-controlled, parallel-group, event-driven, Phase III study to assess the   | Title: S tudy with E ndothelin R eceptor A ntagonist in P ulmonary arterial Hy pertension to improve cli N ical outcome: A multicenter, double-blind, randomized, placebo-controlled, parallel-group, event-driven, Phase III study to assess the   | Title: S tudy with E ndothelin R eceptor A ntagonist in P ulmonary arterial Hy pertension to improve cli N ical outcome: A multicenter, double-blind, randomized, placebo-controlled, parallel-group, event-driven, Phase III study to assess the   | Title: S tudy with E ndothelin R eceptor A ntagonist in P ulmonary arterial Hy pertension to improve cli N ical outcome: A multicenter, double-blind, randomized, placebo-controlled, parallel-group, event-driven, Phase III study to assess the                                                                                                                                                                                                             | Title: S tudy with E ndothelin R eceptor A ntagonist in P ulmonary arterial Hy pertension to improve cli N ical outcome: A multicenter, double-blind, randomized, placebo-controlled, parallel-group, event-driven, Phase III study to assess the                                                                                                                                                                                                             | Title: S tudy with E ndothelin R eceptor A ntagonist in P ulmonary arterial Hy pertension to improve cli N ical outcome: A multicenter, double-blind, randomized, placebo-controlled, parallel-group, event-driven, Phase III study to assess the                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| effects of macitentan on Study identifier                                                                                                                                                                                                           | morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. AC-055-302 (SERAPHIN; Module 5.3.5.1)                                                                                                                         | morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. AC-055-302 (SERAPHIN; Module 5.3.5.1)                                                                                                                         | morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. AC-055-302 (SERAPHIN; Module 5.3.5.1)                                                                                                                         | morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. AC-055-302 (SERAPHIN; Module 5.3.5.1)                                                                                                                                                                                                                                                                                                                                   | morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. AC-055-302 (SERAPHIN; Module 5.3.5.1)                                                                                                                                                                                                                                                                                                                                   | morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. AC-055-302 (SERAPHIN; Module 5.3.5.1)                                                                                                                                                                                                                                                                                                                                   |
| Design                                                                                                                                                                                                                                              | multicenter, double-blind, placebo-controlled, parallel-group, event-driven, Phase 3 study                                                                                                                                                          | multicenter, double-blind, placebo-controlled, parallel-group, event-driven, Phase 3 study                                                                                                                                                          | multicenter, double-blind, placebo-controlled, parallel-group, event-driven, Phase 3 study                                                                                                                                                          | multicenter, double-blind, placebo-controlled, parallel-group, event-driven, Phase 3 study                                                                                                                                                                                                                                                                                                                                                                    | multicenter, double-blind, placebo-controlled, parallel-group, event-driven, Phase 3 study                                                                                                                                                                                                                                                                                                                                                                    | multicenter, double-blind, placebo-controlled, parallel-group, event-driven, Phase 3 study                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                              | Duration of main phase:                                                                                                                                                                                                                             | Duration of main phase:                                                                                                                                                                                                                             | Duration of main phase:                                                                                                                                                                                                                             | EOT: approximately 3.8 years* Screening period up to 28 days                                                                                                                                                                                                                                                                                                                                                                                                  | EOT: approximately 3.8 years* Screening period up to 28 days                                                                                                                                                                                                                                                                                                                                                                                                  | EOT: approximately 3.8 years* Screening period up to 28 days                                                                                                                                                                                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                                              | Duration of Run-in phase:                                                                                                                                                                                                                           | Duration of Run-in phase:                                                                                                                                                                                                                           | Duration of Run-in phase:                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                                                                              | Duration of Extension phase:                                                                                                                                                                                                                        | Duration of Extension phase:                                                                                                                                                                                                                        | Duration of Extension phase:                                                                                                                                                                                                                        | 28-day safety follow-up or inclusion in the open- label (OL) extension (SERAPHIN OL)                                                                                                                                                                                                                                                                                                                                                                          | 28-day safety follow-up or inclusion in the open- label (OL) extension (SERAPHIN OL)                                                                                                                                                                                                                                                                                                                                                                          | 28-day safety follow-up or inclusion in the open- label (OL) extension (SERAPHIN OL)                                                                                                                                                                                                                                                                                                                                                                          |
| Hypothesis                                                                                                                                                                                                                                          | Superiority                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                                                                                                   | Macitentan 10 mg, OD                                                                                                                                                                                                                                | Macitentan 10 mg, OD                                                                                                                                                                                                                                | Macitentan 10 mg, OD                                                                                                                                                                                                                                | N=242                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=242                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=242                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Treatments groups                                                                                                                                                                                                                                   | Macitentan 3 mg, OD                                                                                                                                                                                                                                 | Macitentan 3 mg, OD                                                                                                                                                                                                                                 | Macitentan 3 mg, OD                                                                                                                                                                                                                                 | N=250                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=250                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=250                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Treatments groups                                                                                                                                                                                                                                   | Placebo                                                                                                                                                                                                                                             | Placebo                                                                                                                                                                                                                                             | Placebo                                                                                                                                                                                                                                             | N=250                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=250                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=250                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Endpoints and definitions                                                                                                                                                                                                                           | Primary endpoint                                                                                                                                                                                                                                    | the time to the first morbidity or mortality event up to EOT - - - -                                                                                                                                                                                | the time to the first morbidity or mortality event up to EOT - - - -                                                                                                                                                                                | Death, or onset of a treatment-emergent adverse event (AE) with a fatal outcome occurring within 4 weeks of study treatment discontinuation, or Atrial septostomy or hospitalization for atrial septostomy, or Lung transplantation or hospitalization for lung transplantation, or Initiation of intravenous or subcutaneous prostanoids (e.g., epoprostenol, treprostinil) or hospitalization for initiation of intravenous or subcutaneous prostanoids, or | Death, or onset of a treatment-emergent adverse event (AE) with a fatal outcome occurring within 4 weeks of study treatment discontinuation, or Atrial septostomy or hospitalization for atrial septostomy, or Lung transplantation or hospitalization for lung transplantation, or Initiation of intravenous or subcutaneous prostanoids (e.g., epoprostenol, treprostinil) or hospitalization for initiation of intravenous or subcutaneous prostanoids, or | Death, or onset of a treatment-emergent adverse event (AE) with a fatal outcome occurring within 4 weeks of study treatment discontinuation, or Atrial septostomy or hospitalization for atrial septostomy, or Lung transplantation or hospitalization for lung transplantation, or Initiation of intravenous or subcutaneous prostanoids (e.g., epoprostenol, treprostinil) or hospitalization for initiation of intravenous or subcutaneous prostanoids, or |
| Endpoints and definitions                                                                                                                                                                                                                           | Main secondary endpoint                                                                                                                                                                                                                             | 6MWD                                                                                                                                                                                                                                                | 6MWD                                                                                                                                                                                                                                                | - Other worsening of PAH Change in 6MWD from baseline to Month 6                                                                                                                                                                                                                                                                                                                                                                                              | - Other worsening of PAH Change in 6MWD from baseline to Month 6                                                                                                                                                                                                                                                                                                                                                                                              | - Other worsening of PAH Change in 6MWD from baseline to Month 6                                                                                                                                                                                                                                                                                                                                                                                              |
| Database lock                                                                                                                                                                                                                                       | 26-April-2012                                                                                                                                                                                                                                       | 26-April-2012                                                                                                                                                                                                                                       | 26-April-2012                                                                                                                                                                                                                                       | 26-April-2012                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26-April-2012                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26-April-2012                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Results and Analysis                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                          | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                          | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Analysis description                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                              | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                              | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Analysis population and time point description Descriptive statistics and estimate variability                                                                                                                                                      | Intent to treat (All-randomized set: all randomized patients irrespective of whether or not they received study drug)                                                                                                                               | Intent to treat (All-randomized set: all randomized patients irrespective of whether or not they received study drug)                                                                                                                               | Intent to treat (All-randomized set: all randomized patients irrespective of whether or not they received study drug)                                                                                                                               | Intent to treat (All-randomized set: all randomized patients irrespective of whether or not they received study drug)                                                                                                                                                                                                                                                                                                                                         | Intent to treat (All-randomized set: all randomized patients irrespective of whether or not they received study drug)                                                                                                                                                                                                                                                                                                                                         | Intent to treat (All-randomized set: all randomized patients irrespective of whether or not they received study drug)                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                     | Treatment group                                                                                                                                                                                                                                     | Treatment group                                                                                                                                                                                                                                     | Macitentan 10 mg                                                                                                                                                                                                                                    | Macitentan 10 mg                                                                                                                                                                                                                                                                                                                                                                                                                                              | Macitentan 3 mg                                                                                                                                                                                                                                                                                                                                                                                                                                               | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                     | Number of subject                                                                                                                                                                                                                                   | Number of subject                                                                                                                                                                                                                                   | N=242                                                                                                                                                                                                                                               | N=242                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=250                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=250                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                     | Patients with at least one confirmed event (PAH morbidity or mortality)                                                                                                                                                                             | Patients with at least one confirmed event (PAH morbidity or mortality)                                                                                                                                                                             | 76 (31.4%)                                                                                                                                                                                                                                          | 76 (31.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 95 (38%)                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 116 (46.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                                                                                                     | Number of subject                                                                                                                                                                                                                                   | Number of subject                                                                                                                                                                                                                                   | N=242                                                                                                                                                                                                                                               | N=242                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=248                                                                                                                                                                                                                                                                                                                                                                                                                                                         | N=249                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                     | Mean (±SD) change from baseline in 6MWD                                                                                                                                                                                                             | Mean (±SD) change from baseline in 6MWD                                                                                                                                                                                                             | 12.5 ± 83.54 m                                                                                                                                                                                                                                      | 12.5 ± 83.54 m                                                                                                                                                                                                                                                                                                                                                                                                                                                | 7.4 ± 93.15                                                                                                                                                                                                                                                                                                                                                                                                                                                   | -9.4 ± 100.59                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                                                                                                                                                                                                                      | Primary endpoint                                                                                                                                                                                                                                    | Primary endpoint                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                             | Macitentan 10 mg vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                   | Macitentan 10 mg vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                     | Hazard ratio                                                                                                                                                                                                                                        | Hazard ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.547                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.547                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                     | Kaplan-Meier - Logrank test 97.5% CL                                                                                                                                                                                                                | Kaplan-Meier - Logrank test 97.5% CL                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.392 to 0.762                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.392 to 0.762                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                             | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                       | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                       | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                                | Primary endpoint        | Comparison groups                        | Macitentan 3 mg vs placebo   |
|--------------------------------|-------------------------|------------------------------------------|------------------------------|
|                                | Primary endpoint        | Hazard ratio Kaplan-Meier - Logrank test | 0.704                        |
|                                | Primary endpoint        | 97.5% CL                                 | 0.516 to 0.960               |
|                                | Primary endpoint        | P-value                                  | 0.0108                       |
| Effect estimate per comparison | Main secondary endpoint | Comparison groups                        | Macitentan 10 mg vs placebo  |
| Effect estimate per comparison | Main secondary endpoint | Mean Wilcoxon rank sum                   | 22.0 m                       |
| Effect estimate per comparison | Main secondary endpoint | 97.5% CL of mean                         | 3.2 to 40.8 m                |
| Effect estimate per comparison | Main secondary endpoint | P-value                                  | 0.0078                       |
| Effect estimate per comparison | Main secondary endpoint | Comparison groups                        | Macitentan 3 mg vs placebo   |
| Effect estimate per comparison | Main secondary endpoint | Mean Wilcoxon rank sum                   | 16.8 m                       |
| Effect estimate per comparison | Main secondary endpoint | 97.5% CL of mean                         | -2.7 to 36.4 m               |
| Effect estimate per comparison | Main secondary endpoint | P-value                                  | 0.0122                       |

CL  =  confidence  limits;  EoT  =  end  of  treatment  (Patients  could  discontinue  study  treatment  at  any  time following randomization. EOT coincided with end of study for patients who were still on study drug on the date of study completion: 30 January 2012, announced by Actelion); HR = hazard ratio;

*From first patient, first visit (25 May 2008) to last patient, last visit (15 March 2012)

## Clinical studies in special populations

Not applicable (see previous section for subgroup analyses).

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

This application is based on the results of a single, long-term, double-blind pivotal Phase 3 study, AC-055-302/SERAPHIN. The pivotal study included a clinically relevant primary endpoint (time to clinical worsening or time to first morbidity or mortality event).

SERAPHIN is the largest study conducted so far in PAH (n=742) and included a wide population of  PAH  patients  (n=742)  with  different  ages,  aetiologies,  FC  and  background  medications. However, some populations were under-represented. There was limited recruitment of paediatric patients  in  SERAPHIN  (n=20).  Unlike  the  adult  population,  70%  of  the  paediatric  patients discontinued  the  medication  because  of  disease  progression,  which  do  not  support  the  use  of macitentan in children.

Almost all patients were in WHO FC II-III, while only 1 patient was in FC I and only 14 patients were in FC IV. As a result, patients on FC I and IV have been removed from the indication due to the very limited data available. Idiopathic PAH was the most common aetiology (55%) followed by  PAH  due  to  connective  tissue  (30%)  and  PAH  due  to  congenital  shunts  (8%).  This  latter subpopulation only included PAH  associated to corrected simple congenital systemic-topulmonary  shunts,  since  patients  with  PAH  associated  with  non-corrected  simple  congenital systemic-to-pulmonary shunts and combined and complex systemic-to-pulmonary shunts were excluded.  Therefore,  'PAH  due  to  congenital  shunts'  has  been  excluded  from  the  indication initially applied for.

At baseline, the majority (approximately  64%)  of  patients  were  receiving  at  least  one background  PAH  therapy  at  baseline.  Sildenafil  was  the  most  common  PAH  therapy  and  was taken by approximately 58% of patients across the groups.

<div style=\"page-break-after: always\"></div>

The patients were predominantly Caucasian (54.5%) or Asian (27.7%), reflecting the fact that the majority of patients were recruited at centres in Europe and Asia. Approximately 43.7% of the patients enrolled in the SERAPHIN study met the criteria of right heart failure at baseline. The analysis of the primary and main secondary outcome in the population with heart failure was consistent with the results in the overall study population. In addition, a planned sample size resizing  was conducted during the study, resulting in an increase in the initially planned sample size. Additional analysis shows no influence of the sample size increase in the final study results.

The study was well designed and also well conducted.

## Efficacy data and additional analyses

The primary endpoint analysis demonstrated a clinically relevant effect of macitentan 10 mg to reduce the risk of occurrence of a morbidity or mortality event in the study population, which was below the prespecified significance criteria (p&lt;0.001) for a 'conclusive study' [HR: 0.547 (97.5%  CLs  0.392,  0.762,  logrank  p  &lt;  0.0001].  In  contrast,  the  corresponding  HR  for  the macitentan  3  mg  group  versus  placebo  was  0.704  [97.5%  CI:  0.516  to  0.960;  logrank  p  = 0.0108).  The  treatment  effect  with  macitentan  on  the  primary  endpoint  was  established  early and was sustained during treatment (median duration of more than 2 years). For the 10 mg dose it corresponded to an overall relative risk reduction of 45% and a number-needed-to-treat (NNT) of 6 patients (95% CLs 4.48, 10.80) to avoid one event at 2 years. Results of sensitivity analyses for the primary endpoint were consistent with those of the main analysis.

The Applicant was asked to perform a sensitivity analysis of the primary endpoint using the components recommended in the PAH guideline (EMEA/CHMP/EWP/356954/2008).

The most frequent first-reported morbidity or mortality event in all groups was 'other worsening of  PAH'  (28.8%  macitentan  3  mg,  24.4%  macitentan  10  mg,  37.2%  placebo).  The  effect  of macitentan  10  mg  was  generally  consistent  across  subgroup  and  sensitivity  analyses.  In  the time-to-event analysis, the HR versus placebo for the occurrence of a CHMP-defined event in the macitentan 10 mg dose group was 0.550 (97.5%CI: 0.417, 0.725; logrank p&lt;0.0001). In the macitentan  3  mg  group  was  0.737  (97.5%  CI:  0.568,  0.956;  p=0.0083).  The  corresponding relative  risk  reductions  versus  placebo  were  45%  and  26%,  respectively,  which  are  broadly similar  to  the  results  of  the  main  analysis.The  applicant's  reanalysis  was  consistent  with  the analysis of the main outcome as defined in SERAPHIN.

The  secondary  endpoints  (change  in  6MWD,  separate  components  of  the  primary  endpoint, hemodynamic  endpoints,  dyspnoea  symptoms,  NT-pro-BNP  levels  and  QoL  endpoints  were considered exploratory and appropriate. The tested doses (3 mg and 10 mg) were well justified on the basis of PD data and the median exposure exceeded 2 years. Based on the PK/PD and efficacy data provided, the recommendation of the 10mg dose is appropriately justified.

Regarding mortality, the proportion of patients with death as the first event was 8.4% in the macitentan 3 mg group, 6.6% in the macitentan 10 mg group, and 6.8% in the placebo group, questioning any claim for a mortality benefit with macitentan. This is further confirmed in the competing  risk  analysis  (fig  OE-06).  Although  the  mortality  results  are  not  inconsistent  with those of the main composite endpoint, the point estimate tends to be of a lesser magnitude than that of the composite endpoint (mainly driven by worsening of PAH), and statistical significance is  not  achieved  for  mortality.  According  to  the  'Guideline  on  the  clinical  investigations  of

<div style=\"page-break-after: always\"></div>

medicinal products for the treatment of pulmonary arterial hypertension (Doc. Ref. EMEA/CHMP/EWP/356954/2008): ' Specific  claims  on  mortality  can  only  be  supported  by  longterm  controlled  studies  including  death  as  a  primary  endpoint '.  While  acknowledging  the  big effort of the company to conduct the largest clinical trial so far in PAH, a mortality claim cannot be included in section 4.1 due to the above-mentioned reasons.

During the procedure, the CHMP requested the applicant to propose a wording of the indication in line  with  the  PAH  guideline,  and  the  SERAPHIN  results  showing  delay  in  'time  to  clinical worsening'. The applicant did not accept, arguing that this is already stated in Section 5.1 for several PAH medicines (bosentan, ambrisentan, sildenafil) based on less stringent criteria than those  implemented  in  SERAPHIN.   The  applicant  also  argued  that  delay  in  \"time  to  clinical worsening\"  may  not  be  an  appropriate  reflection  of  the  SERAPHIN  data  and  may  not  be  an incentive to further improved drug development in PAH. The applicant then proposed a claim of 'delay  in  progression  of  the  disease',  arguing  that  primary  endpoint  in  SERAPHIN  measured progression of the disease. However, this proposal was rejected by the CHMP as this would imply that macitentan is a disease-modifying agent, whereas the main effect of ERAs is vasodilation.

Finally,  the  applicant  proposed  a  new  wording  without  including  any  specific  claim  in  the indication but including a cross-reference to section 5.1. This proposal was deemed acceptable by the CHMP, and should be interpreted in light of the broader body of evidence with macitentan from  SERAPHIN in comparison with other PAH studies where claims have been limited to the 6MWT and/or symptoms. However, as comparative studies are lacking, no final conclusions can be drawn on their relative benefit in patients with PAH.

A total of 27 patients did not complete the study and therefore vital status was missing at EOS, i.e., lost to follow-up, etc.). Missing data were well balanced by treatment group. The results of the sensitivity analyses using the Best-case, Base-case and Worst-case scenarios were similar to that of the primary analysis for the time to death up to EOS, with risk reductions ranging from 33% to 16% across all analyses (none of them statistically significant). The primary analysis risk reduction of 23% falls well within that range.

The secondary endpoint of placebo-corrected median change in 6MWD from baseline to Month 6 showed similar treatment effects versus placebo in the macitentan 3 mg (median 14.0 m, 97.5% CLs 2.0, 27.0 p=0.0122) and macitentan 10 mg groups (median 15.0 m, 97.5% CLs 2.0, 28.0, p =  0.0078).  The  p-value  for  improvement  in  6MWD  is  above  the  0.001  value  prefixed  in  the protocol to consider the results as conclusive. In addition, the clinical relevance of a 15 m median improvement is questionable. Therefore, it is agreed the Applicant's proposal not to reflect the improvement in exercise capacity in the indication.

The composite of hospitalization or death due to PAH up to EOT + 7 days was reduced by 50% versus placebo with macitentan 10 mg [HR: 0.50 (97.5% CLs 0.34, 0.75, logrank p&lt;0.0001)], thus providing consistent support for a benefit of macitentan 10 mg versus placebo.

Exploratory  results  in  WHO  FC,  Borg  dyspnoea  index,  Quality  of  life,  hospitalizations,  change versus  placebo  in  NT-pro-BNP  and  hemodynamics  were  consistent  with  those  of  the  primary endpoint.

A majority of patients (approximately 64%) of patients were receiving at least one background PAH  therapy  at  baseline.  Sildenafil  was  the  most  common  PAH  therapy  and  was  taken  by

<div style=\"page-break-after: always\"></div>

approximately 58% of patients across the groups and the effect of macitentan was consistent in patients with or without background PAH therapy at baseline. These data are considered robust enough to support the indication of the use of macitentan alone or as combination therapy on top of the standard of care.

## 2.5.4. Conclusions on the clinical efficacy

Clinical data available supports the efficacy of macitentan 10 mg OD in the long-term treatment of  PAH.  The  efficacy  has  been  shown  in  adult  patients  with  functional  class  II  and  III,  as monotherapy or in combination with other PAH therapies (PDE-5 inhibitors and prostanoids), in a PAH  population  with  idiopathic  and  heritable  PAH,  PAH  associated  with  connective  tissue disorders, and PAH associated with corrected simple congenital heart disease.

## 2.6. Clinical safety

The applicant has provided data of several pooled safety datasets comprising the pivotal study, the  Phase  2  studies,  data  from  the  phase  I  studies  and  data  from  the  Phase  3  trials  in  other indications  (essential  hypertension  and  IPF).  No  studies  with  an  active  comparator  have  been presented with this application.

The  first  pool  (Pool  1)  includes  the  Phase  2/3  completed  controlled-trials  (AC-055-201,  AC055B201, and AC-055-302 SERAPHIN). Nevertheless, results of this pool will likely be driven by SERAPHIN trial  that  recruited  more  than  700  patients.  The  second  pool  (Pool  2)  includes  the pivotal trial (AC-055-302/SERAPHIN) and its ongoing open-label extension (AC-055303/SERAPHIN  OL)  with  the  aim  of  providing  information  on  the  long-term  safety  profile  of macitentan. Only the SERAPHIN study and its open-label extension were conducted in the target population, as study AC-055-201 was performed in patients with essential hypertension, study AC-055B201  was  conducted  in  patients  with  idiopathic  pulmonary  fibrosis  (IPF)  and  clinical pharmacology studies were conducted in volunteers.

## Patient exposure

A  total  of  1299  patients  were  enrolled  in  phase  2  and  3  studies.  Of  them,  863  patients  were exposed to macitentan.

The safety dataset size seems adequate for the PAH indication.

## Pool 1Placebo-controlled trials (SERAPHIN PAH; MUSIC IPF; AC-055-201 in essential hypertension)

Of the 863 patients exposed to any dose of macitentan, 533 received treatment for at least 6 months (including 317 exposed to macitentan 10 mg); 447 patients received treatment for at least 12 months (including 258 exposed to macitentan 10 mg).

<div style=\"page-break-after: always\"></div>

## Pool 2 - PAH patients (SERAPHIN and SERAPHIN OL)

675 patients were treated with macitentan in the targeted indication, with a mean exposure of 126 weeks (up to 202 weeks). Around 60% were exposed for 96 weeks or more, corresponding to 1321 patient-years exposure.

## Open-label extension trial

Of the 550 patients exposed to 10 mg macitentan during the ongoing open-label extension trial in PAH indication, 164 patients have been treated for at least 6 months, and 127 patients have been treated for at least 12 months (excluding previous exposure time during the double-blind phase).

Table S-01. Overall exposure to macitentan in Phase 2 and Phase 3 studies

|                                                         | Totalnumber ofpatients enrolled   | Patients macitentan (any dose)   | Patients exposedtothe proposeddose (10 mg)   | Patientswithlong-term safetydata(anydose)a   | Patientswithlong-term safetydata(anydose)a   |
|---------------------------------------------------------|-----------------------------------|----------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                                         |                                   |                                  |                                              | ≥6months                                     | ≥12months                                    |
| Placebo-controlled (AC-055-201, AC-055B201, AC-055-302) | 1299                              | 863                              | 423                                          | 533b                                         | 447c                                         |
| Open-labelPAH extension trial (AC-055-303)d             | 550                               | 550                              | 550                                          | 164°                                         | 127°                                         |
| Postmarketing                                           | 0                                 | 0                                | 0                                            | 0                                            | 0                                            |
| Compassionate use                                       | 0                                 | 0                                | 0                                            | 0                                            | 0                                            |

Patientsexposedtoanydoseofmacitentanfor atleast6or12months;note thatinstudyAC-055-201,allpatients were exposed for less than 6 months, and are therefore not included in this column.

Ofthese,25Spatientswereexposedto theproposeddoseof10mgfor≥12months.

bOfthese,317patientswereexposed to the proposed doseof10 mgfor≥6months.

Exposuretomacitentan(10mg)duringtheopen-labelextensiontoSERAPHIN;excludestimeofexposuretoprevious treatment in the double-blind PAH study (AC-055-302).

No active comparators were used in thrials in PAH or IPF indications.

Source:IntegratedSafety Analysis,Appendix5,Table 4 and Appendix6,Table 2[D-12.601];refers toexposure in

Phase 2and 3studies, up to the cut-off date of 26April 2012.

PAH=pulmonaryarterialhypertension

It is also important to highlight the additional exposure from the following 2 indications:

## Ischaemic digital ulcers associated with systemic sclerosis

245 and 193 patients, respectively, were receiving double-blind study treatment with macitentan 3  or  10  mg  or  placebo  in  the  ongoing  studies  AC-055C301  and  AC-055C302  in  patients  with ischaemic digital ulcers associated with systemic sclerosis. Up to the 29 March 2013 cut-off date, the duration of exposure to double-blind treatment was up to 63.7 weeks (median 24.1 weeks) and 59.3 weeks (median 22.7 weeks), respectively.

## Recurrent gliobastoma

As of 7 February 2013, 13 patients were enrolled and exposed to daily macitentan doses of 30 mg  up  to  120  mg  in  the  ongoing  study  in  recurrent  glioblastoma  (AC-055-115).  Maximum exposure to macitentan 30 mg was 391 days, to macitentan 60 mg was 59 days, to macitentan 90 mg was 147 days and to macitentan 120 mg was 107 days.

## Adverse events

In the double-blind PAH population, the overall incidence of AEs in the macitentan groups was similar  to  that  in  the  placebo  group.  PAH  (i.e.,  worsening  of  PAH)  was  the  most  frequently reported (30 %, 21 % and 34.9 % for macitentan 3mg, 10mg and placebo). Right ventricular failure (14.8%, 13.2 % and 22.5 % for macitentan 3mg, 10mg and placebo), which is the most clinically  relevant long-term complication of PAH was also reported at a lower incidence in the macitentan treatment groups than in the placebo group.

<div style=\"page-break-after: always\"></div>

Table 31 Adverse events in the double-blind PAH population by preferred term (at least 3.0% in the total macitentan group)

|                                | 3 mg (N=250) n (%)   | 10 mg (N=242) n (%)   | Total Macitentan (N=492) n (%)   | Placebo (N=249) n (%)   |
|--------------------------------|----------------------|-----------------------|----------------------------------|-------------------------|
| Number of patients with AEs    | 240 (96.0)           | 229 (94.6)            | 469 (95.3)                       | 240 (96.4)              |
| PULMONARYARTERIALHYPERTENSION  | 75 (30.0)            | 53 (21.9)             | 128 (26.0)                       | 87 (34.9)               |
| UPPERRESPIRATORYTRACTINFECTION | 50 (20.0)            | 37 (15.3)             | 87 (17.7)                        | 33 (13.3)               |
| OEDEMAPERIPHERAL               | 40 (16.0)            | 44 (18.2)             | 84 (17.1)                        | 45 (18.1)               |
| NASOPHARYNGITIS                | 37 (14.8)            | 34 (14.0)             | 71 (14.4)                        | 26 (10.4)               |
| RIGHTVENTRICULAR FAILURE       | 37 (14.8)            | 32 (13.2)             | 69 (14.0)                        | 56 (22.5)               |
| HEADACHE                       | 33 (13.2)            | 33 (13.6)             | 66 (13.4)                        | 22 (8.8)                |
| ANAEMIA                        | 22 (8.8)             | 32 (13.2)             | 54 (11.0)                        | 8 (3.2)                 |
| DIZZINESS                      | 24 (9.6)             | 26 (10.7)             | 50 (10.2)                        | 27 (10.8)               |
| BRONCHITIS                     | 20 (8.0)             | 28 (11.6)             | 48 (9.8)                         | 14 (5.6)                |
| DYSPNOEA                       | 26 (10.4)            | 18 (7.4)              | 44 (8.9)                         | 22 (8.8)                |
| COUGH                          | 20 (8.0)             | 21 (8.7)              | 41 (8.3)                         | 30 (12.0)               |
| CHEST PAIN                     | 20 (8.0)             | 19 (7.9)              | 39 (7.9)                         | 20 (8.0)                |
| URINARY TRACT INFECTION        | 16 (6.4)             | 21 (8.7)              | 37 (7.5)                         | 14 (5.6)                |
| DIARRHOEA                      | 14 (5.6)             | 22 (9.1)              | 36 (7.3)                         | 17 (6.8)                |
| INSOMNIA                       | 17 (6.8)             | 17 (7.0)              | 34 (6.9)                         | 10 (4.0)                |
| SYNCOPE                        | 21 (8.4)             | 11 (4.5)              | 32 (6.5)                         | 21 (8.4)                |
| HYPOTENSION                    | 14 (5.6)             | 15 (6.2)              | 29 (5.9)                         | 11 (4.4)                |
| HYPOKALAEMIA                   | 13 (5.2)             | 14 (5.8)              | 27 (5.5)                         | 14 (5.6)                |
| ARTHRALGIA                     | 15 (6.0)             | 11 (4.5)              | 26 (5.3)                         | 10 (4.0)                |
| PALPITATIONS                   | 14 (5.6)             | 12 (5.0)              | 26 (5.3)                         | 13 (5.2)                |
| PHARYNGITIS                    | 11 (4.4)             | 15 (6.2)              | 26 (5.3)                         | 7 (2.8)                 |
| BACK PAIN                      | 16 (6.4)             | 9 (3.7)               | 25 (5.1)                         | 21 (8.4)                |
| INFLUENZA                      | 11 (4.4)             | 14 (5.8)              | 25 (5.1)                         | 4 (1.6)                 |
| NAUSEA                         | 13 (5.2)             | 12 (5.0)              | 25 (5.1)                         | 13 (5.2)                |
| RESPIRATORYTRACTINFECTIONVIRAL | 9 (3.6)              | 15 (6.2)              | 24 (4.9)                         | 9 (3.6)                 |
| SINUSITIS                      | 11 (4.4)             | 11 (4.5)              | 22 (4.5)                         | 6 (2.4)                 |
| FATIGUE                        | 11 (4.4)             | 9 (3.7)               | 20 (4.1)                         | 15 (6.0)                |
| GASTROENTERITIS                | 12 (4.8)             | 8 (3.3)               | 20 (4.1)                         | 3 (1.2)                 |
| PNEUMONIA                      | 10 (4.0)             | 10 (4.1)              | 20 (4.1)                         | 13 (5.2)                |
| EPISTAXIS                      | 11 (4.4)             | 8 (3.3)               | 19 (3.9)                         | 9 (3.6)                 |
| PYREXIA                        | 9 (3.6)              | 9 (3.7)               | 18 (3.7)                         | 9 (3.6)                 |
| RESPIRATORY TRACT INFECTION    | 9 (3.6)              | 9 (3.7)               | 18 (3.7)                         | 10 (4.0)                |
| THROMBOCYTOPENIA               | 6 (2.4)              | 12 (5.0)              | 18 (3.7)                         | 7 (2.8)                 |
| VOMITING                       | 8 (3.2)              | 10 (4.1)              | 18 (3.7)                         | 17 (6.8)                |
| DYSPEPSIA                      | 10 (4.0)             | 7 (2.9)               | 17 (3.5)                         | 14 (5.6)                |
| PAIN IN EXTREMITY              | 10 (4.0)             | 7 (2.9)               | 17 (3.5)                         | 15 (6.0)                |
| ABDOMINALPAIN UPPER            | 5 (2.0)              | 11 (4.5)              | 16 (3.3)                         | 11 (4.4)                |
| CONSTIPATION                   | 9 (3.6)              | 7 (2.9)               | 16 (3.3)                         | 6 (2.4)                 |
| GASTRITIS                      | 10 (4.0)             | 6 (2.5)               | 16 (3.3)                         | 7 (2.8)                 |
| ABDOMINAL PAIN                 | 8 (3.2) (2.8)        | 7 (2.9) (3.3)         | 15 (3.0) 15 (3.0)                | 4 (1.6) (1.6)           |
| SKIN ULCER                     | 7 (2.8)              | 8 (3.3)               | 15 (3.0)                         | 3 (1.2)                 |

Note: For each preferred term, a patient is counted once if the patient had one or more events in that category. Denominators for percentages are based on number of patients in Safety Population for each treatment group. Preferred terms are sorted in descending order of the Total Macitentan frequency count.

AE = adverse event

StudyAC-055-302

Source: Appendix 5, Table 31 and Table 36

Other  AEs  reported  were:  upper  respiratory  tract  infection  (20%,  15.3  %  and  13,3%  for macitentan  3mg,  10mg  and  placebo),  anaemia  (8.8  %,  13.2  %  and  3.2  %,  respectively), thrombocytopenia (2.4 %, 5.0 % and 2.8 %), oedema peripheral (16%, 18.2 % and 18,1%), hypotension (5.6% and 6.2%, and 4.4 %), headache (13.2% and 13.6%, 8.8%), insomnia (6.8 %, 7.0 % and 4.0%), urinary tract infection (6.4%, 8.7 % and 5.6 %), gastroenteritis (4.8 %, 3.3 % and 1, 2%), skin ulcers (2.8%, 3.3 % and 1.2%), abdominal pain (3.2 %, 2.9 % and 1,6 %), and drug hypersensitivity (1.2%, 0.8 % and 0%). Around 95% of patients of the pooled double-blind PAH population had at least one AE (96%, 94.6% and 96.4% for macitentan 3mg, 10mg and placebo). Similar distribution of AEs was observed in other groups of patients.

In the pool 1, the majority of patients experienced at least one AE (more than 80% in the three treatment groups). The most common AEs were similar to double blind PAH population. These AEs  would  be  reflecting  disease  progression  in  the  placebo  group  (and  in  the  3mg  treatment group). In the pool 2, while the proportion of patients with any AEs increased from 63.3% at 0-6 months  of  macitentan  exposure  to  75.2%  at  6-12  months  and  slightly  increased  up  to  30 months  of  macitentan  exposure  (85.4%),  indicating  that  the  longer  the  exposure,  the  higher percentage of AEs. The percentage of patients with any SAE was constant (around 15-20%) over time. With respect to AEs, the incidence liver abnormalities, oedema and anaemia increased up

<div style=\"page-break-after: always\"></div>

to  30  months  of  exposure  while  the  incidence  decreased  or  was  maintained  for  hypotension, renal  impairment,  respiratory  infections,  malignancies  or  MACE.  In  none  of  the  analyses  was there evidence of dose-response relationship.

Hypotension: In  the  double-blind  PAH  trial,  there  was  also  a  higher  incidence  of  hypotension relative  to  placebo  (6.0%,  7.0%  and  4.4%  for  macitentan  3  mg,  10  mg,  and  placebo, respectively).  However,  hypotension  as  an  SAE  was  reported  less  frequently  for  macitentan (0.4% and 0.8% for macitentan 3mg and 10mg) than for placebo (1.2%), and only 1 patient on macitentan 10 mg discontinued due to this AE. Hypotension cases were predominantly reported in  female  patients  and  there  was  no  indication  of  an  increased  incidence  in  other  potentially vulnerable subgroups, such as the elderly. Hypotension cases were not associated to a higher incidence of dizziness or syncope in the macitentan group. No data have been provided for the Pool 1 as it includes patients coming from the essential hypertension study.

| Table73                                                                                                                   | Hypotensionbysubgroupin thedouble-blindPAHpopulation   | Hypotensionbysubgroupin thedouble-blindPAHpopulation   | Hypotensionbysubgroupin thedouble-blindPAHpopulation   |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                                                                                           | Macitentan 3 mg                                        | Macitentan 10mg                                        | Placebo                                                |
| Sub-group by sex Male Female                                                                                              | 0 7.48 (14/189)                                        | 2.1% (1/48) 7.28 (14/194)                              | 3.1 (2/65) 4.9% (9/184)                                |
| Sub-group by age Eiderly Adlults                                                                                          | 3.0% (1/33) 5.7% (12/210) 14.38 (1/7)                  | 3.7% (1/27) 6.7% (14/209)                              | 6.88 (3/44) 3.5% (7/198) 14.3 (1/7)                    |
| Adolescents Sub-group by WHO FC at baseline WHO FC I/II WHO FC III/IV Sub-group by PAH etiology Idiopathie other PAH      | 3.6% (5/138) 8.0% (9/112) 4.9% (8/164)                 | 4.1% (5/121) 8.3% (10/121) 6.1% (9/147)                | 1.5° (2/130) 7.6% (9/119) 3.6% (5/140)                 |
| PAH due to congenital shunts (2/15) PAH due to CVD Sub- group by clinical sigms andl of RHF at baseline (yes/no)          | 13.3 5.7% (4/70) 9.2% (7/76) 4.0% (7/174)              | 4.8% (1/21) 6.8% (5/73) 7.9% (6/76) 5.4% (9/166)       | 3.8% (1/26) 6.18 (5/82) 7.7% (6/78)                    |
| Yes No                                                                                                                    |                                                        |                                                        | 2.9% (5/171)                                           |
| Sub-group by PAH therapy at baseiine (yes/no) Yes No                                                                      | 6.1% (10/164) 4.7% (4/86)                              | 4.5 (7/154) 9.1% (8/88)                                | 3.3% (5/153) 6.3% (6/96)                               |
| cnoxb-cms by race White Asian                                                                                             | 6.6% (9/137) 1.4% (1/70) 9.3% (4/43)                   | 8.1% (11/135) 4.6% (3/65) 2.48 (1/42)                  | 6.9% (9/130) 1. 48 (1/71)                              |
| Other Sub-group by location North America (including Canada) S.                                                           |                                                        |                                                        | 2.18 (1/48)                                            |
| Western Europe Africa and Israel) (ineluding                                                                              | 3.3% (1/30) 2.4% (1/42)                                | 4.3% (1/23) 4.2% (2/48)                                | 6.7% (2/30)                                            |
| Eastern Europe (including Turkey)                                                                                         | 9.5% (6/63)                                            | 12.9% (8/62) 4.4% (3/68)                               | 8.0% (4/50) 6.8% (4/59)                                |
| Asia (including Australia) Latin America                                                                                  | 2.8% (2/71) 9.18 (4/44)                                | 2.48 (1/41)                                            | 1.5 (1/68) 0                                           |
| Baseline renal impairment* No                                                                                             | 4.9% (5/102) 5.7% (6/105)                              | 4.0% (4/100) 7.4% (7/94)                               | 0                                                      |
| Mild Moderate                                                                                                             |                                                        |                                                        | 9.5% (9/95)                                            |
|                                                                                                                           | 7.58 (3/40)                                            | 6.8% (3/44)                                            | 4.3%                                                   |
|                                                                                                                           |                                                        |                                                        | (2/46)                                                 |
| CVD = collagen vascular disease, FC = functional class, PAH = pulmonary arterial hypertension, RHF = right heart failure. |                                                        |                                                        |                                                        |
| ?baselinerenalimpairmentstatuswasunknownfor 2patientsin themacitentan10mggroup. StudyAC-055-302                           |                                                        |                                                        |                                                        |

In  Pool  2,  the  incidence  of  hypotension  was  slightly  more  frequent  at  the  start  of  treatment (2.7%)  compared  to  patients  treated  longer  than  30  months  (0.7%). In  the  IPF  population, similar  percentages  were  observed  for  macitentan  10mg  and  placebo  (5.9%  and  5.1% respectively). Incidence was also higher for the macitentan group when it was presented as per 100 patient-years (5.4% versus 4.3% respectively). In the clinical pharmacology DDI study with macitentan  and  sildenafil,  a  decrease  in  systolic  pressure  by  a  maximum  of  8  mmHg  from  a baseline of 120mmHg was observed.

Considering  that  patients  on  macitentan  are  likely  to  be  treated  concomitantly  with  sildenafil, cases  of  hypotension  (decrease  in  systolic  pressure  from  baseline  and  concomitant  symptoms like  dizziness or syncope) were reviewed. After review, despite the fact that hypotension does

<div style=\"page-break-after: always\"></div>

not seem particularly worrisome in PAH patients even in combination with other PAH therapy, it is considered a class effect of ERAs and data on hypotension from SERAPHIN have been included in section 4.8 of the Opsumit SmPC.

Infections: The incidence of respiratory infection AEs in patients on macitentan 3 mg and 10 mg was higher than in placebo, both in Pool 1 (36%, 33.1% and 24.6%, respectively) and in the double-blind  PAH  population  (43.6%,  40.9%  and  28.5%).  Nevertheless,  the  majority  of respiratory infections occurred in the upper respiratory tract and few resulted in discontinuation of the study (none in pool 1 and 0.8% in macitentan 3mg in the double-blind PAH population). The  applicant  states  that  this  higher  incidence  may  be  due  to  a  reporting  bias,  as  nasal congestion  symptoms  are  observed  in  relation  to  the  effect  of  vasodilation  of  the  drug  which seems  reasonable.  It  is  reassuring  that  when  incidence  is  adjusted  by  exposure  results  are similar for macitentan a placebo (23.1, 22.6 and 18.8 events per 100 patient-years for the two doses  of  macitentan  and  placebo)  for  Pool  1.  In  case  of  double-blind  PAH  population  similar results are found (22.8, 20.5 and 17.4 events/100 patient-years). Regarding Pool 2, around 20% of  patients  presented  respiratory  infections  over  the  treatment,  with  no  clear  exposure-timedependent pattern.

| Table80                                                  | Respiratory infection AEs in the double-blind PAH safety population   | Respiratory infection AEs in the double-blind PAH safety population   | Respiratory infection AEs in the double-blind PAH safety population   | Respiratory infection AEs in the double-blind PAH safety population   |
|----------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                          | 3mg (N=250) n (%)                                                     | 10mg (N=242) n (8)                                                    | Total Macitentan (N=492) n(8)                                         | Placebo (N=249) n(8)                                                  |
| Number of patientswith any SMQ Respiratory Infection AE  | 140 (56.0)                                                            | 126 (52.1)                                                            | 266 (54.1)                                                            | 108 (43.4)                                                            |
| Upper  respiratory infection Lower respiratory infection | 109 (43.6) 38 (15.2)                                                  | 99 (40.9) 41 (16.9)                                                   | 208 (42.3) 79 (16.1)                                                  | 71 34 (13.7)                                                          |
| Respiratory,infection AEs per 100 patient-years          | 29.3                                                                  | 26.1                                                                  | 27.7                                                                  | 26.5                                                                  |
| Upper respiratory Lower respiratory                      | 22.8                                                                  | 20.5 8.5                                                              | 21.7 8.2                                                              | 17.4                                                                  |
| infection infection                                      | 8.0                                                                   |                                                                       |                                                                       | 8.3                                                                   |
|                                                          |                                                                       |                                                                       | 563                                                                   |                                                                       |
| Numberof AEs                                             | 287                                                                   | 276                                                                   |                                                                       | 207                                                                   |
| Crudle ：incidence                                        |                                                                       |                                                                       |                                                                       |                                                                       |
| UPPERRESPIRATORY TRACTINFECTION                          | 50 (20.0)                                                             | 37 (15.3)                                                             | 87 (17.7)                                                             | 33 (13.3)                                                             |
| NASOPHARYNGITIS                                          | 37 (14.8)                                                             | 34 (14.0)                                                             | 71 (14.4)                                                             | 26 (10.4)                                                             |
| BRONCHITIS                                               | 20 (8.0)                                                              | 28 (11.6)                                                             | 48 (9.8)                                                              | 1 4 (5.6)                                                             |
| PHARYNGITIS                                              | 11 (4.4)                                                              | 15 (6.2)                                                              | 26 (5.3)                                                              | 7 (2.8)                                                               |
| INFLUENZA                                                | 11 (4.4)                                                              | 14 (5.8)                                                              | 25 (5.1)                                                              | 4 (1.6)                                                               |
| RESPIRATORYTRACTINFECTIONVIRAL                           | 6 (3.6)                                                               | 15 (6.2)                                                              | 24 (4.9)                                                              | 9 (3.6)                                                               |
| SINUSITIS                                                | 11 (4.4)                                                              | 11 (4.5)                                                              | 22 (4.5)                                                              | 6 (2.4)                                                               |
| PNEUMONIA                                                | 10 (4.0)                                                              | 10 (4.1)                                                              | 20 (4.1)                                                              | 13 (5.2)                                                              |
| RESPIRATORYTRACT INFECTION                               | 6 (3.6)                                                               | 9 (3.7)                                                               | 18 (3.7)                                                              | 10 (4.0)                                                              |
| LOWERRESPIRATORY TRACTINFECTION                          | 6 (2.4)                                                               | 7 (2.9)                                                               | 13 (2.6)                                                              | 4 (1.6)                                                               |
| RHINITIS                                                 | 3 (1.2)                                                               | 8 (3.3)                                                               | 11 (2.2)                                                              | 2 (0.8)                                                               |
| LARYNGITIS                                               | 6 (2.4)                                                               | 1 (0.4)                                                               | 7 (1.4)                                                               | 2 (0.8)                                                               |
| TRACHEOBRONCHITIS                                        | 5 (2.0)                                                               | 2 (0.8)                                                               | 7 (1.4)                                                               | 2 (0.8)                                                               |
| TRACHEITIS                                               | 2 (0.8)                                                               | 4 (1.7)                                                               | 6 (1.2)                                                               | 0                                                                     |
| PHARYNGOTONSILLITIS                                      | 2 (0.8)                                                               | 1 (0.4)                                                               | 3 (0.6)                                                               | 1 (0.4)                                                               |
| TONSILLITIS                                              | 0                                                                     | 3 (1.2)                                                               | 3 (0.6)                                                               | 0                                                                     |
| ACUTE SINUSITIS                                          | 2 (0.8)                                                               | 0                                                                     | 2 (0.4)                                                               | 0                                                                     |
| LOBARPNEUMONIA VIRALUPPERRESPIRATORYTRACTINFECTION       | 2 (0.8)                                                               | 0                                                                     | 2 (0.4)                                                               | 0 0                                                                   |
| BRONCHITIS BACTERIAL                                     | 2 (0.8)                                                               | 0                                                                     | 2 (0.4)                                                               | 0                                                                     |
|                                                          | 0                                                                     | 1 (0.4)                                                               | 1 (0.2)                                                               |                                                                       |
| BRONCHITISVIRAL                                          | 0                                                                     | 1 (0.4)                                                               | 1 (0.2)                                                               | 2 (0.8)                                                               |
| CHRONICSINUSITIS                                         | 1 (0.4)                                                               | 0                                                                     | 1 (0.2)                                                               | 0                                                                     |
| HIN1 INFLUENZA                                           | 1 (0.4)                                                               | 0                                                                     | 1 (0.2)                                                               | 0 0                                                                   |
| LARYNGITIS VIRAL                                         | 0 (0.4)                                                               | 1 (0.4)                                                               | 1 (0.2) 1 (0.2)                                                       | 2 (0.8)                                                               |
| LUNG INFECTION                                           | 1                                                                     | 0                                                                     | 1 (0.2)                                                               |                                                                       |
| LUNG INFECTIONPSEUDOMONAL PNEUMONIA INFLUENZAL           | 0                                                                     | 1 (0.4)                                                               | 1 (0.2)                                                               | 0 0                                                                   |
|                                                          | 1 (0.4)                                                               | 0                                                                     | 1 (0.2)                                                               |                                                                       |
| PNEUMONIAMORAXELLA PNEUMONIANECROTISING                  | 1 (0.4) 0                                                             | 0 (0.4)                                                               | 1 (0.2)                                                               | 0 0                                                                   |
|                                                          |                                                                       | 1                                                                     | (0.2)                                                                 | 0                                                                     |
| PNEUMONIAPNEUMOCOCCAL ACUTE TONSILLITIS                  | 1 (0.4) 0                                                             | 0 0                                                                   | 1 0                                                                   | 2 (0.8)                                                               |
| BRONCHOPNEUMONIA                                         | 0                                                                     | 0                                                                     | 0                                                                     | 1 (0.4)                                                               |

AEsper100patient-yearsExposure derived as (%)=100(incidence/[total treatment duration days/365].

AE = adverse event, PAH = pulmonary arterial hypertension, PT = preferred term, SMQ = standardized MedDRA query Note:For eachpreferred term,a patient is counted once if thepatient had one or more events in that category. Denominators for percentages are based on number of patients in Safety Population for each treatment group.

Preferred terms thatwerenot reported (incidence =O%)for any treatment arenot displayed.

PTs aresortedindescendingorderoftheTotalMacitentanfrequencycount.

StudyAC-055-302

Source:Appendix 5,Table 79,Table 89,Table 91,Table 105,Table 115,and Table 117

<div style=\"page-break-after: always\"></div>

Other  infections: In  the  double-blind  PAH  population  there  was  certain  a  imbalance  in  the incidence  of  AEs  of  urinary  tract  infections  and  gastroenteritis  in  patients  who  received macitentan compared to those who received placebo (6.4%, 8.7% and 5.7% for macitentan 3 mg,  10  mg  and  placebo  respectively).  However,  such  infections  were  not  associated  with  an excess of SAEs or AEs leading to discontinuation, or an increase in reporting rate over time.

Oedemas: In the double-blind PAH population the incidence of oedemas was similar in the total macitentan group (20.9%) and the placebo group (20.5%). In the 10 mg group the incidence was marginally higher than in placebo. However, when adjusted on the basis of patients years of exposure, the incidence in the macitentan group (11 events /100 patients years) was actually lower than in placebo (12. 5 events/100 patients years). Similar incidences of oedemas were also observed for macitentan and placebo in the Pool 1 population.

| Table 53                                  | Edema AEs in the double-blind PAH population   | Edema AEs in the double-blind PAH population   | Edema AEs in the double-blind PAH population   | Edema AEs in the double-blind PAH population   |
|-------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                                           | 3 mg (N=250) n (e)                             | 10 mg (N=242) n (e)                            | Total Maeitentan (N=492) n (e)                 | Placebo (N=249) n (b)                          |
| Number of patients with any SMQ Oedeme AE | 50(20.0)                                       | 53(21.9)                                       | 103(20.9)                                      | 51(20.5)                                       |
| Oedema AEs per 1o0 patient-years          | 10.5                                           | 11.0                                           | 10.7                                           | 12.5                                           |
| Nimber of AEs                             | 72                                             | 69                                             | 141                                            | 63                                             |
| Crudle ineidence                          |                                                |                                                |                                                |                                                |
| OEDEMA.PERIPHERAL                         | (16.0)                                         | (18.2)                                         | 84 (17.1)                                      | (18.1)                                         |
| PULMONARYOEDEMA                           | (1.6)                                          | 1 (0.4)                                        | 5 (1.0)                                        |                                                |
| FLUID OVERLOAD                            | 3 (1.21                                        | 1 (0.4)                                        | 4 (0.8)                                        | (0.4)                                          |
| FLUID RETENTION                           | (1.6)                                          | 0                                              | 4 (0.8)                                        | (0.4)                                          |
| PERICARDIAL,EEEUSION                      | 1 [0.4)                                        | 3 (1.2)                                        | 4 (0.8)                                        | 1 (0.4)                                        |
| PLEURALEFEUSION                           | 2 (0.8)                                        | 2 (0.8)                                        | 4 (0.8)                                        | (0.8)                                          |
| HYDROTHORAK                               | 0                                              | 2 10.8)                                        | 2 (0.4)                                        |                                                |
| HYPERUOLAFMIA                             | 2 (0.8)                                        | 0                                              | 2 (0.4)                                        | 000                                            |
| ASCITES                                   | 1 (0.4)                                        |                                                | 1 (0.2)                                        | 1 (0.4)                                        |
| GENERALISED OEDEMA                        | 0                                              | 1 (0.4)                                        | 1 (0.2)                                        | 1 (0.4)                                        |
| LOCALISED OEDEMA                          | 0                                              | 1 (0.4)                                        | 1 (0.2)                                        | 0                                              |
| LYMPHOEDEMA.                              | 1 (0.4)                                        | 0                                              | 1 (0.2)                                        | 0                                              |
| PELVIC FLUID COLIECTION                   | 0                                              | 1 [0.4)                                        | 1 (0.2)                                        | 0                                              |
| JOINT SRELLING                            | 0                                              | 0                                              | 0                                              | 1 (f*0)                                        |

Note: For each prefered term, a patient is coumted once if the patient had one or more events in that category.

AE = adverse event, PAH = pulmonary arterial hypertension, PT = preferred term

Denominators for percentages are based on number of patients in Safety Population for each treatment group.

AEs per 100 patient-years Exposure derived as (%6) = 100(incidence/[total treatment duration days/365].

Preferred terms that were not reported (incidence = O%) for any treatment are not displayed.

PIs are sorted in descending order of the Total Macitentan frequency coumt.

Study AC-055-302

Souce: Appendix 5, Table 7l and Table 97

Oedema as SAE in the Pool 1 was uncommon with macitentan treatment (0.6%, 0.7% and 1.1% for the macitentan groups and placebo) and no patients discontinued treatment due to this AE.

In  the  double-blind  PAH  population,  the  incidence  of  peripheral  oedemas  was  higher  in  the elderly (30.3%, 25.9% and 18.2% for macitentan 3mg, 10mg and placebo) compared to adults (14.3%, 17.7% and 18.6%, respectively). Nevertheless in the Pool 1 a clearly higher incidence of oedema  was  not  seen  in  the  elderly  for  the  proposed  dose  (22.2%,  13.0%  and  9.1%  for macitentan 3mg and 10mg and placebo) compared to the adult population (11.6%, 14.2% and 14.9%).  Higher  incidence  was  only  observed  with  the  lowest  dose  (3mg).  This  is  surprising considering that there is a known dose-dependent effect of ERAs.

<div style=\"page-break-after: always\"></div>

For the Pool 2, the longer periods of time receiving macitentan were associated with a higher incidence  of  oedema  (from  8.9%  for  0-6  months  of  exposure  to  12%  for  patients  treated  for more than 30 months).

A higher rate of oedema with macitentan 3 mg than with macitentan 10 mg was found in elderly patients. No relationship with diuretic use was found in a post-hoc analysis and therefore it might correspond to a chance finding.

Data  on  oedema/fluid  retention  during  SERAPHIN  have  been  included  in  section  4.8  of  the Opsumit SmPC.

<!-- image -->

| Table 55                                                                                                                                                               | Peripheral edema AEs by subgroup in the double-blind PAH population   | Peripheral edema AEs by subgroup in the double-blind PAH population   | Peripheral edema AEs by subgroup in the double-blind PAH population   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                                                                                                                        | Hacitentan 3 mg                                                       | Hacitentan 10 mg                                                      | Placebo                                                               |
| Sub-group by sex Male                                                                                                                                                  | 14.88 (9/61)                                                          | 18.80 (8b/6)                                                          | 13.89 (99/6)                                                          |
| Female                                                                                                                                                                 | 16.48 131/1891                                                        | 18.06 (35/194)                                                        | 19.69 (36/184)                                                        |
| s6e lq dnorb-qmg Eiderly                                                                                                                                               | 30.38 (10/33)                                                         | 25.96 (7/27)                                                          | 18.24 (pb/a)                                                          |
| Adults                                                                                                                                                                 | 14.38 (30/210)                                                        | 17.76 (37/209)                                                        | 18.74 (37/198)                                                        |
| Sub-group by WHo Fc at baseiine WHO FC I/II                                                                                                                            | 11.68 (16/138)                                                        | 22.36 (27/121)                                                        | 14.66 (19/130)                                                        |
| WHO FC III/IV                                                                                                                                                          | 21.46 (24/112)                                                        | 14.06 (17/121)                                                        | 21.80 (26/119)                                                        |
| Bub-group by PAH etiology. Idiopathie other PAH PAH aue to congenital shunts                                                                                           | 15.20 (25/164)                                                        | 16.30 (24/147)                                                        | 15.79 (22/140)                                                        |
|                                                                                                                                                                        | 20.08 (3/15)                                                          | 28.60 (6/21)                                                          | 15.40 (4/26)                                                          |
| PAH due to CUD                                                                                                                                                         | 17.18 (12/70)                                                         | 19.26 (14/73)                                                         | 23.29 (19/82)                                                         |
| Sub-group by_clinieal sigms and Symptomy of RHr at baseline (yes/no) Yes                                                                                               | 22.48 (17/76)                                                         | 17.16 (13/76)                                                         | 26.99 (21/78)                                                         |
| No                                                                                                                                                                     | 13.20 (23/174)                                                        | 18.76 (31/166)                                                        | 14.0% (24/171)                                                        |
| Sub-group1 by PAH therapy at baseiine (yes/no) Yes No. (11/86)                                                                                                         | 17.78 (29/164) 12.86                                                  | 19.56 (30/154) 15.96 (14/88)                                          | 23.50(36/153) 9.48(9/96)                                              |
| White                                                                                                                                                                  | 15.30 (21/137)                                                        |                                                                       |                                                                       |
| Sub-group by race                                                                                                                                                      | 22.98 (16/70)                                                         | 17.86 (24/135)                                                        | 16.26 (21/130) 18.34 (13/71)                                          |
| Aaian                                                                                                                                                                  |                                                                       | 23.16 (15/65)                                                         | 22.99 (11/48)                                                         |
| Other Sub-group by location                                                                                                                                            | 7.09 (3/43)                                                           | 11.90 (5/42)                                                          | (10/30)                                                               |
| North America (including Canada) Western Europe (ineluding S. Africa andl Israel)                                                                                      | 33.38 (10/30)                                                         | 39.16 (9/23)                                                          | 33.39                                                                 |
|                                                                                                                                                                        | 16.76 (7/42)                                                          | 20.80(10/48)                                                          | 18.09 (09/6)                                                          |
| Eastern Europe (ineludling Turkey!                                                                                                                                     | 7.99(5/63)                                                            | 8.10 (5/62)                                                           | 10.26 (69/9)                                                          |
| Asia (ineluding Australia)                                                                                                                                             | 21.18(15/71)                                                          | 22.16 (15/68)                                                         | 20.6% (14/68)                                                         |
| Latin America 6.8% (1/8) AE = adverse event, CVD = collagen vascular disease, FC = fumctional class, PAH = pulmonary arterial hypertension, RHF = night heart failure. |                                                                       | 12.26 (5/41)                                                          | 14.39 (6/421                                                          |

Malignancies: In the double-blind PAH population lower incidence adjusted by exposure was seen in  the  macitentan  10  mg  group  compared  to  the  placebo  group.  In  addition,  there  was  no increase  over  time  in  the  reporting  rate  of  malignancies.  In  some  cases,  short  latency  or confounding factors such as medical history of malignancy were documented, and in a few cases malignancy was not confirmed. In Pool 1 there was a slight excess of malignancies in patients treated with the macitentan 3 mg compared to placebo (1.7 versus 1.4 per patient/year). Similar figures  were  seen  for  patients  on  the  macitentan  10  mg  (1.8  per  patient/year).  The  small numbers do not allow drawing sound conclusions although malignancies have not been described as a safety concern with other ERAs.

<div style=\"page-break-after: always\"></div>

Menstrual disorders and ovarian cyst: In the double-blind PAH SERAPHIN study, an imbalance was recorded in the reporting of menstrual disorders (6.9% for macitentan 3 mg, 5.1% for 10 mg and 1.1% in the placebo group). No consistent drug-exposure pattern could be identified as latency  varied  from  1  to  35  months.  There  were  confounding  factors  in  most  patients (concomitant  anticoagulants,  hormonal  contraception,  medical  history  or  concomitant  events). These events have not been described as AEs with other ERAs. The data available are insufficient to establish a causal relationship between macitentan and menstrual disorders or ovarian cysts. However, due to the numerical imbalance observed, menstrual disorders and ovarian cysts have been considered important potential risks for macitentan.

Other  AEs:  The  most  frequently  reported  AE  for  macitentan  in  other  clinical  studies  was headache.  Other  AEs  were:  nasopharyngitis,  rhinitis,  hypotension;  upper  respiratory  tract infection  and  syncope,  dysmenorrhoea,  peripheral  oedema.  Those  are  in  line  with  the  AEs reported  in  PAH  studies.  No  deaths,  SAEs,  or  severe  intensity  AEs  were  reported  in  the macitentan-treated  healthy  subjects.  AEs  leading  to  discontinuation  of  study  treatment  were reported in two studies. In the drug-drug interaction (DDI) study with ketoconazole, one subject discontinued study treatment due to AEs of increased AST, ALT, and gammaglutamyltransferase (GGT)  during  treatment  with  ketoconazole  (18  days)  and  13  days  after  a  single  dose  of macitentan 10 mg.

IPF study: The overall incidence of treatment-emergent AEs was 97.5% in the macitentan group and 98.3% in the placebo groups. Worsening of IPF was the most frequently reported AE (21.0% macitentan, 25.4% placebo). Dyspnea (20.2% macitentan,15.3% placebo), peripheral oedema (11.8%  macitentan,  6.8%  placebo),  anaemia  (10.9%  macitentan  only),  pneumonia  (9.2% macitentan, 6.8% placebo) and nausea (7.6% macitentan, 3.4% placebo), occurred at a higher incidence  in  patients  on  macitentan  than  on  placebo.  The  incidences  of  cough  and  pulmonary hypertension were lower on macitentan (18.5% and 0.8%, respectively) than on placebo (35.6% and 5.1%, respectively). The majority of AEs were of mild or moderate intensity. Only 7 out of 178 enrolled patients had pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) reported in their medical history: 4 in the placebo arm and 3 in the macitentan 10 mg group. None of these 7 patients had a fatal outcome. Considering the very low number of patients with PH/PAH  at  baseline,  no  meaningful,  comparative  analysis  could  be  conducted  based  on  the presence or absence of concomitant PH/PAH.

## Serious adverse event/deaths/other significant events

Overall  SAEs:  For  PAH  patients  a  higher  incidence  of  SAEs  was  observed  on  placebo  than  on macitentan (52%, 45% and 55% for macitentan 3 mg, 10 mg and placebo, respectively) (Table 36). The most frequent were pulmonary arterial hypertension and right ventricular failure both related to progression of the disease. In Pool 1, as expected, the percentage of patients reporting SAEs was higher for macitentan 3mg (42.4%) and placebo (42, 7%) compared to macitentan 10mg (35.0%). The most frequent were pulmonary arterial hypertension and right ventricular failure both related to progression of the disease. Pneumonia was reported as SAE in around 2% of patients in all treatment groups. Anaemia was more frequent in both macitentan groups (1.6% and 1.4%) than in placebo (0.3%).

<div style=\"page-break-after: always\"></div>

MACE:  The  overall  incidence  of  major  adverse  cardiovascular  events  (MACE)  was  comparable between  the  macitentan  and  placebo  groups.  Cardiovascular  deaths  were  less  frequent  in macitentan groups than in placebo (Table 91).

<!-- image -->

| Table91                                                                                                                                                                                                                                                                      | Deaths due tocardiacAEsup to28 days after endof treatmentin the double-blind PAH population by preferred term   | Deaths due tocardiacAEsup to28 days after endof treatmentin the double-blind PAH population by preferred term   | Deaths due tocardiacAEsup to28 days after endof treatmentin the double-blind PAH population by preferred term   | Deaths due tocardiacAEsup to28 days after endof treatmentin the double-blind PAH population by preferred term   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                              | 3mg (N=250) n (8)                                                                                               | 10 mg (N=242) n (8)                                                                                             | Total Macitentan (N=492) n (8)                                                                                  | Placebo (N=249) n(8)                                                                                            |
| Numberofpatients who cied SUDDEN DEATH SUDDEN CARDIAC DEATH                                                                                                                                                                                                                  | 3 (1.2)                                                                                                         | 6 (2.5)                                                                                                         | 9(1.8)                                                                                                          | 8 (3.2)                                                                                                         |
| DEATH CARDIOGENIC SHOCK ACUTEMYOCARDIALINEARCTION ARRHYTHMIA CARDIACARREST CARDIO-RESPIRATORYARREST ACUTELEFTVENTRICULARFAILURE CARDIACFAILURECONGESTIVE CARDIOPULMONARYFAILURE LEFTVENTRICULARFAILURE Death=unspecifieddeath StudyAC-055-302 Source: Appendix 5, Listing 13 | 1 (0.4) 10000 (0.4) 1 (0.4) 0 00 0 0                                                                            | 211011010000 (0.8) (0.4) (0.4) 18:23 (0.4)                                                                      | ３２１０１１１１０0００ (0.6) (0.4) (0.2) 8:2 (0 2) (0.2)                                                                  | 0 2 (0.8) 1200001111 (0.4) (0.8) 18.4) (8.4) (0.4) (0.4)                                                        |
| AE=adverseevent,PAH=pulmonaryarterialhypertension Note:theremaybemorethanoneAEwithoutcomedeathfor any1patient.                                                                                                                                                               | AE=adverseevent,PAH=pulmonaryarterialhypertension Note:theremaybemorethanoneAEwithoutcomedeathfor any1patient.  | AE=adverseevent,PAH=pulmonaryarterialhypertension Note:theremaybemorethanoneAEwithoutcomedeathfor any1patient.  | AE=adverseevent,PAH=pulmonaryarterialhypertension Note:theremaybemorethanoneAEwithoutcomedeathfor any1patient.  | AE=adverseevent,PAH=pulmonaryarterialhypertension Note:theremaybemorethanoneAEwithoutcomedeathfor any1patient.  |

## Deaths:

Deaths occurred in a similar percentage in patients on macitentan and placebo both in the double blind PAH study (8,8% for macitentan 3 mg, 6,6% for macitentan 10 mg and 8,4% for placebo) and in the pool 1 (7,1% for macitentan 3mg, 5,9% for macitentan 10mg and 6,8% for placebo) (Table 34). Most of the deaths were considered as related to underlying condition (progressing right heart or respiratory failure).

<div style=\"page-break-after: always\"></div>

Table34

## Deathsupto28daysafterendoftreatmentinthedouble-blindPAH populationbypreferredterm

Total

Note:DenominatorsforpercentagesarebasedonnumberofpatientsinSafetyPopulationforeachtreatmentgroup. PreferredtermsaresortedindescendingorderoftheTotalMacitentanfrequencycount.

|                                           | 3mg (N=250) n （%)   | 10mg (N=242) n (8)                  | Macitentan (N=492) n （%)   | Placebo (N=249) n （%)                         |
|-------------------------------------------|---------------------|-------------------------------------|----------------------------|-----------------------------------------------|
| Numberof patientswhodied                  | 22 (8.8)            | 16 (6.6)                            | 38 (7.7)                   | 21                                            |
| RIGHTVENTRICULARFAILURE                   | 461210 (1.6)        | 62201100110: (2.5) (0.8) (0.8) 8:4) | 10 (2.0)                   | (8.4) 630120 Y:2 (8.4) (0.8) 10 (0.4) 1 (0.4) |
| PULMONARYARTERIALHYPERTENSION             | (2 4)               |                                     | 8 (1 6)                    |                                               |
| SUDDEN DEATH                              |                     |                                     | 3 (0. 6)                   |                                               |
| RESPIRATORYFAILURE                        | (0 8)               |                                     | (0 4)                      |                                               |
| SUDDENCARDIACDEATH                        | (0.4)               |                                     | 4）                         |                                               |
| ACUTEMYOCARDIALINEARCTION                 |                     |                                     |                            |                                               |
| ACUTERESPIRATORYFAILURE                   | (0.4)               |                                     | 1 D                        |                                               |
| ANGIOSARCOMA                              | (0.4)               |                                     |                            |                                               |
| ARRHYTHMIA                                |                     |                                     |                            |                                               |
| BACTERIALSEPSIS                           |                     | 8:2)                                | 1                          |                                               |
| CARDIACARREST                             | (0.4)               |                                     |                            |                                               |
| CARDIO-RESPIRATORYARREST                  | 001001              | 8:4)                                | 1                          |                                               |
| DEATH                                     |                     | 11                                  |                            |                                               |
| DIARRHOEAINFECTIOUS                       | (0.4)               |                                     |                            |                                               |
| GASTROINTESTINALHAEMORRHAGE HAEMATEMESIS  | (0.4)               |                                     | 1                          |                                               |
| HYPOVOLAEMICSHOCK                         |                     | (0.4)                               | 1                          |                                               |
|                                           | TOT (0.4)           | 1                                   | 1 (0                       |                                               |
| METABOLICACIDOSIS                         | 4）                  |                                     | 1                          |                                               |
| METASTATICNEOPLASM                        | 8 4)                |                                     | 1                          |                                               |
| MULTI-ORGANDISORDER                       | (8:4)               |                                     | 1                          | 000                                           |
| MULTI-ORGAN FAILURE                       | 0                   | 1 (0.4)                             | 1 0                        | 000                                           |
| OESOPHAGEALVARICESHAEMORRHAGE             | (0.4)               |                                     | 1                          |                                               |
| PNEUMONIA INFLUENZAL                      | (0.4)               |                                     | 1 (0                       |                                               |
| PULMONARYEMBOLISM                         |                     | (0.4)                               | 1 (O                       | (0.4)                                         |
| ROAD_TRAFFICACCIDENT                      | 1 4                 | 1                                   | 1                          |                                               |
| SEPTIC SHOCK SYSTEMICSCLEROSIS            | (0.4)               | (0.4)                               | 1 1 口                      | 100                                           |
| ACUTELEFTVENTRICULARFAILURE               |                     | 1                                   |                            | 1 (0.4)                                       |
|                                           |                     |                                     | 100                        | 1                                             |
| CARDIACFAILURECONGESTIVE CARDIOGENICSHOCK | 1000                |                                     |                            | (0.4)                                         |
| CARDIOPULMONARYFAILURE                    | o0                  | o0                                  |                            | 2 (0.8) 1 (0.4)                               |
| LEFTVENTRICULARFAILURE                    |                     |                                     |                            | 1 (0.4)                                       |
| PANCREATICMASS                            |                     |                                     |                            | 1 (0.4)                                       |
| RENALFAILURE                              | 000                 | 000                                 |                            | 1 (0.4)                                       |
| SEPSIS                                    |                     |                                     | 0000                       | 1 (0.4)                                       |
|                                           |                     |                                     |                            | (0.4)                                         |
| SYSTEMICLUPUSERYTHEMATOSUS                |                     |                                     |                            |                                               |

CauseofDeath isfromtheDispositionCRF,wherecoded

Preferredtermsmayhavemorethanonecauseofdeathforany1patient.Apatientiscountedonceifthepatienthadone or more events in that category.

StudyAC-055-302

Source: Appendix 5.Table 149

Two  deaths  were  considered  as  related  to  macitentan  treatment.  One  was  due  to  right ventricular failure associated to jaundice within the context of right ventricular failure progression (SERAPHIN study in PAH). The other was due to pulmonary embolism (MUSIC study in IPF). The 2  deaths  are  unlikely  to  be  related  to  the  drug.  In  the  first  case  hepatic  enzyme  alterations increased  over  time  despite  the  drug  was  discontinued  and  the  patient  died  100  days  after withdrawal. In the second case, pulmonary thromboembolism is a common cause of death in IPF patients.

## Laboratory findings

## Liver abnormalities:

Other  ERAs  have  shown  dose-dependent  LFT  abnormalities,  specifically  increases  in  serum aminotransferases  that  can  be  associated  to  hepatotoxicity.  The  mechanism  is  not  fully understood but is considered to be related in part to inhibition of bile acid export.

In the SERAPHIN study, ALT and AST were measured at screening and at monthly intervals after initiation  of  study  treatment  until  at  least  28  days  after  the  EOT.  In  Pool  1  10.3%,  9%  and 11.9% in the macitentan 3mg, 10mg and placebo groups, respectively, had liver abnormalities compared to placebo. A higher proportion of patients, however, discontinued treatment in the macitentan groups (2.3% and 2.6%) versus placebo (1.1%). Similarly a higher incidence was observed for the placebo group in the double-blind PAH population, but, again, the percentage of patients who discontinued was higher for the macitentan groups.  In addition, both in the Pool 1 and in the double-blind PAH populations, more SAEs and more AEs leading to discontinuations

<div style=\"page-break-after: always\"></div>

were reported in patients on macitentan than on placebo. In relation to the clinically relevant serum  aminotransferase  abnormalities  observed  both  in  the  Pool  1  and  double-blind  PAH populations, there does not seem to be relevant differences between the macitentan groups and placebo, except for patients with AST or ALT &gt; 8xULN where higher percentages were seen for patients on macitentan in both safety populations.

Table46 Incidenceofliverfunctionabnormalitiesoccurringfromtreatment startup to28 days after EoT in the pooled double-blind safety set (Pool 1)

|                                                       | <3mg (N=129) n (%)   | 3mg (N=311) n (s)   | 10mg (N=423) n(8)   | Total Macitentan (N=863) n(2)   | Placebo (N=370) n (≥)   |
|-------------------------------------------------------|----------------------|---------------------|---------------------|---------------------------------|-------------------------|
| ALT or AST> 3XULN n n. (含)                            | 3(2.4) 125           | 307 11  (3.6)       | 414 13 (3.1)        | 846 27 (3.2)                    | 360 14 (3.9)            |
| ALT or AST> 5XULN n. n. (含)                           | 125 1 (0.8)          | 307 4(1.3)          | 414 8 (1.9)         | 846 13 (1.5)                    | 360 7(1.9)              |
| ALT or AST>8XUIN n n. (8)                             | 125 1  (0.8)         | 307 4 (1.3)         | 414 6 (1.4)         | 846 11 (1.3)                    | 360 2 (0.6)             |
| ALT or AST 3 x ULN and TBIL n > 2xULNat anytime n (含) | 125 0                | 301 5(1.7)          | 398 5 (1.3)         | 824 10 (1.2)                    | 349 5 (1.4)             |

Note: Denominatorfor percentages based on number of non-missing observationsfor each treatment group and total. Incidencebasedonthenumberofpatientswithatleastonepost-baselineabnormalityforeachcategory. Patient 1406/11104 (placebo) is not counted in source table since TBIL &gt; 2 x ULN as reported by a 1ocal1aboratory was

ALT=alanine aminotransferase,AST=aspartate aminotransferase,EOT=endof treatment,TBIL=totalbilirubin, ULN =upper limit of the normal range notincludedintheclinicaldatabase.Patient9103/12093(macitentan3mg)wasincorrectlyincludedinsourcetable,

2xULNinsourcetable,sinceTBIL&gt;2xULNwasobservedmorethan28daysaftertreatmentdiscontinuation.

StudiesAC-055-201,AC-055B201,AC-055-302

Source:Appendix 5, Tab1e 167,and, D-12.559: Annex 1, narratives

## Table 47 Incidenceofliverfunctionabnormalitiesoccurringfromtreatment start upto28days after EOT in thedouble-blind PAH safety population

|                                                  | 3 mg (N=250) n (%)   | 10 mg (N=242) n (%)   | Total Macitentan (N=492) n (%)   | Placebo (N=249) n (%)   |
|--------------------------------------------------|----------------------|-----------------------|----------------------------------|-------------------------|
| ALT orAST>3xULN n n (8)                          | 247 10 (4.0)         | 236 8(3.4)            | 483 18 (3.7)                     | 244 11 (4.5)            |
| ALT orAST>5xULN n n (8)                          | 247 4 (1.6)          | 236 6 (2.5)           | 483 10 (2.1)                     | 244 5 (2.0)             |
| ALT orAST>8xULN n. n. (%)                        | 247 4 (1.6)          | 236 5 (2.1)           | 483 (1.9)                        | 244 1 (0.4)             |
| ALT or AST >3xULNand TBIL> 2xULNatanytime n n(8) | 241 4 (1.7)          | 230 4(1.7)            | 471 8 (1.7)                      | 237 5 (2.1)             |

ULN =upper limit of the normal range

ALT=alanine aminotransferase,AST=aspartate aminotransferase,EOT=end of treatment,TBIL=total bilirubin,

Note:Denominatorforpercentagesbasedonnumberof non-missing observationsforeachtreatmentgroupand total. Incidencebased on the number of patients with at least onepost-baseline abnormality for each category.

Patient1406/11104(placebo)wasnot includedinsource tablesinceTBIL&gt;2xULNasreported by a1ocallaboratory wasnotincludedintheclinicaldatabase.Patient9103/12093(macitentan3mg)wasincorrectlyincludedinsource table,despite TBIL&lt; 2xULN.

StudyAC-055-302

Source:Appendix5,Table168,andD-12.559,Annex1:narratives

<div style=\"page-break-after: always\"></div>

<!-- image -->

Based on the review of all the data, the ILSB concluded that there is no definite hepatotoxicity signal from macitentan. However, as stated before, hepatotoxicity is a well-known AE associated to ERAs.  While  a lack of hepatotoxic potential is not  excluded,  macitentan  should  be contraindicated  in  patients  with  baseline  values  of  transaminases  &gt;  3xUL,  in  line  with  the exclusion criteria applied in the SERAPHIN trial after 5 cases of liver transaminases &gt;3xULN were reported  in  the  dose-finding  study  in  mild-to-moderate  essential  hypertension  (AC-055-201), which led to the Sponsor's decision to end the dose-finding study earlier than planned.

Nine  of  the  10  Hy's  law  cases  (ALT&gt;3xULN  and  total  bilirubin  &gt;2xULN)  were  reported  in  the double-blind PAH population (4 on macitentan 10 mg, 3 on macitentan 3 mg and 2 on placebo). In addition, 5 cases with ALT&gt;8xULN and total bilirubin&lt;2xULN were also identified. Most cases finally recovered but there were 5 cases in all with a result of death. Although in all cases there seems to be confounding factors and they could be related to worsening of PAH or IPF a cautious approach  seems  appropriate  including  monitoring  of  patients,  changes  in  the  SmPC  and  RMP measures.

A post-hoc analysis of hepatic events has been conducted in patients at high risk (those who had a history of liver disease at screening) (n=114). The analysis does show an increase in hepatic events  between  patients  at  high  risk  and  those  without  risk  factors,  but  without  differences between macitentan and placebo in both strata. Summarized information on hepatic events from ongoing or recently completed studies with macitentan (e.g. MUSIC IPF, ischaemic digital ulcers, glioblastoma) has been provided by the Applicant (cut-off date: 30 June 2013).

The pattern of hepatic events (AEs related to hepatobiliary disorders as well as the incidence of liver test elevation) is different across indications. In the PAH population, the lower incidence of hepatic events in macitentan-treated  patients versus placebo is likely to be related to an efficacy of  macitentan  versus  placebo  in  preventing  right  sided  heart  failure  and  associated  hepatic congestion, which is the main cause of transaminase elevations in patients with PAH.

The incidence of ALT and/or AST &gt; 3xULN (3.4% in the SERAPHIN study in the 10 mg group with a  median  exposure  of  116  weeks)  is  well  within  the  range  observed  with  ambrisentan  (3.6% from Kaplan-Meier estimate at 1 year in 483 patients) and below that which had been observed with  bosentan  in  PAH  (11%-14%  at  the  target  dose  of  250  mg/day).  However, there  are  no head-to-head clinical studies to conclude that macitentan provides an improved safety profile in comparison with other ERAs (i.e.: bosentan, ambrisentan).

<div style=\"page-break-after: always\"></div>

Although no hepatic signal was observed in the SERAPHIN study in PAH, an imbalance in adverse hepatobiliary events was found in IPF and in patients with essential hypertension. In conclusion, with  the  data  available,  a  potential  association  between  macitentan  and  risk  of  liver  toxicity cannot be definitively ruled out.

The SmPC information on liver safety with macitentan, regarding posology, contraindications and warnings, has been revised and is aligned with the SmPC of ambrisentan, as the hepatotoxicity risk seems similar.

Renal  function:  No  clinical  data  is  available  for  patients  with  severe  renal  impairment.  In addition, patients administered macitentan 10 mg with mild to moderate renal impairment had a higher reported rate of anaemia and/or hypotension (Table 90.2), which has been included in the revised SPC.

Table  90.2  AEs  related  to  renal  impairment,  categorised  by  baseline  renal  function status; number of patients with AEs (PAH double-blind population; AC-055-302)

|                                       | Renalfunctionimpairmentatbaseline   |        |    |                                |     |        |                       |        |            |        |         |         |                    |                 |                 |           |                    |    |        |
|---------------------------------------|-------------------------------------|--------|----|--------------------------------|-----|--------|-----------------------|--------|------------|--------|---------|---------|--------------------|-----------------|-----------------|-----------|--------------------|----|--------|
|                                       | None                                |        |    |                                |     |        |                       |        | Mild       |        |         |         |                    | Moderate-severe |                 |           |                    |    |        |
| Treatmentgroup                        | 3mg N=102 n (%)                     |        |    | 10mg Placebo N=100 N=103 n (%) |     |        | 3mg N=105 n (%) n (%) |        | N=94 n (%) |        | 10mg    |         | Placebo N=95 n (%) | 3mg N=40 n (%)  | 10mg N=44 n (%) |           | Placebo N=46 n (%) |    |        |
| Numberofpatientswhoexperienced:       |                                     |        |    |                                |     |        |                       |        |            |        |         |         |                    |                 |                 |           |                    |    |        |
| atleastlAE                            | 96 (94.1)                           |        | 93 | (93.0)                         | 100 | (97.1) | 101                   | (96.2) | 89         | (94.7) |         | 90      | (94.7)             | 40 (100)        | 43              | (97.7)    |                    | 46 | (100)  |
| atleastl AE leadingto discontinuation | 12                                  | (11.8) | 11 | (11.0)                         | 11  | (10.7) | 11                    | (10.5) | 10         | (10.6) | 10      |         | (10.5)             | 9 (22.5)        | 4               | (9.1)     |                    | 10 | (21.7) |
| atleastlSAE                           | 50                                  | (49.0) | 40 | (40.0)                         | 56  | (54.4) | 53                    | (50.5) | 42         | (44.7) | 50      | (52.6)  |                    | 25              | (62.5)          | 26 (59.1) |                    | 30 | (65.2) |
| anyAEofspecial interesta              | 43                                  | (42.2) | 51 | (51.0)                         | 58  | (56.3) | 60                    | (57.1) | 45         | (47.9) | 60      |         | (63.2)             | 30              | (75.0)          | 31        | (70.5)             | 35 | (76.1) |
| SpecifiedAEsrelatedtorenalimpairment: |                                     |        |    |                                |     |        |                       |        |            |        |         |         |                    |                 |                 |           |                    |    |        |
| PAH                                   | 22                                  | (21.6) | 22 | (22.0)                         | 30  | (29.1) | 35                    | (33.3) | 16         | (17.0) | 40      | (42.1). | 17                 | (42.5)          | 15              | (34.1)    |                    | 17 | (37.0) |
| Oedemaperipheral                      | 10                                  | (9.8)  | 20 | (20.0)                         | 20  | (19.4) | 20                    | (19.0) | 13         | (13.8) | 14      | (14.7)  | 10                 | (25.0)          | 10              |           | (22.7)             | 11 | (23.9) |
| Anaemia                               | 8                                   | (7.8)  | 7  | (7.0)                          | 3   | (2.9)  | 7                     | (6.7)  | 16         | (17.0) | 4       | (4.2)   |                    | 7 (17.5)        | 9               |           | (20.5)             | 1  | (2.2)  |
| RVF                                   | 12                                  | (11.8) | 11 | (11.0)                         | 22  | (21.4) | 15                    | (14.3) | 12         | (12.8) | 19      | (20.0)  | 8                  | (20.0)          | 8               |           | (18.2)             | 13 | (28.3) |
| Hypotension                           | 5                                   | (4.9)  | 4  | (4.0)                          | 0   |        | 6                     | (5.7)  | 7          | (7.4)  | 9 (9.5) |         |                    | 3 (7.5)         |                 | 3         | (6.8)              | 2  | (4.3)  |
| Renalfailure                          | 0                                   |        | 0  | 2                              |     | (1.9)  | 0                     |        | 2          | (2.1)  |         | 0       |                    | 3 (7.5)         |                 | 0         |                    | 0  |        |
| Renalfailureacute                     | 1                                   | (1.0)  | 0  | 0                              |     |        | 2                     | (1.9)  | 1          | (1.1)  |         | 0       | 2                  | (5.0)           |                 | 0         |                    | 0  |        |
| Blood uric acid increased             |                                     |        |    |                                |     |        | 1                     | (1.0)  |            | 0      | 1       |         | (1.1) 一            |                 |                 |           |                    |    |        |
| Renalimpairment                       |                                     |        |    |                                |     |        | 1                     | (1.0)  |            | 0      | 0       |         |                    |                 |                 |           |                    |    |        |

Anaemia (AEs and laboratory data): Like with other ERAs, decrease in haemoglobin concentrations was a laboratory abnormality observed with macitentan that was associated to a dose-dependent increase in  the  incidence  of  anaemia  compared  to  placebo  (Figure  1).  In  the double-blind PAH population, the mean maximum reduction from baseline in haemoglobin was 0.73 g/dL in the macitentan 3 mg group (baseline 15.5 g/dL) and 1.1 g/dL in the macitentan 10 mg group at month 3 (baseline 15.6 g/dL). This effect was apparent at 3 months and it was stable  thereafter.  In  the  PAH  population,  haemoglobin  &lt;  10  g/dL  was  recorded  in  5.8%  and 8.7% of patients on macitentan 3 mg and 10 mg, respectively, compared with 3.4% on placebo. In most cases the decreases were associated to a medical history of anaemia or were reported in the  setting  of  concurrent  clinical  events  including,  in  some  cases,  bleeding.  Importantly,  the incidence  of  SAEs  of  anaemia  in  macitentan-treated  patients  was  relatively  low  (2.4  % macitentan 3 mg, 2.9 % macitentan 10 mg) and it was the cause of discontinuation only in a single  patient  at  each  macitentan  dose.  Blood  transfusions  were  given  more  frequently  to patients treated with macitentan than to those treated with placebo.

<div style=\"page-break-after: always\"></div>

In general, these data indicate that macitentan exhibits a moderate, non progressive and doserelated haemoglobin reduction. As for other ERA, the initiation of treatment is not recommended in patients with clinically significant anemia as stated in the proposed SmPC.

Leukocyte and platelets counts: In the double-blind PAH population, macitentan was associated with  modest and non dose-dependent decreases in mean leukocyte count from baseline to EOT (macitentan 3 mg: 0.9×109/mL, macitentan 10 mg: 0.7×109/mL, placebo: 0.0×109/mL) (Table 94),  corresponding  to  a 9%  decrease  from  baseline  (7.5×109/mL)  with  the 10  mg dose.  Two patients (2/218, 0.9%), both on macitentan 10 mg, had shifts from baseline to CTC grade 3 (1.0 to &lt; 2.0×109/L). No infections were observed in either of these patients.

A small proportion of PAH patients, in both placebo and macitentan groups, showed markedly reduced platelet counts (to &lt; 50.0 × 109/L), with or without bleeding complications, at some time during the study. Resolution occurred during continued macitentan treatment and there was an absence of recurrence after treatment reinitiating.

Coagulation tests: Macitentan prolonged the values of some coagulation tests (e.g.: prothrombin time) in preclinical studies.

Bleeding  events:  There  is  a  slightly  higher  incidence  of  bleeding  events  reported  in  the macitentan  groups  (19.6%  and  18.6%  in  the  macitentan  3  mg  and  10  mg  respectively) compared to placebo (14.5%). This was mainly driven by the higher incidence of gynaecological bleedings (6.9% and 5.1% in the macitentan 3 mg and 10 mg respectively) compared to placebo (1.1%).  Importantly,  there  is  no  dose  response  observed  in  all  these  reported  bleedings.  In general, concomitant administration of antithrombotics or PDE5 inhibitors was associated with a higher  bleeding  rate,  which  is  expected.  No  direct  causal  relationship  can  be  found  between macitentan administration and the increased bleeding events. There are  no  known  PK interactions between macitentan and warfarin or sildenafil.

## Vital signs

Heart rate: No effect of macitentan on heart rate was apparent in the overall pooled double-blind safety set.

Electrocardiography: See 'Secondary pharmacology\" section.

## Safety in special populations

## Intrinsic factors:

Age: The table below provides a summary of adverse events per age group for patients in Pool 1, comparing  events  occurring  in  patients  treated  with  10  mg  macitentan  with  those  receiving placebo.

<div style=\"page-break-after: always\"></div>

Table 68. Summary of adverse events displayed by age group (Pool 1)

| Age (years)                     | $9>              | $9>    | $9>                 | 65-74            | 65-74              | 75-84            | 75-84              | 85+             | 85+               |
|---------------------------------|------------------|--------|---------------------|------------------|--------------------|------------------|--------------------|-----------------|-------------------|
| Treatnentgroup                  | 10mg N=308 n (%) |        | placebo N=282 n (%) | 10 mg N=97 n (%) | placebo N=69 n (%) | 10 mg N=18 n (%) | placebo N=18 n (%) | 10 mg N=0 n (%) | placebo N=1 n (%) |
| Adverseevents                   |                  |        |                     |                  |                    |                  |                    |                 |                   |
| Total                           | 263              | (85.4) | 241 (85.5)          | 84 (86.6)        | 59 (85.5)          | 16 (88.9)        | 16 (88.9)          | 0               | 1 (100.0)         |
| Fatal                           | 19               | (6.2)  | 18 (6.4)            | 6 (6.2)          | 4 (5.8)            | 3 (16.7)         | 2 (11.1)           | 0               | 0                 |
| Serious                         | 109              | (35.4) | 119 (42.2)          | 33 (34.0)        | 29 (42.0)          | 6 (33.3)         | 9 (50.0)           | 0               | 1 (100.0)         |
| Withdrawal                      | 26               | (8.4)  | 29 (10.3)           | 11 (11.3)        | 10 (14.5)          | 4 (22.2)         | 6 (33.3)           | 0               | 1 (100.0)         |
| CNS (confusion/ extrapyramidal) | 10               | (3.2)  | 8 (2.8)             | 3 (3.1)          | 2 (2.9)            | 0                | 0                  | 0               | 0                 |
| AE related to falling           | 10               | (3.2)  | 21 (7.4)            | 2 (2.1)          | 3 (4.3)            | 2 (11.1)         | 0                  | 0               | 0                 |
| CV events                       | 1                | (0.3)  | 2 (0.7)             | 3 (3.1)          | 2 (2.9)            | 0                | 1 (5.6)            | 0               | 0                 |
| Cerebrovascular events          | 2                | (0.6)  | 1 (0.4)             | 2 (2.1)          | 1 (1.4)            | 1 (5.6)          | 0                  | 0               | 0                 |
| Infections                      | 163              | (52.9) | 134 (47.5)          | 48 (49.5)        | 30 (43.5)          | 11 (61.1)        | 10 (55.6)          | 0               | 0                 |

Source:Table 5,Appendix 5

Withdrawal = adverse events leading to permanent discontinuation of study medication

AE = adverse event; CNS = central nervous system; CV = cardiovascular.

With respect to specific adverse events, in the elderly PAH-patient population (&gt; 65 years), there was a higher incidence of dyspnoea in the macitentan 3 mg group (18.2%) and 10 mg group (14.8%) compared to the placebo group (11.4). Oedema AEs were reported at a higher incidence in elderly PAH patients treated with macitentan compared to placebo (there were no oedema AEs in adolescents). The incidences were 30.3%, 25.9% and 18.2% in the macitentan 10 mg, 3 mg and  placebo  groups,  respectively.  There  was  no  dose-dependency  and  in  a  logistic  regression analysis, no statistically significant interaction between age and treatment was observed.

There was no obvious effect of PAH disease severity at baseline (WHO FC I/II vs III/IV) on the pattern of AEs across the age groups.

The pattern of AEs was generally similar for males and females both for Pool 1 and the doubleblind  PAH  population.  Evaluation  by  subgroup  in  the  double-blind  PAH  population  showed  that most hypotension AEs were reported in female patients. In the macitentan 10 mg group, 16 of the 17 patients with hypotension AEs were female (incidence of 8.2% vs 2.1% in males). The AE urinary tract infection was reported at a higher incidence in females than in males.

Race/ethnicity  is  only  described  for  the  double-blind  PAH  population,  as  the  IPF  study  (AC055B201) and essential  hypertension  study  (AC-055-201)  comprised  almost  exclusively  White patients.  Subgroup  differences  on  the  basis  of  race/ethnicity  and  geographical  region  were unremarkable.

The analysis of AEs for Pool 1 did not reveal any clear or consistent differences in the pattern of AEs  on  the  basis  of  no,  mild  or  moderate-severe  baseline  renal  impairment.  No  correlation between the severity (mild, moderate, or severe) of hepatic impairment and the mean plasma exposure to macitentan and its metabolites, ACT-132577 and ACT-373898, was apparent in a study  in  subjects  with  hepatic  impairment.  Other  than  infections  and  oedema,  subgroup differences on the basis of baseline PAH therapy were unremarkable.

<div style=\"page-break-after: always\"></div>

## Pregnancy and lactation

In the clinical development program, there were a total of 7 pregnancies (5 on macitentan 3 mg and  2  on  placebo).  All  occurred  in  the  double-blind  PAH  population.  Of  the  5  patients  in  the macitentan 3 mg group, one had a therapeutic abortion, one had a spontaneous abortion. Both patients subsequently restarted macitentan treatment. The spontaneous abortion was assessed by the investigator as unrelated to study treatment. One patient had an abortion scheduled, but died  due  to  worsening  of  PAH  before  the  scheduled  date.  For  the  other  2  macitentan-treated patients, both permanently discontinued treatment and continued the pregnancy. Both women gave  birth  prematurely.  In  one  case  the  baby  had  hyaline  membrane  disease  complicated  by sepsis, a grade 4 intracranial haemorrhages and poor skin condition. Three days after birth, the baby died from persistent hypotension, due to extreme prematurity. No obvious dysmorphism was  noted  and  the  prenatal  screening  at  Week  18  had  shown  no  anomaly.  The  death  was reported  as  unrelated  to  study  treatment.  In  the  second  case,  the  baby  had  no  neonatal abnormalities  and  survived.  Both  placebo-treated  patients  had  therapeutic  abortions,  one  of whom  subsequently  restarted  study  treatment,  while  the  other  permanently  discontinued treatment.  It  is  not  known  whether  macitentan  is  excreted  into  human  breast  milk.  In  rats, macitentan  and its  metabolites  were  excreted  into  milk  during  lactation.  Breast-feeding  is  not recommended during treatment with macitentan.

## Overdose

There  is  no  experience  with  accidental  overdose  of  macitentan.  Single  doses  of  up  to  and including  600  mg  were  administered  in  healthy  subjects.  This  dose  was  associated  with headache,  nausea  and  vomiting.  In  the  case  of  overdose,  general  supportive  treatment  is recommended.  Considering  the  high  degree  of  protein  binding,  macitentan  is  not  likely  to  be removed by dialysis.

## Rebound effect

Available data do not indicate that the discontinuation of macitentan 10 mg is associated with any AE suggestive of a rebound effect.

## Ability to drive and use machines

No  studies  on  the  effect  of  macitentan  on  the  ability  to  drive  and  use  machines  have  been performed, as an effect is not anticipated.

## Potential for abuse

There is no indication of any potential for abuse from clinical studies or from current knowledge of ERAs in general.

Testicular safety: see \"pharmacodynamic\" section.

## Immunological events

All cases of hypersensitivity appear to be associated with concomitant medications and seasonal allergy, not with macitentan. Only one case was considered by the investigator to be related to treatment.

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

See  'pharmacodynamics'  section  for  safety  related  to  drug-drug  interaction  with  sildenafil (increase in headache and hypotension). No other information is available.

## Discontinuation due to AES

Around 10% of patients discontinued due to AEs both in the pool 1 and the double blind PAH population.  Pulmonary  arterial  hypertension  and  right  ventricular  failure,  both  related  to  the underlying  condition,  were  more  frequent  in  the  placebo  group  in  these  populations.    As expected, anaemia and increase in aminotransferases were more frequency in the macitentan groups.

## 2.6.1. Discussion on clinical safety

The applicant has provided data of several pooled safety datasets comprising the pivotal study, the  phase  II  studies,  data  from  the  phase  I  studies  data  from  the  phase  III  trials  in  other indications  (essential  Hypertension  and  IPF).  No  studies  with  an  active  comparator  have  been presented  with  this  application.  According  to  the  applicant,  675  patients  were  treated  with macitentan in the targeted indication, with a mean exposure of 126 weeks (up to 202 weeks). Around 60% were exposed for 96 weeks or more, corresponding to 1321 patient-years exposure. The safety dataset size seems adequate for the PAH indication.

There is clinical information on specific serious AE or serious AE that could represent an alert that have  been  identified with other ERAs.  Therefore, a focus was  done  on  hepatotoxicity, vasodilatation, decrease in haemoglobin and teratogenicity among others.

## Adverse events:

## Overall AEs:

Double-blind PAH population (SERAPHIN study):

The overall incidence of AEs in the macitentan groups was similar to that in the placebo group. PAH (i.e., worsening of PAH) was the most frequently reported.

Right ventricular failure, which is the most clinically relevant long-term complication of PAH was also reported at a lower incidence in the macitentan treatment groups than in the placebo group.

Other AEs reported were: upper respiratory tract infection, anaemia, thrombocytopenia, oedema peripheral, hypotension, headache, insomnia, urinary tract infection, gastroenteritis, skin ulcers, abdominal pain and drug hypersensitivity.

Around 95% of patients of the pooled double-blind PAH population had at least one AE. Similar distribution of AEs was observed in other groups of patients.

In the pool 1, the majority of patients experienced at least one AE (more than 80% in the three treatment groups). The most common AEs were similar to double blind PAH population. These

<div style=\"page-break-after: always\"></div>

AEs  would  be  reflecting  disease  progression  in  the  placebo  group  (and  in  the  3mg  treatment group).

In the pool 2, the proportion of patients with any AEs increased from 63.3% at 0-6 months of macitentan  exposure  to  75.2%  at  6-12  months  and  slightly  increased  up  to  30  months  of macitentan exposure (85.4%), indicating that the longer exposure the higher percentage of AEs. The percentage of patients with any SAE was quite constant (around 15-20%) over time.

With respect to AEs, the incidence liver abnormalities, oedema and anaemia increased up to 30 months  of  exposure  while  the  incidence  decreased  or  was  maintained  for  hypotension,  renal impairment, respiratory infections, malignancies or MACE.

A dose-response relationship was found for anaemia but not for other AEs.

In summary, the applicant has analysed some safety topics considered of special interest based on the experience with other ERAs, the nonclinical safety data, and findings in the studies. These topics  refer  to  AEs  and  laboratory  findings  denoting  hypotension,  respiratory  and  other infections,  oedema/fluid  retention,  liver  abnormalities,  anaemia/haemoglobin  decrease,  renal impairment, malignant neoplasms, menstrual disorders and ovarian cysts myocardial infarction and cerebrovascular events, as well as effects of macitentan on QTc and other ECG variables.

## Hypotension:

Double-blind PAH population (SERAPHIN study):

There was a higher incidence of hypotension relative to placebo for macitentan 3 mg and 10 mg. Hypotension  cases  were  not  associated  to  a  higher  incidence  of  dizziness  or  syncope  in  the macitentan group.

Despite hypotension does not seem particularly worrisome in PAH patients it is considered a class effect of ERAs and data on hypotension from SERAPHIN has been reflected in section 4.8 of the Opsumit SmPC.

## Infections:

Respiratory infections:

The incidence of respiratory infection AEs in patients on macitentan 3 mg and 10 mg was higher than  in  placebo,  both  in  the  double-blind  PAH  population  and  in  Pool  1.  Nevertheless,  the majority  of  respiratory  infections  occurred  in  the  upper  respiratory  tract  and  few  resulted  in discontinuation  of  the  study.  The  applicant  states  that  this  higher  incidence  may  be  due  to  a reporting bias, as nasal congestion symptoms are observed in relation to the effect of vasodilator of the drug which seems reasonable.

It is reassuring that when incidence is adjusted by exposure results are similar for macitentan a placebo for the two doses of macitentan and placebo for the Pool 1. In case of double-blind PAH population also similar results are found. Regarding Pool 2, around 20% of patients presented respiratory  infections  over  the  treatment,  with  no  clear  exposure  time-dependent  pattern.  In conclusion,  nasopharyngitis,  bronchitis  pharyngitis  have  been  included  in  section  4.8  of  the SmPC.

<div style=\"page-break-after: always\"></div>

## Other infections:

In the double-blind PAH population there was certain imbalance in the incidence of AEs of urinary tract infections and gastroenteritis in patients who received macitentan compared to those who received placebo. However, such infections were not associated with an excess of SAEs or AEs leading  to  discontinuation,  or  an  increase  in  reporting  rate  over  time.  The  information  is appropriately reflected in the SmPC.

## Oedemas:

In the double-blind PAH population, the incidence of oedemas was similar in the total macitentan group and the placebo group. In the 10 mg group the incidence was marginally higher than in placebo. However, when adjusted on the basis of patient years of exposure, the incidence in the macitentan group was actually lower than in placebo.

Similar  incidences  of  oedemas  were  observed  also  for  macitentan  and  placebo  in  the  Pool  1 population. In the double-blind PAH population, the incidence of peripheral oedemas was more common in the elderly compared to adults. Nevertheless in the Pool 1 a clearly higher incidence of oedema was not seen in the elderly for the proposed dose compared to the adult population.

A higher rate of oedema with macitentan 3 mg than with macitentan 10 mg was found in elderly patients. No relationship with diuretic use was found in a post-hoc analysis and therefore it might correspond to a chance finding.

In  conclusion,  a  specific  description  on  oedema/fluid  retention  during  SERAPHIN  has  been included in section 4.8 of the Opsumit SmPC.

## Malignancies:

In  the  double-blind  PAH  population  lower  incidence  adjusted  by  exposure  was  seen  in  the macitentan 10 mg group compared to the placebo group. In addition, there was no increase over time  in  the  reporting  rate  of  malignancies.  In  the  Pool  1  there  was  a  slight  excess  of malignancies in patients treated with the macitentan 3 mg compared to placebo. Similar figures were seen for patients on the macitentan 10 mg.

In conclusion, the small numbers do not allow drawing sound conclusions although malignancies have  not  been  described  as  a  safety  concern  with  other  ERAs.  Therefore,  no  information  is included in the SmPC.

## Menstrual disorders and ovarian cyst:

In the double-blind PAH SERAPHIN study, an imbalance was recorded in the reported menstrual disorders  and  there  were  confounding  factors  in  most  patients.  These  events  have  not  been described as AEs with other ERAs.

At  present,  the  data  available  are  insufficient  to  establish  a  causal  relationship  between macitentan and menstrual disorders or ovarian cysts. However, due to the numerical imbalance observed, menstrual disorders and ovarian cysts have been considered important potential risks for macitentan.

## Other AEs:

<div style=\"page-break-after: always\"></div>

The most frequently reported AE for macitentan in other clinical studies was headache. Other AEs were:  nasopharyngitis,  rhinitis,  hypotension;  upper  respiratory  tract  infection  and  syncope dysmenorrhoea, peripheral oedema. Those are in line with the AEs reported in PAH studies.

## IPF study:

The overall incidence of treatment-emergent AEs was 97.5% in the macitentan group and 98.3% in  the  placebo  groups.  Worsening  of  IPF  was  the  most  frequently  reported  AE.  Dyspnea, peripheral edema, anemia, pneumonia and nausea, occurred at a higher incidence in patients on macitentan than on placebo.

The incidences of cough and pulmonary hypertension were lower on macitentan than on placebo. The majority of AEs were of mild or moderate intensity on placebo. Only 7 out of 178 enrolled patients had pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) reported in their  medical history. None of these 7 patients had a fatal outcome. Considering the very low number  of  patients  with  PH/PAH  at  baseline,  no  meaningful,  comparative  analysis  could  be conducted based on the presence or absence of concomitant PH/PAH.

## SAEs:

For  PAH  patients  a  higher  incidence  of  SAEs  was  observed  for  macitentan  3  mg,  10  mg  and placebo,  respectively  PAH  and  right  ventricular  failure  both  related  to  progression  of  the diseases.  In  Pool  1,  as  expected,  the  percentage  of  patients  reporting  SAEs  was  higher  for macitentan 3mg and placebo compared to macitentan 10mg. The most frequent were pulmonary arterial  hypertension  and  right  ventricular  failure  both  related  to  progression  of  the  disease. Pneumonia was also reported as SAE in around 2% of patients in all treatment groups. Anaemia was more frequent in both macitentan groups than in placebo.

MACE:  The  overall  incidence  of  major  adverse  cardiovascular  events  (MACE)  was  comparable between the macitentan and placebo groups. However, the incidence of cerebrovascular events was  a  bit  higher  in  patients  on  both  macitentan  groups  versus  placebo.  On  the  other  hand, cardiovascular deaths were less frequent in macitentan groups than in placebo.

## Deaths:

Deaths occurred in a similar percentage in patients on macitentan and placebo both in the double blind  PAH  study  and  in  the  pool  1.  Most  of  deaths  were  considered  as  related  to  underlying condition (progressing right heart or respiratory failure). Two deaths were considered as related to macitentan treatment, one was due to right ventricular failure associated to jaundice within the  context  of  right  ventricular  failure  progression  in  a  PAH  study.  The  other  was  due  to pulmonary embolism in an IPF patient. However, they are unlikely to be related to the drug.

## Laboratory findings:

## Liver abnormalities (AEs and laboratory data):

Other  ERAs  have  shown  dose-dependent  liver  abnormalities,  specifically  increases  in  serum aminotransferases that can be associated to hepatotoxicity. The mechanism for this is not fully understood but is considered to be related in part to inhibition of bile acid export.

<div style=\"page-break-after: always\"></div>

In the double-blind PAH safety population the incidence of liver abnormality AEs was 10.8% in the total macitentan group and 16.1% in the placebo group.

The incidences in the macitentan 3 mg and 10 mg groups were 12.0% and 9.5%, respectively, indicating a dose-related reduction. The AE incidence findings are supported by laboratory data indicating liver abnormalities compared to placebo.

In relation to clinically relevant serum aminotransferase abnormalities observed both in the Pool 1 and double-blind PAH populations, no relevant differences between the macitentan groups and placebo were observed, except for patients with AST or ALT &gt; 8xULN where higher percentages were seen for patients on macitentan in both safety populations.

A post-hoc analysis of hepatic events does show an increase in hepatic events between patients at  high  risk  and  those  without  risk  factors,  but  without  differences  between  macitentan  and placebo in both strata.

The pattern of hepatic events is different across indications.

In  the  PAH  population,  the  lower  incidence  of  hepatic  events  in  macitentan-treated  patients versus  placebo  is  likely  to  be  related  to  a  better  efficacy  of  macitentan  versus  placebo  in preventing right sided heart failure and associated hepatic congestion, which is the main cause of transaminase elevations in patients with PAH.  The incidence of ALT and/or AST &gt; 3xULN (3.4% in the SERAPHIN study in the 10 mg group with a median exposure of 116 weeks) is well within the  range  observed  with  ambrisentan  (3.6%  from  Kaplan-Meier  estimate  at  1  year  in  483 patients) and below that which had been observed with bosentan in PAH (11%-14% at the target dose  of  250  mg/day).  However, there  are  no  head-to-head  clinical  studies  to  conclude  that macitentan provides an improved safety profile in comparison with other ERAs (i.e.: bosentan, ambrisentan).  Although  no  hepatic  signal  was  observed  in  the  SERAPHIN  study  in  PAH,  an imbalance  in  hepatobiliary  adverse  events  was  found  in  IPF  and  in  patients  with  essential hypertension. In conclusion, with the data available, a potential association between macitentan and risk of liver toxicity cannot be definitely ruled out.

While a lack of hepatotoxic potential is  not  excluded,  macitentan  should  be contraindicated  in patients  with  baseline  values  of  transaminases  &gt;  3xULN  and  in  patients  with  severe  hepatic impairment.

Although in all cases confounding factors can be identified related to worsening of PAH or IPF, a cautious  approach  is  considered  appropriate  including  monitoring  of  patients,  appropriate measures and warnings in the SmPC. In the RMP , appropriate risk minimisation measures have been put in place. (patient card, HCP prescriber kit..)

## Renal function:

No  clinical  data  is  available  for  patients  with  severe  renal  impairment.  In  addition,  patients administered macitentan 10 mg with mild to moderate renal impairment had a higher reported rate of anaemia and/or hypotension&gt; This is appropriately reflected in the SmPC.

## Anaemia (AEs and laboratory data):

Like  with  other  ERAS,  decrease  in  haemoglobin  concentrations  was  a  laboratory  abnormality observed with macitentan that was associated to a dose-dependent increase in the incidence of anaemia  compared  to  placebo.  In  the  double-blind  PAH  population,  the  mean  maximum

<div style=\"page-break-after: always\"></div>

reduction from baseline in haemoglobin was 0.73 g/dL in the macitentan 3 mg group and 1.1 g/dL in the macitentan 10 mg group at month 3.

In the PAH population, haemoglobin &lt; 10 g/dL was recorded in 5.8% and 8.7% of patients on macitentan 3 mg and 10 mg, respectively, compared with 3.4% on placebo.

In general, these data indicate that macitentan exhibits a moderate, non progressive and doserelated haemoglobin reduction.

As for other drugs of the same group, the initiation of treatment is not recommended in patients with clinically significant anemia as stated in the SmPC. In addition the applicant provided further information  discussing  the  appropriateness  of  making  dose  reduction  recommendations  in  the event of reductions in haemoglobin or hematocrit. After review of the available data, the CHMP considered that no dose reduction is required.

## Leukocyte counts:

In  the  double-blind  PAH  population,  macitentan  was  associated  with  modest  and  non  dosedependent  decreases  in  mean  leukocyte  count  from  baseline  to  EOT,  corresponding  to  a  9% decrease  from  baseline  with  the  10  mg  dose.  No  infections  were  observed  in  either  of  these patients.

## Platelet counts:

A small proportion of PAH patients, in both placebo and macitentan groups, showed markedly reduced  platelet  counts,  with  or  without  bleeding  complications  during  the  study.  Resolution occurred during continued macitentan treatment and there was an absence of recurrence after treatment re-initiation.

## Bleeding events:

There  is  a  slightly  higher  incidence  of  bleeding  events  reported  in  the  macitentan  groups compared to placebo. This was mainly driven by the higher incidence of gynaecological bleedings compared  to  placebo.  In  general,  concomitant  administration  of  antithrombotics  or  PDE5 inhibitors  was  associated  with  a  higher  bleeding  rate,  which  is  expected.  No  direct  causal relationship  can  be  found  between  macitentan  administration  and  the  increased  occurrence  of bleeding  events.  There  are  no  known  PK  interactions  between  macitentan  and  warfarin  or sildenafil.

## Vital signs:

No effect of macitentan on heart rate was apparent in the overall pooled double-blind safety set.

<div style=\"page-break-after: always\"></div>

## Safety in special populations:

## Intrinsic factors:

In the elderly PAH-patient population (&gt; 65 years), there was a higher incidence of dyspnoea in the macitentan 3 mg group and 10 mg group compared to the placebo group, respect the rest of populations.

Oedema AEs were reported at a higher incidence in elderly PAH patients treated with macitentan compared to placebo. There was no dose-dependency and no statistically significant interaction between age and treatment was observed. There was no obvious effect of PAH disease severity at baseline (WHO FC I/II vs III/IV) on the pattern of AEs across the age groups.

The pattern of AEs was generally similar for males and females both for Pool 1 and the doubleblind PAH population.

Evaluation by subgroup in the double-blind PAH population showed that most hypotension AEs were  reported  in  female  patients.  The  AE  urinary  tract  infection  was  reported  at  a  higher incidence in females than in males.

Race/ethnicity  is  only  described  for  the  double-blind  PAH  population,  as  the  IPF  study  (AC055B201) and essential hypertension study (AC-055-201) comprised almost exclusively Caucasian patients.

Subgroup differences on the basis of race/ethnicity and geographical region were unremarkable

## Pregnancy and lactation:

In the clinical development program, there were a total of 7 pregnancies all in the double-blind PAH population. Based on review of the cases, no specific conclusion can be drawn in relation to macitentan.

In  view  of  the  teratogenicity  observed  in  non-clinical  studies,  macitentan  is  contraindicated during pregnancy. Furthermore, if appropriate, the need for reliable contraception and monthly pregnancy tests during treatment is mentioned in section 4.6 of the SmPC with corresponding warnings in section 4.4.

It  is  not  known  whether  macitentan  is  excreted  into  human  breast  milk.  However,  in  rats, macitentan and its metabolites were excreted into milk during lactation. Thus, breast-feeding is not recommended during treatment with macitentan.

## Overdose:

There is no experience with accidental overdose of macitentan. In the case of overdose, general supportive treatment is recommended.  Considering  the  high  degree  of protein binding, macitentan is not likely to be removed by dialysis.

## Rebound effect:

The results did not indicate that the discontinuation of macitentan 10 mg was associated with any AE suggestive of a rebound effect.

## Ability to drive and use machines:

No  studies  on  the  effect  of  macitentan  on  the  ability  to  drive  and  use  machines  have  been performed, as an effect is not anticipated.

<div style=\"page-break-after: always\"></div>

There is no indication of any potential for abuse from clinical studies or from current knowledge of ERAs in general.

## Hypersensitivity:

All  of  the  cases  of  hypersensitivity  appear  to  be  associated  with  concomitant  medications  and seasonal allergy, not with macitentan. Only one case was considered by the investigator to be related to treatment.

## Discontinuation to AEs:

Around 10 % of patients discontinued due to AEs both in the pool 1 and the double blind PAH population.  Pulmonary  arterial  hypertension  and  right  ventricular  failure,  both  related  to  the underlying  condition,  were  more  frequent  in  the  placebo  group  in  these  populations.    As expected, anaemia and increase in aminotransferases were more frequency in the macitentan groups.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

## 2.6.2. Conclusions on the clinical safety

Overall, macitentan seems to have a safety profile similar to that of other ERAs. The adverse events most frequently reported were right heart failure, pulmonary arterial hypertension (both in  principle  related  to  the  underlying  condition),  oedemas,  upper  tract  infection,  anaemia  and liver abnormalities.

Although  there  are  no  major  safety  concerns  related  to  macitentan,  a  potential  association between  macitentan  and  risk  of  liver  toxicity  cannot  be  definitively  ruled  out.  The  SmPC  of Opsumit has been aligned with that of ambrisentan regarding hepatic safety (contraindication in patients at risk, and recommendation for regular monitoring), as the hepatotoxicity risk seems comparable. In addition, in view of the teratogenicity observed in non-clinical studies, macitentan is  contraindicated  during  pregnancy.  Furthermore,  the  need  for  reliable  contraception  and monthly  pregnancy  tests  during  treatment  is  reflected  in  section  4.6  of  the  SmPC  with corresponding warnings in section 4.4 of the SmPC.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The CHMP considered that the Pharmacovigilance system as described by the applicant fulfils the legislative requirements.

## 2.8. Risk Management Plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

<div style=\"page-break-after: always\"></div>

## PRAC Advice

Based  on  the  PRAC  review  of  the  Risk  Management  Plan  version  5,  the  PRAC  considers  by consensus  that  the  risk  management  system  for  macitentan  (Opsumit)  in  the  treatment  of pulmonary arterial hypertension is acceptable.

## Safety concerns

The applicant identified the following safety concerns in the RMP:

Table 2.1 Summary of the Safety Concerns

| Important identified risks   | Anaemia, decrease in haemoglobin concentration Hepatotoxicity Teratogenicity                                                                                                                                                                          |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Symptomatic hypotension Thrombocytopenia Leukopenia Menstrual disorders (primarily bleeding) Ovarian cysts Pulmonary oedema associated with PVOD testicular disorders and male infertility Potential off-label use (including in paediatric patients) |
| Missing information          | Paediatric patients Elderly patients aged > 75 years Patients with moderate to severe hepatic impairment Patients with severe renal impairment and/or undergoing dialysis.                                                                            |

PVOD = pulmonary oedema associated with veno-occlusive disease

The PRAC agrees that the safety concerns listed by the MAH are appropriate.

## Pharmacovigilance plans

The PRAC, having considered the data submitted, was of the opinion that routine pharmacovigilance is sufficient to identify and characterise the risks of the product.

The PRAC also considered that routine PhV is sufficient to monitor the effectiveness of the risk minimisation measures.

## Risk minimisation measures

## 3. Proposal for risk minimisation measures

| Safety concern                                 | Routine risk minimisation measures                                                     | Additional risk minimisation measures                                                 |
|------------------------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Anaemia, decrease in haemoglobin concentration | SmPC Warning in section 4.4 Inclusion in ADR table in section 4.8 Inclusion in the PIL | Controlled distribution Risk minimisation tools (HCP brochure, prescribing checklist) |

<div style=\"page-break-after: always\"></div>

| Hepatotoxicity                                   | SmPC Contraindication in section 4.3 Warning in section 4.4 Inclusion in section 4.8 under laboratory abnormalities Inclusion in the PIL                                                                                                      | Controlled distribution Risk minimisation tools (HCP brochure, prescribing checklist                   |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Teratogenicity                                   | SmPC Contraindication for pregnancy, women of child-bearing potential not using contraception and lactation in section 4.3. Warning for women of child bearing potential in section 4.4. Recommendations in section 4.6. Inclusion in the PIL | Controlled distribution Risk minimisation tools (HCP brochure, prescribing checklist and patient card) |
| Symptomatic hypotension                          | SmPC Warning in section 4.4 for patients with severe renal impairment Inclusion in section 4.8                                                                                                                                                | None                                                                                                   |
| Thrombocytopenia                                 | SmPC Inclusion in section 4.8 under laboratory abnormalities                                                                                                                                                                                  | None                                                                                                   |
| Leukopenia                                       | SmPC Inclusion in section 4.8 under laboratory abnormalities                                                                                                                                                                                  | None                                                                                                   |
| Menstrual disorders (primarily bleeding)         | None                                                                                                                                                                                                                                          | None                                                                                                   |
| Ovarian cysts                                    | None                                                                                                                                                                                                                                          | None                                                                                                   |
| Pulmonary oedema associated with PVOD            | SmPC Warning in section 4.4                                                                                                                                                                                                                   | None                                                                                                   |
| Testicular disorders and male infertility        | SmPC Statement in section 4.6                                                                                                                                                                                                                 | None                                                                                                   |
| Off-label use (including in paediatric patients) | SmPC Definition of target patient population in section 4.1 Information about lack of data in paediatric patients in section 4.2 Inclusion in the PIL                                                                                         | None                                                                                                   |
| Missing information in paediatric Patients       | SmPC Statement in sections 4.2 Inclusion in the PIL                                                                                                                                                                                           | None                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Missing information in elderly patients above 75 years                                  | SmPC Statement in section 4.2 Warning in section 4.4 Inclusion in PIL                                                                             | None   |
|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| Missing information in patients with moderate to severe hepatic impairment              | SmPC Statement in section 4.2 Contraindication in section 4.3 for patients with severe hepatic impairment Warning in section 4.4 Inclusion in PIL | None   |
| Missing information in patients with severe renal impairment and/or undergoing dialysis | SmPC Statement in section 4.2 Warning in section 4.4                                                                                              | None   |

The  PRAC  is  of  the  opinion  that  the  proposed  risk  minimisation  measures  are  sufficient  to minimise the risks of the product in the proposed indication.

The CHMP endorsed this advice without changes.

Of  note,  an  updated  RMP  version  6  was  submitted  as  the  final  version  for  the  opinion incorporating  minor  changes  related  to  the  finalisation  of  SmPC  wording  after  the  PRAC discussion.

## 3.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 4. Benefit-Risk Balance

## Benefits

## Beneficial effects

This application is based on the results of a single, long-term, double-blind pivotal Phase 3 study, AC-055-302/SERAPHIN.  The  pivotal  study  included  a  clinically  relevant  primary  endpoint  (the time  to  first  morbidity-mortality  event).  The  secondary  endpoints  (change  in  6MWD,  separate components of the primary endpoint, change in WHO FC, haemodynamic endpoints, dyspnoea symptoms, NT-pro-BNP levels and QoL endpoints) were considered exploratory and appropriate. The tested doses (3 mg and 10 mg) were well justified on the basis of PD data and the median exposure exceeded 2 years.

SERAPHIN is the largest study conducted to date in PAH (n=742) and included a wide population of PAH patients with different aetiologies, Function Class and background medications. One of the

<div style=\"page-break-after: always\"></div>

positive contribution of the current application is that it addresses combination therapy, which is an unmet need in PAH.

The primary endpoint analysis demonstrated a clinically relevant effect of macitentan 10 mg to reduce the risk of occurrence of the primary endpoint in the study population, which was below the pre-specified significance criteria (p&lt;0.001) for a 'conclusive study' [HR: 0.547 (97.5% CLs 0.392,  0.762,  logrank  p  &lt;  0.0001].  The  treatment  effect  with  macitentan  on  the  primary endpoint was established early and was sustained during treatment (median duration of more than 2 years).The 10mg dose was considered the appropriate dose on the basis of efficacy and safety results. For the 10 mg dose the treatment effect corresponded to an overall relative risk reduction of 45% and a number-needed-to-treat (NNT) of 6 patients (95% CLs 4.48, 10.80) to avoid  one  event  at  2  years.  Results  of  sensitivity  analyses  for  the  primary  endpoint  were consistent  with  those  of  the  main  analysis.  In  a  reanalysis  of  the  primary  endpoint  using  the components recommended in the PAH guideline (EMEA/CHMP/EWP/356954/2008), the HR versus placebo for the occurrence of a CHMP-defined event in the macitentan 10 mg dose group was 0.550 (97.5%CI: 0.417, 0.725; logrank p&lt;0.0001). In the macitentan 3 mg group, the HR was 0.737 (97.5% CI: 0.568, 0.956; p=0.0083). The corresponding relative risk reductions versus placebo were 45% and 26%, respectively, which are broadly similar to the results of the main analysis.  In  addition,  the  effect  of  macitentan  10  mg  on  the  primary  outcome  was  generally consistent across subgroup analyses. At baseline, the majority (approximately 64%) of patients were  receiving  at  least  one  background  PAH  therapy.  Sildenafil  was  the  most  common  PAH therapy  and  was  taken  by  approximately  58%  of  patients  across  the  groups.  Macitentan administered  on  top  of  sildenafil  or  inhaled  prostanoids  showed  benefits,  with  minimal  PK interactions.

The majority of secondary and exploratory endpoints (e.g.: the composite of hospitalization or death  due  to  PAH,  deaths  related  to  PAH,  all  cause  death,  improvement  in  WHO  FC,  Borg dyspnoea index, Quality of life, reduced hospitalizations, change versus placebo in NT-pro-BNP and hemodynamic parameters), provided consistent support for a benefit of macitentan 10 mg versus placebo.

## Uncertainty in the knowledge about the beneficial effects

Not all the components of the chosen primary composite in SERAPHIN are equally robust. In the main  analysis,  the  rate  of  death  was  comparable  between  the  placebo  (6.8%)  and  the macitentan 10 mg arms (6.6%), while there is a numerical increase in the reported deaths in the macitentan 3 mg arm (8.4%) compared to the other 2 arms. In addition, no robust statistical effect was found in the time to death analyses. Although the mortality results for macitentan 10 mg are not inconsistent with those of the main composite endpoint, the point estimate tends to be of a lesser magnitude than that of the composite endpoint (mainly driven by worsening of PAH),  and  statistical  significance  is  not  achieved  for  mortality.  In  addition,  beyond  statistical significance, the conclusions about a benefit in survival with the 10 mg dose were based on a limited  number  of  deaths  within  a  single  pivotal  trial.  Furthermore,  according  to  the  PAH Guideline (EMEA/CHMP/EWP/356954/2008): ' Specific claims on mortality can only be supported by long-term controlled studies including death as a primary endpoint '. A mortality claim cannot be  included  in  section  4.1  due  to  the  above-mentioned  reasons.  A  description  of  the  effect observed on deaths in section 5.1 of the SmPC is considered sufficient.

<div style=\"page-break-after: always\"></div>

The  most  frequent  first-reported  component  of  the  primary  endpoint  in  all  groups  was  'other worsening of PAH' (28.8% macitentan 3 mg, 24.4% macitentan 10 mg, 37.2% placebo), driving the  positive  results  of  the  study.  This  implies  that  the  main  benefit  was  in  delaying  clinical worsening events (worsening of PAH).

During the procedure, the applicant proposed a new wording without including any specific claim in  the  indication  but  including  a  cross-reference  to  section  5.1.  This  proposal  was  deemed acceptable by the CHMP, and should be interpreted in light of the more robust evidence with macitentan from SERAPHIN regarding delay in clinical worsening of PAH in comparison to other PAH  therapies  where  claims  have  been  limited  to  the  change  in  6MWT  and/or  symptoms. However, as comparative studies are lacking, no final conclusions can be drawn on their relative benefit in patients with PAH.

With respect to missing data, a total of 27 patients did not complete the study and therefore vital status was missing at EOS, i.e., lost to follow-up, etc.). Additional data provided by the Company shows that missing data were well balanced by treatment groups. In addition, the results of the sensitivity analyses using the Best-case, Base-case and Worst-case scenarios were similar to that of the primary analysis for the time to death up to EOS, with risk reductions ranging from 33% to  16%  across  all  analyses  (none  of  them  statistically  significant).  The  primary  analysis  risk reduction of 23% falls well within that range.

Some subpopulations were under-represented in the pivotal study. Almost all patients were in WHO FC II-III, while only 1 patient was in FC I and only 14 patients were in FC IV. Therefore, the  indication  has  been  restricted  to  patients  on  FC  II  and  III.  Idiopathic  PAH  was  the  most common  aetiology  (55%)  followed  by  PAH  due  to  connective  tissue  (30%)  and  PAH  due  to congenital  shunts  (8%).  This  latter  subpopulation  only  included  PAH  associated  to  corrected simple congenital systemic-to-pulmonary shunts, since patients with PAH associated with noncorrected simple congenital systemic-to-pulmonary shunts and combined and complex systemicto-pulmonary  shunts  were  excluded.  Therefore,  'PAH  due  to  congenital  shunts'  has  not  been included in the approved indication.

Regarding paediatric population (12-18), their actual representation in the clinical study and the scarce  efficacy  and  safety  data  available  does  not  support  a  recommendation  of  use  for macitentan in children. Therefore, the safety and efficacy of Opsumit in children have not yet been  established,  as  included  in  the  product  information.  Further  data  is  awaited  upon completion of planned studies in paediatric patients.

Only about 20 patients were in the age range between 75-84 years in the pivotal trial. Therefore, macitentan should be used with caution in that population, as included in the product information

The p-value for improvement in 6MWD (one of the secondary outcomes) was above the 0.001 value  predefined  in  the  protocol  to  consider  the  results  as  conclusive.  In  addition,  the  clinical relevance of the 15 m median improvement obtained with macitentan 10 mg versus placebo is questionable. Therefore, the Applicant's proposal of not including the improvement in exercise capacity  in  the  indication  is  endorsed.  Results  of  the  6MWT  showed  no  difference  between treatment naïve patients and patients administered macitentan in combination with other PAH therapies (median=13 m; 95%CI: -5 to 31 and median =15 m; 95%CI: 2 to 30). No plausible explanation is available at present.

<div style=\"page-break-after: always\"></div>

Results  showed  some  improvement  in  PVR  and  CI  with  dose  response  in  treatment  naïve patients, but not in patients already on PAH-specific therapies. Within SERAPHIN, higher baseline NT-proBNP levels and higher absolute values at Month 6 were associated with a higher risk of morbidity  and  mortality,  however  no  prognostic  value  of  change  from  baseline  was  observed. Finally, no head-to-head comparisons are available with other ERAs. Therefore, it is unknown if macitentan would provide some benefit in efficacy compared with bosentan or ambrisentan.

## Risks

## Unfavourable effects

Overall, macitentan seems to have a safety profile similar to that of other ERAs. The adverse events most frequently reported were right heart failure, pulmonary arterial hypertension (both in  principle  related  to  the  underlying  condition),  liver  abnormalities,  anaemia,  oedemas  and upper tract infection.

Elevations of liver aminotransferases (AST, ALT) have been associated with the treatment with ERAs,  including  macitentan.  This  toxic  effect  on  the  liver  seems  to  be  time-dependent,  with higher incidence with longer exposition to macitentan. In relation to the clinically relevant serum aminotransferase  abnormalities  observed  the  safety  pool,  there  does  not  seem  to  be  relevant differences between  macitentan and placebo in elevated aminotransferases &gt;3×ULN (3.2% vs. 3.9%) or Hy's law cases (1.2% vs. 1.4%), but the rate of AST/ALT elevations &gt;8xULN where higher in patients on macitentan versus placebo (1,3% vs 0,6%). In addition, the phase II study in mild-to-moderate essential hypertension was ended earlier than planned after 5 cases of liver transaminases &gt;3xULN were reported (study AC-055-201).

Because  a  lack  of  hepatotoxic  potential  cannot  be  excluded,  Opsumit  is  not  to  be  initiated  in patients with elevated aminotransferases (&gt;3×ULN) at baseline or in patients with severe hepatic impairment, in line with the exclusion criteria applied in the SERAPHIN study. Liver enzyme tests should  be  obtained  prior  to  initiation  of  Opsumit.  Patients  should  be  monitored  for  signs  of hepatic injury and monthly monitoring of ALT and AST is recommended.

As  with  other  ERAs,  treatment  with  macitentan  has  been  associated  with  a  decrease  in haemoglobin  concentration,  including  some  cases  that  may  blood  cell  transfusion.  Therefore, Opsumit is not recommended in patients with severe anaemia and haemoglobin concentrations should  be  measured  prior  to  initiation  of  treatment  and  tests  repeated  during  treatment  as clinically indicated.

Hypotension is considered a class effect of ERAs and some SmPC amendments, in particular in patient at risk of hypotension (e.g.: elderly, renal insufficiency, concomitant treatment with other vasodilators, may be necessary.

Although  the  product  has  a  low  potential  for  drug-drug  interactions,  some  of  them  (PK interactions with strong inducers/inhibitors of CYP3A4 and PD interactions with vasodilators) may be of clinical relevance.

Macitentan was teratogenic in animal studies and therefore it is contraindicated during pregnancy and in women of child-bearing potential who are not using reliable contraception. There is a need for  reliable  contraception  and  monthly  pregnancy  tests  during  treatment.  The  contraindication

<div style=\"page-break-after: always\"></div>

has been extended to breastfeeding, as there is preclinical evidence of excretion into milk during lactation and a risk to the newborns/infants cannot be excluded.

These unfavourable effects may be manageable in standard clinical practise.

## Uncertainty in the knowledge about the unfavourable effects

The incidence of oedemas seems to be lower with the high macitentan dose (10 mg) than with the low macitentan dose in the elderly as compared to the adult population.

A causal relationship between macitentan and menstrual disorders or ovarian cyst is difficult to establish at the present time due to the overall low incidence of events, the confounding factors identified  in  patients  with  an  event,  and  also  due  to  the  absence  of  dose-dependency  or  the presence of a specific temporal pattern. These events have been considered as potential risks in the RMP.

There are very limited data of macitentan in patients with IPF and associated PH/PAH (7 patients from the MUSIC-IPF study). However, the overall data with macitentan in IPF do not show any safety signal.

The SmPC (sections 4.2 and 4.4) reflects the limited clinical experience in patients over the age of 75 years, and therefore macitentan should be used with caution in this population.

There is also a higher rate of discontinuation due to liver related AEs in the macitentan groups, showing a dose response of 2.4% and 3.3% in the macitentan 3 mg and 10 mg respectively compared to the rate of 1.6% on the placebo group. These results can not totally negate the concern of hepatotoxicity. A post-hoc analysis of hepatic events has been conducted in patients at high risk (those who had a history of liver disease at screening; n=114). The analysis does show an increase in hepatic events between patients at high risk and those without risk factors, but  without  differences  between  macitentan  and  placebo  in  both  strata.  After  review  of summarized  information  on  hepatic  events  from  ongoing  or  recently  completed  studies  with macitentan (e.g. MUSIC IPF, ischaemic digital ulcers, glioblastoma), it can be concluded that the pattern of hepatic events (AEs related to hepatobiliary disorders as well as the incidence of liver test elevation) is different across indications.

In  the  PAH  population,  the  lower  incidence  of  hepatic  events  in  macitentan-treated  patients versus placebo is likely to be related to the efficacy of macitentan versus placebo in preventing right  sided  heart  failure  and  associated  hepatic  congestion,  which  is  the  main  cause  of transaminase elevations in patients with PAH.  The incidence of ALT and/or AST &gt; 3xULN (3.4% in the SERAPHIN study in the 10 mg group with a median exposure of 116 weeks) is well within the  range  observed  with  ambrisentan  (3.6%  from  Kaplan-Meier  estimate  at  1  year  in  483 patients) and below that which had been observed with bosentan in PAH (11%-14% at the target dose  of  250  mg/day).  However, there  are  no  head-to-head  clinical  studies  to  conclude  that macitentan provides an improved safety profile in comparison with other ERAs (i.e.: bosentan, ambrisentan).  Although  no  hepatic  signal  was  observed  in  the  SERAPHIN  study  in  PAH,  an imbalance  in  hepatobiliary  adverse  events  was  found  in  IPF  and  in  patients  with  essential hypertension. In conclusion, with the data available, a potential association between macitentan and risk of liver toxicity cannot be definitively ruled out.

<div style=\"page-break-after: always\"></div>

Macitentan prolonged the values of some coagulation tests (e.g.: prothrombin time) in preclinical studies.  There  are  no  clinical  data  suggesting  a  potential  interference  of  macitentan  with coagulation tests in humans.

There is a slightly higher incidence of bleeding events reported in the macitentan groups (19.6% and 18.6% in the macitentan 3 mg and 10 mg respectively) compared to placebo (14.5%). This was mainly driven by the higher incidence of gynaecological bleedings (6.9% and 5.1% in the macitentan 3 mg and 10 mg respectively) compared to placebo (1.1%). Importantly, there is no dose response observed in all these reported bleedings. In general, concomitant administration of  antithrombotics  or  PDE5  inhibitors  was  associated  with  a  higher  bleeding  rate,  which  is expected. No direct causal relationship can be found between macitentan administration and the increased bleeding events. There are no known PK interactions between macitentan and warfarin or sildenafil.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Prevention of PAH-related morbidity/mortality is the most important target in PAH. This is the first application in PAH that provides a pivotal study appropriately designed and powered to show an outcome benefit of a specific therapy in patients with PAH. The benefit of macitentan 10 mg versus placebo in the chosen primary endpoint was highly clinically relevant, corresponding to an overall relative risk reduction of 45% and a number-needed-to-treat (NNT) of approximately 6 patients needed to prevent an event at 2 years, and was accompanied by consistent favourable effects in other clinically relevant  endpoints  (e.g.:  improvement  in  WHO  FC,  dyspnoea symptoms, quality of life, reduced hospitalizations, and hemodynamic parameters). However, the positive results were mainly driven by events signifying clinical worsening rather hospitalisation. In  addition,  SERAPHIN  study  had  some  drawbacks  related  to  mortality  data  that  preclude including a mortality claim (see section about 'uncertainty in the knowledge about the beneficial effects').

The  unfavourable  effects  were  mainly  class  effects  seen  with  other  ERAs  (e.g.:  oedemas, anaemia transaminase increase) that are manageable in standard practice.

## Benefit-risk balance

The importance and magnitude of the clinically relevant favourable effects of macitentan on the clinical course of PAH exceeds the importance and magnitude of the unfavourable effects.

## Discussion on the benefit-risk balance

Clinical data available supports the efficacy of macitentan 10 mg OD in the long-term treatment of PAH in adults. The efficacy has been shown in adult patients with functional class II and III, as monotherapy or in combination with other PAH therapies (PDE-5 inhibitors and prostanoids), in a PAH  population  with  idiopathic  and  heritable  PAH,  PAH  associated  with  connective  tissue disorders,  and  PAH  associated  with  corrected  simple  congenital  heart  disease.  The  agreed indication  does  not  include  any  specific  claim  and  should  be  interpreted  in  light  of  the  more robust evidence with macitentan from SERAPHIN regarding delay in clinical worsening of PAH in comparison  with  other  PAH  therapies  where  claims  have  been  limited  to  the  6MWT  and/or symptoms. However, as comparative studies are lacking, no final conclusions can be drawn on their relative benefit in patients with PAH.

<div style=\"page-break-after: always\"></div>

The overall Benefit Risk of Opsumit is positive.

## 5. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Opsumit/macitentan is not similar to sildenafil, iloprost, bosentan and ambrisentan within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## Outcome

Based  on  the  CHMP  review  of  data  on  quality,  safety  and  efficacy,  the  CHMP  considers  by consensus that the risk-benefit balance of Opsumit for the following indication:

Opsumit,  as  monotherapy  or  in  combination,  is  indicated  for  the  long-term  treatment  of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III.

Efficacy  has  been  shown  in  a  PAH  population  including  idiopathic  and  heritable  PAH,  PAH associated  with  connective  tissue  disorders,  and  PAH  associated  with  congenital  heart  disease (see section 5.1).

is favourable and therefore recommends  the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal products on 'restricted' medical prescription, reserved for use in certain specialised areas (see Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the Marketing Authorisation

## · Periodic Safety Update Reports

The marketing authorisation holder shall submit the first periodic safety update report for this product  within  6  months  following  authorisation.  Subsequently,  the  marketing  authorisation holder  shall  submit  periodic  safety  update  reports  for  this  product  in  accordance  with  the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the    agreed  RMP  presented  in  Module  1.8.2 of  the  Marketing  Authorisation and  any  agreed subsequent updates of the RMP.

An updated RMP should be submitted:

<div style=\"page-break-after: always\"></div>

- At the request of the European Medicines Agency;
- Whenever  the  risk  management  system  is  modified,  especially  as  the  result  of  new information  being  received  that  may  lead  to  a  significant  change  to  the  benefit/risk profile  or  as  the  result  of  an  important  (pharmacovigilance  or  risk  minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

## · Additional risk minimisation measures

Healthcare Professional brochure addressing the important identified risks of anaemia, hepatotoxicity and teratogenicity as well as the need for patient communication regarding these risks.

Prescribing checklist for healthcare professionals to address the risk(s) of anaemia, hepatotoxicity, and teratogenicity

Educational material for patients and/or carers to address the risk(s) of anaemia, hepatotoxicity and teratogenicity

Patient alert card

## Conditions  or  restrictions  with  regard  to  the  safe  and  effective  use  of  the  medicinal product

The MAH shall agree the details of the Prescriber kit and a controlled distribution system with the National Competent Authority and implement it prior to launch in that Member State. The MAH shall ensure that prior to prescribing all healthcare professionals who intend to prescribe and/or dispense Opsumit are provided with a Prescriber Kit containing the following:

- The Summary of Product Characteristics for Opsumit
- Prescribing checklists
- Healthcare Professional brochure containing information about Opsumit
- Patient reminder cards

The  prescribing  checklist  should  remind  prescribers  of  the  contraindications,  warnings  and precautions as well as the following key elements:

- o to  provide  patients  with  appropriate  information  regarding  the  safe  use  of  the product
- o To  ensure  females  of  childbearing  potential  are  not  pregnant  and  are  on  reliable contraception prior to starting Opsumit
- o to provide patients with the patient card
- o the need for baseline and monthly pregnancy tests and monitoring of haemoglobin levels and liver function.

The Healthcare Professionals brochure should contain the following key elements:

- o That patients should be capable of complying with the requirements for the safe use of Opsumit

<div style=\"page-break-after: always\"></div>

- o the  risk  of  anaemia,  hepatotoxicity  and  teratogenicity  and  the  need  for  reliable contraception
- o the need for baseline and:
-  monthly pregnancy tests
-  regular monitoring of haemoglobin levels
-  regular monitoring of liver function.
- o The importance of telling patients to report immediately any possible pregnancy that occurs during Opsumit use.

The  patient  reminder  card  for  patients  prescribed  Opsumit  should  include  the  following  key elements:

- That Opsumit is teratogenic in animals
- That pregnant women must not take Opsumit
- That women of childbearing potential must use reliable contraception
- The need monthly pregnancy tests for
- The need for regular blood tests because Opsumit causes a decrease in haemoglobin
- The need for regular monitoring of liver function because Opsumit has hepatotoxic potential

## · Obligation to complete post-authorisation measures

Not applicable.

## Specific  Obligation  to  complete  post-authorisation  measures  for  the  marketing authorisation under exceptional circumstances

Not applicable.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented:

1. The  Member  State  shall  agree  the  details  of  the  Prescriber  kit  and  a  controlled distribution  system with the Marketing Authorisation Holder (MAH) and must implement such programme nationally prior to launch to ensure that:

- Prior  to  prescribing  (where  appropriate,  and  in  agreement  with  the  National Competent  Authority,  dispensing)  all  healthcare  professionals  who  intend  to prescribe  (and  dispense)  are  provided  with  a  prescriber  kit  containing  the following:
- o Educational Health Care Professional's kit
- o Educational brochures for Patients
- o Patient cards

<div style=\"page-break-after: always\"></div>

- o Summary  of  Product  Characteristics  (SmPC)  and  Package  Leaflet  and Labelling.

These conditions reflect the advice received from the PRAC.

## New Active Substance Status

Based on the CHMP review of data on the quality properties of the active substance, the CHMP considers that macitentan is qualified as a new active substance.

## Paediatric Data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan [P/0087/2012] and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.